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ABSTRACT 
A possible hormonal basis for the premenstrual syndrome 
(MS) was tested by measurement of progesterone, oestradiol and 
aldosterone throughout the menstrual cycle in subjects with PMS 
and in controls, ih plasma. 
An antiserum was raised against progesterone-llo(- hemi- 
succinate-BSA in rabbits and a radioimmunoassay developed, and 
oestradiol was assayed after extraction using a specific antiserum, 
Sephadex LH-20 microcolumns were used to purify aidosterone from 
plasma extracts before radioimmunoassay. The sensitivity, 
precision, accuracy and specificity of all the assays were found 
to be satisfactory. 
When ten control and 20 PIOIS cycles were compared, it was 
found that the midluteal peak of progesterone (from 8 to 5 days 
premenstrually) was lower (P< 0.02), and plasma oestradiol levels 
were higher in the last 4 days of the cycle (P< 0.01), in the 
PMS group. 
The pattern of aldosterone in the menstrual cycle of non- 
fasting controls showed higher levels after ovulation but there 
was not a pronounced pre-ovulatory peak. There were no marked 
differences between the PMS and control groups. 
When a further 90 subjects with PMS were studied, a third 
of these had progesterone levels below the 90 per cent confidence 
limits of the controls. There was an inverse relationship 
between progesterone and serum prolactin levels in the luteal 
phase. Women complaining chiefly of physical symptoms, such as 
water, retention, had higher progesterone levels than those 
complaining chiefly of irritability and depression, but 
progesterone levels did not correlate with psychiatric ill-health. 
In a clinical trial of dydrogesterone, it was shown that 
progesterone levels were slightly reduced in the dydrogesterone- 
treated cycles despite clinical improvement. 
These results support the concept that endocrine imbalance may 
occur in some PMS patients but not all. The aetiology of the 
various forms of the syndrome is still obscure but possible 
mechanisms are discussed. 
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1. THE MENSTRUAL CYCLE . 
There are many examples of biological processes which 
are rhythmic or cyclical in character, and the human menstrual cycle 
is perhaps one of the most complex. Therefore, to investigate a 
disorder such as the premenstrual syndrome, it is necessary to 
understand processes in the 'normal'cycle. 
External factors affecting the cycle are not well under- 
stood, although such factors as the moon (Menaker & Menaker, 1959) 
and pheromones (McClintock, 1971) have been mentioned. 
Several authors have attempted to provide definitive 
figures for the average menstrual cycle, for instance Chiazze, Brayer, 
Macisco, Parker & Duffy (1968) in a study of at least ten cycles each 
from over 2000 women found that the average cycle length per woman 
was 29.1+7.5 days. Other estimates of the average length of the 
human cycle have varied from 27.3 to 31.9 days-(Presser, 1974). 
Differences are probably due to differences in the samples of women, 
especially with regard to age. In one longitudinal study (Treloar, 
Boynton, Behn, & Brown, 1967) it was found that cycles were longer 
and more variable in length in the post menarche and premenopausal 
years, although cycles tended to get progressively shorter from the 
twenties to the forties. 
The two reference points of the cycle are ovulation and 
menstruation, and it is the post-ovulatory"(luteal) phase which is 
most constant (Presser, 1974). 
The intrinsic events of the cycle have been investigated 
fairly thoroughly, especially the endocrinological and physiological 
aspects, although the social and psychological aspects are rather 
more controversial. 
A review of all these events will be undertaken in the 
14 
hope of throwing some light on the aetiology of the premenstrual 
syndrome. 
1.1. HORMONAL CHANGES IN THE CYCLE 
1.1.1. The control of ovulation 
The most important processes of the cycle, from the 
evolutionary point of view, are those that control ovulation and 
facilitate implantation. These events are under the control of the 
hypothalamus, pituitary and ovary, with interactions between the 
rest of the central nervous system. The individual hormones have 
a characteristic pattern of secretion and it is important to establish 
these patterns before causative relationships can be worked out, 
especially in humans where experimental studies. are more difficult. 
Present knowledge of hormonal events comes largely from 
radioimmunoassay data, obtained in the last ten or so years, although 
earlier work established the basic patterns. 
Gonadotrophic releasing factor 
Gonadotrophin releasing factor, GRF (or gonadotrophin releasing 
hormone) is a decapeptide released by the hypothalamus with actions 
on the pituitary release of luteinising hormone (LH) and follicle 
stimulating hormone(FSH) (Schally, Arimura, Kastin, Matsuo, Baba, 
Redding, Nair, Debeljuk:, & White, 1971). Semiquantitative bioassay 
methods have been used to measure levels in peripheral blood, and a 
small peak was found at midcycle, at about the time of ovulation 
(Malacara, Seyler & Reichlin, 1972). This was confirmed by 
radioimmunoassay, and GRF immunoreactivity was only consistently 
detectable at midcycle (Arimura, Kastin, Schally, Saito, Kumasaka, 
Yaoi, Nishi & Okhura , 1974). This probably represents a 'leak' of 
the hormone into peripheral blood since GRF is stored in the median 
eminence (Crighton, Scheider & McCann) and is secreted directly 
15 
to the p: itary via the portal systems. 
The Gona". otrophins 
Patterns of FSH and LH have been extensively studied, 
firstly in urine and later in serum. McArthur, Worcester, & Ingersoll 
(1958), using a specific bioassay, the ventral prostate test, first 
demonstrated that a peak in LH excretion occurred at day 16 of the 
cycle. The first report of FSH excretion used a specific ovarian 
augmentation assay in mice (Brown, 19-5c Holmstrom & Salhanik, 
(1956) showed high levels during menses in their small group of 
women, but changes in the rest of the cycle were' inconsistett. 
Fukushima, Stevens, Gantt & Vorys (1964), using a different bioassay, 
established that a second rise always occurred around midcycle. -These 
results were confirmed by many bioassay and some immunological assay 
methods for TZ (Brown, Klopper & Lorraine, 1958), and FSH (Persson & 
McCormick, 1968), although the data obtained were limited by the 
problem of sensitivity. However, an accurate picture of temporal 
events was made possible by radioinmunoassay methods which gave 
adequate sensitivity and specificity in urine and blood. Bagshawe, 
Wilde & Orr (1966)showed that both urinary and serum LH reached a 
sharp peak at midcycle, with low levels throughout the rest of the 
cycle, and this was confirmed by others (Odell, Ross & Rayford 1967; 
Stevens, 1969). It was also confirmed that FSH had two peaks in the 
cycle, one early in the follicular phase and a second at or near 
ovulation, and that the midcycle peaks of LH and FSH coincided 
(Midgley & Jaffe, 1968*, Faiman & Ryan, 1967). Other workers have 
since reported gonadotrophin levels together with other hormones 
in the normal menstrual cycle, and these will be discussed below. 
The ovarian steroids 
Cestrogens 
The individual oestrogens oestradiol, oestriol and 
oestrone was first measured in urine in the classic studies of 16 
Brown (1955a). The methodology is discussed on page 60 . Brown found 
that all three oestrogens were very low at the beginning of the cycle 
but rose to a peak at midcycle. They then fell sharply but rose 
to a second, smaller peak in the luteal phase, falling again in 
the last few days of the cycle before menstruation. Oestradiol 
was present in smaller amounts than oestrone and oestriol, but the 
total oestrogen output could be as little as 5 Vg/24 hours. Baird 
& Guevara (1969) reported the first levels in blood, using a double 
isotope method, and correlated oestrone and oestradiol levels with 
IAH. They found that oestradiol levels started to rise before any 
rise in LH, and postulated that another trophic factor was responsible. 
Oestradiol is thought to be the most important oestrogen 
produced by the follicles, since it occurs at greater concentration 
than oestrone in follicular fluid (Smith & Ryan, 1962) and is the 
major radioactive metabolite of 
14C-acetate 
preincubated with 
follicles or corpora lutea (Ryan & Smith, 1961) . The ratio of oestradiol 
to oestrone shows a significant predominance of oestradiol during 
the pre-ovulatory period(Baird & Guevara, 1969). Therefore oestradiol 
has been regarded as the most important oestrogen to study in 
the menstrual cycle and since the technique of radioimmunoassay (RIA) 
several studies of daily levels have been carried out. All have 
shown the midcycle peak and a secondary oestradiol peak in the luteal 
phase(Abraham, Swerdloff, Tulchinsky, Hopper & Odell, 1971; Mikhail, 
Wu, Ferin & Vande Wiele, 1970). 
Progesterone 
The first general indication of progesterone secretion 
came from neasurement of its urinary metabolite, pregnanediol. 
Kiopper (1957), "using a chemical method carried out the first reliable 
clinical measurements. He found that pregnanediol excretion was very 
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low throughout the follicular phase, at less than one milligram 
daily. It began to rise after ovulation, reaching a peak of between 
2 and 5 mg. daily at about day 21 of the cycle. Level. - then fell 
several days before menstruation and continued to decline for a few 
days after its onset. Klopper (1957) pointed out the wide variability 
in the levels of pregnanediol in the luteal peak. 
Plasma progesterone was found to follow the same pattern 
as its urinary metabolite, with tenfold increases in the luteal 
compared to the follicular phases, when double isotope or electron 
capture GLC methods were used (see p. 58). 
The development of competitive protein binding assays 
and RIA enabled repetitive sampling of plasma throughout the cycle 
(Neill, Johansson, Datta & Knobil, 1967; Yoshiiui & Lipsett, 1968), 
where the same pattern was seen. 
Cther Ovarian Steroids , 
Competitive protein binding (CPB) and RIA techniques have 
also been applied to the measurement of 17a-0H progesterone (Strott, 
Yoshimi, Ross & Lipsett, 1969; Abraham, Swerdloff, Tulchinsky, Hopper 
& Odell, 1971). This progestogen shows a rise parallel-to progesterone 
in the luteal phase and also a midcycle peak, coinciding with the LH 
peak. 
Plasma pregnenolone shows a slight tendency to rise in 
the luteal phase but this only becomes a significant difference when 
values are pcoled for six subjects (Abraham, Buster, Kyle, Corrale & 
Teller, 1973). Pregnenolone is the precursor for both the ovarian 
and the adrenal cortical steroids, co it is possible that the ovarian 
pattern may be masked by metabolism occurring in the adrenal (see Fig 6.1) 
Another progestogen studied is 2OX-dihydroprogesterono. 
While the values for this steroid and progesterone are about the same 
in the follicular phase (less than 2 ng/ml) and they both reach a 
1s 
peal; in the luteal phase, the lutoal values for 20 a-dihydro- 
progesterone are about one fifth of those of progesterone (Florensa, 
Sommerville, Harrison, Johnson & Youssefnajadian, 1976). 
iiormor_a"! relationships in the control of ovulation 
An integration of all the hormonal events of the cycle 
was finally accomplished in the early 1970s by daily measurements 
of aLL the hormonal components in individual women. The lengths 
of the cyci^7 have been standardised using the day of the LH peak as 
day U. Studies were carried out by Ross, Cargille, Lipsett, Rayfcrd, 
Marshall, Struct & Rodbard (1970) in 16 cycles, by Dyrenfurth, 
Jewelewicz, Warren, Ferin & Vande Wiele (1974) for 40 cycles and by 
MiEhell, Nakamura, Crosigneni, Stone, Kharma, Nagata & Thorneycroft 
(1971) for 10 cycles. 
An example of the composite pattern is shown in Fig-1.1. 
From these composite graphs events leading up to ovulation can be 
clearly seen. From the onset of bleeding FSH levels are raised 
while oestradiol is very low, until about day 7. During the following 
week or so the oestrogens rise slowly and then rapidly, reaching a 
midcycle peak, while FSH declines. - Thus FSH is the trophic hormone 
leading to develcpment of the follicles while oestradiol inhibits 
FSH secretion by negative feedback. 
The oestradiol pe. lc at ridcycle occurs marginally before 
the gonadotrophin peaks, and it appears that the oestradiol peak 
triggers a surge of LH and a smaller surge of FSH. It appears that 
changes in gonad:, trophin secretion are brought about by changes in 
pituitary responsiveness to LRF (Nillius, Friberg & Wide, 1973). 
Exogenous oestrogens have been shown to enhance pituitary sensitivity 
to ? LRH (Shaw, Butt & London, 1975). This rather complex action of 
oestrogens on gonadotrephin release, with negative and then positive 
feedback, has been demonstrated experimentally in ovariectomised 
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Figure 1.1. Profiles of serum LH, FSII, progesterone (prog) and 
oestradiol (E2) during ten ovulatory cycles. The day of the LIi 
maximum value is the'reference day. (From Mishell eta., 1971) 
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Once the LH r-ak occurs, ovulation follows (Yussman & Tayrnor, 1970) 
and a corpus luteum is formed, which produces progesterone, and to a 
lesser extent oestrogens and other progestogens. The role of 
progesterone in the IH surge is controversial. There is evidence 
that progesterone starts to rise 16 hours before ovulation (Yussman 
& Taymor, 1970), but that the LH peak precedes the rise in progesterone- 
by 12 hours (Johansson & Wide, 1969). However there is a recent 
indication using RIA that a modest rise in progesterone occurs a day 
or two before the LII peak (Florensa et al,, 1976). This suggests that 
progesterone is secreted by the Graafian follicle or other ovarian 
tissue before the LH peak and there is some indication that this 
progesterone may augment pituitary responsiveness to LRF (Nillius & 
Wide, 1976). 
During the week after the LH peak steroid production by 
the corpus luteum increases, reaching a peak and then declining 
during the second postovulatory week, Unfortunately the exact 
temporal relationship of the decline in steroid secretion and the 
onset of menses cannot be determined from these composite cycles. 
This is due to practice of taking the LH peak as the reference point. 
However in papers where hormones from individuals are shown, (Abraham 
et al., 1971a; Dyrenfurth et al., 1974), it appears that both progesterone 
and oestradiol are very low at menstruation, although Yoshimi & Lipsett 
(1968) noted that in 2 out of 3 of their subjects, progesterone was 
still elevated at the onset of menses. 
Many luteolytic and luteotrophic substances have been 
found in animals (Short, 1964) but in humans the situation is less 
clear. The gonadotrophins are very low in the luteal phase, 
suggesting that the corpus luteum is independent of the pituitary, 
yet hypophysectcmised women require small amounts of LH to maintain 
corpus luteal function (Vande Wiele, Bogumil, Dyrenfurth, Ferin, 
Jewelewicz, Warren, Rizkallah & Mikhail, 1970). Similarly if 11CG 
__ __ _____ ____ _ ____ .. __. _ ,. _ .... . _. .... _.,.,...... , .... wý... ý......,........... ..,........ ý .. 
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is administered during the luteal phase the production of progesterone 
is increased in normal women (Strott et al., 1969). 
The cycle starts again as the corpus luteum regresses, 
the menses occur, and FSH levels begin to rise. This effect is, again, 
not clearly seen in composite cycles but can be seen in individualo 
(Abraham et al., 19714- 
Thus a very complex and precise control is shown in the 
normal menstrual cycle, but it should be emphasised that considerable 
variations occur in individual hormone patterns without apparent 
pathology. It appears that rapid cycles o1' hormone release are 
superimposed onto the much longer menstrual cycle. For instance LU 
hasa pulsatile secretion with a periodicity of 90 minutes and 
oestrogens affect the amplitude of these pulses (Yen, Vandenberg, 
Tsai & Parker, 1974). 
Thus the control of ovulation can be seen as continuous 
adjustment of rapid fluctuations, probably with external factors 
acting via the CNS to alter pulsatile secretions from the pituitary. 
The role of the hypothalamic monoarnines in pituitary function has been 
studied in the rat and other animals. Although the evidence is 
inconclusive, it appears that dopaminergic pathways are inhibitory 
while pathways involving serotonin stimulate gonadotrophin release 
(for review see Smythe, 1977). In human subjects serum LH levels are 
significantly suppressed after the infusion of dopamine (Leblanc, 
Lachelin, Abu-Fadil & Yen, 1976). 
Another group of compounds with possible effects on 
gonadotrophin release are the prostaglandins, since in rats 
prostaglandin E2 can stimulate LH release(Harms, Ojeda & McCann, 1973)" 
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ýýýý The renin-andiotensin-aldosterone system 
There is evidence that the mineralocorticoid aldosterono, 
k 
which is produced by the adrenal cortex, also has a cyclical pattern of 
secretion. The major role of aldosterone is to maintain sodium homdeo- 
stasis, and the mechanism whereby sodium depletion activates aldosterono 
secretion is mediated by factors such as renin substrate, renin enzyme, 
which occurs in the kidney, and angiotensin II. 
Reich (1962) first looked at urinary levels of aldosterono 
in six won en and found that a characteristic excretory pattern occurred. 
Although variation between individuals was very great, increased aldostorone 
excretion was seen at the midcyclef and a second peak was noted at one to 
five days before menstruation. 
A study of aldosterone secretion rates was carried out by 
Gray, Strausfeld, Watanabe, Sims & Solomon (1968). They compared the mid- 
follicular and mid-luteal secretion rates and found a twofold increase in 
the second half of the cycle. Sundsfjord & Aakvaag (1972) obtained similar 
results for the urinary excretion of aldosterone and they also found 
increased plasma reuin activity in the second half of the cycle. They did 
not find any significant change in plasma renin substrate. 
Studies of plasma aldosterone levels were undertaken when radio- 
immunoassay methods became available. Blood samples from supine patients on 
controlled diets were taken throughout the cycle in several studies (Katz 
I 
& Rosafh, 1972, Michelakis, Yoshida & Dormois, 1975). In both theso papers 
a cyclical pattern is seen with higher values in the luteal phase but no 
clear-cut preovulatory peak. In a recent paper, however, Frölich, Brand, 
& van Hall (1976) studied non-fasting ambulant patients and found an additional 
peak of plasma aldosterone on the day prior to ovulation, w; iich is in 
agreement with an earlier study - of aldosteron,, x ". plasma levels 
(Sundsfjord & Aakvaag, 1973). 
The factors underlying the cyclical changes in the renin- 
angiotensin-aldosterone (RAA)'system are not yet understood. Possible 
23 
direct mechanisms include an increase in glomerular filtration rate, 
or an exaggeration of the diurnal translocation of fluid which occurs 
on the assumption of upright posture. The first suggestion is unlikely 
since Gray et al. (1968) could find no increase in creatinine clearance 
during the secretory phase peak of aldosterone. The second idea has not 
been fully resolved in this context, although an interesting study was 
carried out by Edwards & Bayliss (1973). They measured water and 
electrolyte excretion in the menstrual cycle and found no differenoo 
throughout the cycle in supine women. However, on tilting the subjectu 
upright they found decreased urine volume, sodium and potassium 
excretion, and this effect was enhanced in the luteal phase. They 
speculate that the changes with posture were due to an alteration in 
proximal tubular function, an effect which would be heightened in tho 
luteal phase. However differences in proximal tubular function do not 
account at present for all the cyclical changes seen, since Katz &'Romfh 
(1972) and Michelakis et al (1975) found tL luteal. increase in. ** 
plasma aldosterone even in supine women. The effect of posture is not 
fully understood and requires further work. 
Other components of the RAA system have been studied. Katz 
& Romfh (1972) found that while plasma aldosterone and renin activity 
fluctuated in parallel, there was no cyclical pattern of renin substrate 
concentration. This is in agreement with Sundsfjord & Aakvaag (1972). 
There is also evidence that plasma angiotensin II is elevated in the 
second half of the cycle (Sundsfjord & Aakvaag, 1970). 
Thus it appears that the increase in aldosterono is brought 
about by increased renal production of renin, at least in part. It is 
possible that the cyclical pattern of the steroids oestradiol and 
progesterone may be responsible for this. It has been shown that the 
luteal rise in aldosterone is abolished in women taking oral contraceptives 
(Gray et al, 1968) and in women judged to have luteal failure (Sundsfjord 
& Aakvaag; 1972). 
___ 
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The role of the oestrogens is uncertain. Sundsfjord & 
Aakvaag (1972) studied the hormones of women with normal cycles and 
those with luteal failure. In the latter the luteal peak of progesterone 
was abolished, with progesterornvalues of 3ng /ml or less, but oestrogen 
levels in the luteal phase of these women were the same as the normal 
group. However, they found that the luteal peak of aldosterone was also 
abolished. They concluded from this that the oestrogens are not 
responsible for the premenstrual changes in thA RAA system. Laidlaw, 
Ruse & Gornall (1962) had earlier found that physiological doses of 
oestrogens had no effect on aldosterone excretion. 
Yet other workers have shown that ethinyloestradiol increases 
aldosterone excretion (Crane & Harris, 1969), and renin activity 
(Kaulhausen, Muhlbauer, Beck & Breuer, 1974), both of which rise in 
parallel with oestradiol in the luteal phase. However ethinyl osstradiol 
also increases plasma renin substrate, (Pallas, Holzwarth, Stern & Lucas, 
1977) and this does not alter cyclically. Perhaps there are nonparallel 
effects in different parts of the RAA system. In addition the effect of 
synthetic oestrogens such as ethinyl oestradiol must be interpreted with 
caution. 
The role of progesterone is more car-cat. Progesterone has 
natriuretic effects in man at physiological doses and inhibits aldostcrono 
at the renal level. This leads to increased aldosterone secretion which 
will overcome the natriuresis after 3 to 8 days. (Landau, 1913). Sundsfjord 
& Aakvaag (1972) considered that the luteal peak of aldosterone was 
abolished in their luteal failure group as a direct result of the low 
progesterone values. In studies of the effects of progesterone, Laidlaw 
et al (1962) found that physiological doses of progesterone increased 
aldosterone excretion, while Oelkers, Schöneshöfer & Blumel (1974) found 
an increase in plasma renin activity, plasma angiotensin II, and aldosterone 
excretion, but plasma renin substrate concentration remained unchanged 
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Tius the luteal peak of progesterone may fully account for 
the changeL seen in the RAA system at that time. Since no consistent 
changes occur in urine volume, sodium and potassium excretion in the 
luteal phase (Gray et al. 1968), it appears that in most circumstances 
the diuresis and natriuresis brought about by progesterone is compensated 
for by the salt-retaining effect of increased aldosterone secretion. 
However Gray et al (1968) could find no consistent relationship 
between secretion of aldosterone and urinary pregnanediol, in contrast 
to the findings of Jones, Lloyd-Jones, Riondel, Tait, Tait, Buibrook 
& Greenwood (1959) who obtained a good correlation in pregnancy. The 
work of Gray et al (1968) has been criticised on the grounds that the 
salt intake of all the subjects was not controlled (Landau, 1973). 
1.1.3. Prolactin 
In animals serum prolactin follows a marked pattern of 
secretion throughout the oestrus cycle (Neill & Reichart, 1971). In 
women, prolactin has been measured throughout the cycle by several 
investigators but no agreement has been reached as to whether a 
cyclical pattern exists. 
McNeilly & Chard (1974) took daily blood samples from eight 
women with regular cycles, and they also studied the variability of 
prolactin at 15 minute intervals at different stages of the cycle. They 
found-a --mall but nonsignificant rise in serum prolactin at midcycle,, 
associated with the peaks of LH and FSH. They could find no relation- 
ship between prolactin and oestradiol or progesterone. They noted that 
serum prolactin showed considerable fluctuations, apparently at random, 
and also considerable differences between individuals. Other workers have 
found similar results but with increased luteal levels (Franchimont, 
Dourcy, Legros, Reuter, Vrindts-Gevaert, Van Cauwenberger & Gaspard, l976). 
Vekemans, Delvoye, L'Hermite & Robyn (1977) studied serum prolactin in 
34 cycles and found a progressive increase in serum prolactin during the 
follicular phase to reach a peak at the same time as LH. A second peak 
of prolactin was seen in the luteal phase. They studied an additional 17 
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cycles using a slightly different assay method and obtained slightly 
different results, with a sharper peak at ovulation and a less pronounced 
luteal rise. Unfortunately it is impossible to say whether this 
discrepancy is due to true differences in the method or between the two 
groups of women. 
These papers serve to show the difficulties in obtaining 
definitive results for prolactin, especially in view of the extreme 
lability of the hormone (Robyn, Delvoye, Nokin, Vekemans, Badawi, Perez- 
Lopez & L'Hermite, 1973) and the effect of non-specific factors such as 
stress (Noel, Suh & Frantz, 1971). Vekemans et al (1977) found that 
differences between stages of the cycle were quite small, with only a 
50% increase at the most from early follicular levels, yet random changes 
in one day may be as great as 110% (McNeilly & Chard, 1974). Therefore it 
is difficult to see what role serum prolactin may play in the events of 
the menstrual cycle. 
Indeed, when prolactin secretion is suppressed by bromocryptine, 
a specific inhibitor, no effect is seen on LH, oestradiol, or progesterone 
in normal women (del Pozo, Goldstein, Friesen, Brun del Re & Eppenberger, 
1975). Conversely, some cases of high prolactin levels lead to anovulation 
and amenorrhoea, and this is now well documented (Besser, Parke, Edwards, 
Forsyth & McNeilly, 1972; Pepperall, Evans, Brown, Smith, Healy & Burger, 
1977). It has been shown that high prolactin levels abolish the pulsatile 
secretion of LH, suggesting that prolactin is acting at the hypothalamic 
or pituitary level (Bohret. Dahlen & Schneider, 1974). 
Although prolactin at normal physiological levels does not 
appear to influence ovulation, there is a possible role at the local level 
of the Graafian follicle. McNatty, Sawers & McNeilly (1974) studied human 
granulosa cells in culture. The cells were cultured for up to 14 days and 
progesterone production was studied after prolactin was added to the medium. 
Prolactin concentrations of up to 20ng/ml permitted increasing progesterone 
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synthesis but above this progesterone secretion was inhibited. They also 
found that endogenous prolactin levels were lowest in the follicles in the 
late follicular and early luteal phase. 
The changing hormones of the menstrual cycle may in turn 
influence prolactin secretion. It has been shown by Robyn et al (1973) 
that high doses of exogenous oestradiol lead to increased serum prolactin 
in normal women. The administration of progestogens had no effect. 
1.1. i. Other hormones 
It has recently been shown by Frölich et al (1976) that the 
serum levels of dehydroepiandrosterone do not show a well defined cyclical 
pattern. However androstenedione, testosterone and aetiocholanolone levels 
are raised during the ovulatory phase (3 days before ovulation until 4 days 
after). 
There is a statistical difference in plasma cortisol con- 
centrations between the first and second halves of the cycle, with lower 
values at day 24 compared to day 10 (Beck, Morcos, Fawcett, & Watanabe, 
1972). However this only holds true for morning levels of cortisol. West, 
Mahajan, Chavre, Nabors & Tyler (1973) could find no cyclic variation in 
cortisol levels. 
No consistent changes have been reported for the protein 
hormones such as thyroxine (Weeke & Hansen, 1975), although fasting blood 
sugar and glucose tolerance are altered at menstruation (Southam & Gonzaga, 
1965). A recent study (Saxena, Dusitsin, & Lazarus, 1974) could find no 
cyclical pattern for human growth hormone, thyroid stimulating hormone, or 
cortisol in Thai women. 
1.1.5 Catecholamines 
Another interesting group of substances are the catecholamines 
such as adrenaline, noradrenaline anddopamine (which is also prolactin 
inhibitory factor). Although there is little direct evidence that these 
neurohormones themselves vary throughout human menstrual cycles, there is 
indirect evidence from metabolic pathways. 
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The monoamine oxidases are enzymes involved in the 
degradation of the biologically active amines such as 5-hydroxytryptamine 
(5HT) and dopamine. 
Holzbauer & Youdim (1973) studied MAO activity in the rat 
uterus, ovaries, adrenals, and in four regions of the brain, and found 
higher values at diestrus than at metestrus or estrus. In humans, it 
has been shown that cyclical variations occur in endometrial MAO (South- 
gate, Grant, Pollard, Pryse-Davies & Sandler, 1968), with higher Levels 
in the late secretory phase. This suggests that MAO activity may be 
hormonally dependent. Yet in a study of platelet and plasma MAO (Gilmore, 
Robinson, Nies, Sylvester & Ravaris, 1971) no significant difference was 
found between midcycle and premenstrual values. A more recent paper 
(Belmaker, Murphy, Wyatt & Loriaux, 1974) has found that a cyclical pattern 
in platelet MAO does exist, with a decline in the luteal phase. In 
contrast, Klaiber, Kobayashi, Broverman & Hall (1971) found an increase in 
plasma MAO in the luteal phase. Platelet and plasma MAOs appear to be 
distinct proteins, with different responses to inhibitors (Robinson, Lovenberg, 
Keiser & Sjoerdsma, 1968). 
1.2 PHYSIOLOGICAL CHANGES IN THE CYCLE 
The best known event occurring cyclically is the increase 
.n basal body temperature which is seen after ovulation and is a fairly 
reliable indication of progesterone secretion by the corpus luteum (Ross 
of al, 1970). 
There is a significant rise in heart rate and respiration rate 
and a fall in sweat gland activity in the luteal phase (Little & Zahn, 1974). 
These changes may be associated with the rise in body temperature and 
ultimately with the thermogenic effect of progesterone, which has been known 
for many years (Barton & Wiesner, 1945). 
Abramson & Torghele (1961) also found a consistent positive 
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relationship between temperature and daily body weight in a study of 
34 self-selected students. They found peaks in weight at around the 
early follicular (days 3-6) ovulation (days 13-15) and the premenstrual 
phase (days 24-26) and variations of up to 10 pounds were seen. In 
a similar study Golub, Menduke & Conly (1965) could find only negligible 
weight gain in the cycle (less than one pound) and this occurred post- 
menstrually. The differences in these two papers may partly reflect 
the different methods used by these authors to standardise the length 
and stages of the menstrual cycle. 
In a controlled study using psychiatric in-patients 
complaining of premenstrual tension Bruce & Russell (1962) could find 
no weight gain if the patients were on an uncontrolled diet. However, 
in a metabolic ward where diet was controlled, a slight weight gain 
(less than 500 grams) was seen in the last five days of the cycle beforo 
menstruation, and a sharp rise in weight occurred 'at ovulation. 
Water and electrolyte excretion has been measured in both 
the follicular and luteal phase of the cycle in subjects undergoing 
prolonged diuresis (Edwards & Bayliss, 1973). They found no difference 
when patients were supine but statistical differences occurred in up- 
right patients, with lower urine volume and'electrolyte excretion in 
the luteal phase. Gray et al (1968) could find no change in total body 
water, serum sodium and the sodium/potassium ratio in ambulant subjects, 
and this has been confirmed by Michelakis, Stant & Brill (1971) in 
patients with constant salt intake. 
There is some evidence that human uterine fluid potassium is 
increased in the luteal. phase (Clemetson, Kim, de Jesus, Mallikarjuneswara, 
& Wilds, 1973), and this may be an indication of other tissue changes 
pertinent to the problem of cyclical oedema. However, the uterus may be a 
special case since it is a target tissue for the ovarian steroids. While 
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there are changes in prostaglandin levels in the endometrium, reports 
vary as to whether a cyclical pattern exists in blood (Karim & Hillier, 
1975). 
Premenstrual hyperemia of the breasts has been noted for 
many years (Taylor, 19-19) and increase in breast volume also occurs 
in the second half of the cycle (Milligan, Drife & Short, 1975), which 
may have some bearing on premenstrual breast discomfort. There is also 
a report that progesterone causes smooth muscle relaxation, in ureter, 
bowel and stomach (Kumar, 1962), and this may be related to abdominal 
bloatedness, which may be due to the laxity of the anterior abdominal 
wall (Dalton, 1977). 
Many other changes occur in blood properties which are 
related probably to menstruation itself (such as erythrocyte count)and 
the review of Southam & Gonzaga (1965) is still the most extensive account 
of these and other changes. 
1.3. BEHAVIOURAL CHANGES IN THE CYCLE 
The psychophysiology of the menstrual cycle has been studied 
in many different ways, from the point of view of neurobiologista, 
psychologists, and psychiatrists. 
Possibly the most basic approach has been to study cyclic-. 
dependent alterations in electroencephalogram (EE73). Early studies 
showed a slowing effect on the EEG during the premenotrual period. This 
has been confirmed recently by Wuttke, Arnold, Becker, Creutzfeldt, 
Langenstein & Tirsch (1975) who found frequency changes in thee(-band but 
not in the bands which usually indicate abnormality. 
Physiologists have studied changes in the autonomic nervous 
system (ANS). 
Activation of the ANS is traditionally associated with states 
of tension and anxiety. Research in this field has concentrated on changes 
in heart rate, respiration rate, skin potential and sweat gland activity. 
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The only consistent changes found are those which reflect the luteal 
rise in body temperature, such as a rise in heart and respiration rate 
(Little & Zahn, 1974). These authors also found a greater degree of 
autonomic activity at ovulation, coinciding with a greater feeling of 
elation and vigour in their subjects. 
A third approach has been to study psychomotor tasks and work 
performance in the cycle, with a view to social and economic aspects. 
Dalton (1960) reported a decrease in work performance in 27% of school- 
girls premenstrually, although 17% also showed improvement. Pierson & 
Lockhart (1963) studied simple reaction time and speed of arm movement 
and could find no differences at various stages of the cycle. Redgrove 
(1971) looked at work performance of punch card operators and typists' 
and she could find no differences in either group apart from a slight 
increase in output by two out of three typists in the late premenstruum. 
Another group of studies have described cyclical correlations, 
that is the relationship between the phase of the dycle and the 
occurrence of specific events. Correlations have bben reported between 
premenstrual and menstrual phases and suicide or attempted suicide 
(Ribeiro, 1962; Mandell & Mandell, 1967), admission to a hospital with 
acute psychiatric illness(Janowsky, Gornay, Castelnuovo-Tedesco & Stone, 
1969) and accidents (MacKinnon & MacKinnon, 1956). But it has been 
pointed out by Parlee (1973) that some cyclical correlations are citations 
of early work which is anecdotal. For instances an anecdotal report of three 
crashes by menstruating women airline pilots (Whitehead, 1934) is often 
cited as an example of a cyclical correlation (Moos, 1968: Dalton, 1964). 
In summary, the work on autonomic nervous activity and work perform- 
ance in the cycle is rather incomplete in some cases and the relevance to 
the study of mood and behaviour is unknown. Similarly the cyclical 
correlations present problems in interpretation, since it is difficult to 
know how far they can be generalised to all women. However by far the 
largest group of publications have studied mood disorder, and these are 
described in the next section. 
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2. THE PREMENSTRUAL SYNDROME 
The first report in the medical literature was by Frank 
(1931) who noted "rare and unpleasant" symptoms in the premenstrual 
phase of the cycle. One or two striking cases were noted in the 
literature, such as premenstrual weight gain of 12 to 14 pounds 
(Thomas, 1933). The first indication that premenstrual symptoms might be 
more common came from Stieglitz & Kimble (1949) and Morton (1950). 
Stieglitz & Kimble studied 67 women with complaints of some premenstrual 
discomfort and found that a majority suffered from emotional instability, 
headache, andibreast engorgement, while half complained of backache 
and abdominal swelling. Morton (1950) looked at 29 patients and found that 
all had "emotional instability", and he also mentioned increased 
appetite and lower abdominal pain as important symptoms. Oedema of 
the face, hands and ankles was first noted by Frank (1931) and 
Thomas (1933) and later by Morton (1950). 
At about this time two studies had been carried out which lo 1.6d 10 
looked at cyclical changes in small groups of women not selected for 
premenstrual symptoms. Benedek & Rubenstein (1939) used an approach by 
both psychologist and gynaecologist to study the menstrual cycle. 
Altmann, Knowles & Bull (1941) studied ten women in detail and 
found a premenstrual outburst of physical and mental activity 
coupled with high tension, irritability and depression. 
2.1. Terminology 
R. T. Frank, the first author to describe the condition in 1931, 
first used the term premenstrual tension. He described a premenstrual 
feeling of "indescribable tension" with irritability, and "a desire 
to find relief by foolish and ill-considered actions". 
This name has been criticised several times since then. 
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Greenhill & Freed (1940) suggested the term "toxaemia of 
menstruation" on account of the clinical similarity to pre- 
eclamptic toxaemia of pregnancy, which has early symptoms of 
depression, irritability, lethargy, headache, and nausea (Dalton, 
1977). 
In Britain the term premenstrual syndrome was introduced by 
Greene & Dalton (1953), and was widely adopted. However, pre- 
menstrual tension was still considered the most descriptive name 
by Lloyd (1963) since it was considered to reflect the state of 
the tissues as well as the emotions. 
A further suggestion was put forward by Sutherland & Stewart 
(1965). They preferred the terms "cyclical syndrome'' and "cyclical 
tension state",. with the former referring to the physiological 
syndrome occurring in most women, while the latter term describes 
the more severe form which might merit treatment. One reason for 
their preference of these terms is that the word "premenstrual" 
is omitted, since the complex of symptorns sometimes occurs in the 
absence of menstruation for instance at the climacteric (Greene 
& Dalton, 1953). 
The terms in common usage are either premenstrual tension or 
the premenstrual syndrome (PMS), and this last term will be used in 
the following pages. 
2.2 Symptoriatolog 
The chief symptoms experienced by PMS sufferers have been 
described by several authors and the frequency of the main symptoms 
in these patients are summarised in Table 1.1. The differences in 
frequency of the symptoms in Table T. l are probably indicative of 
differences in the terminology of the various authors, since two 
















Depression (-) (-) 60 80 64 
irritability 68. (-) 69 100 6=+ 
Lethargy (-) (-) 13 63 27 
'Emotional (-) 100 
lability' 
Breast tenderness 65 (-) 24 63 27 
Oedema (-) 45 (-) 73 36 
Headache 50 31 69 63 22 
Backache 47 
Increased appetite (-} 59 
Nausea (-) 30 C-) 37 (-) 
No. patients 67 29 84 30 120* 
* combined figures. (-) indicates that the symptom 
or term was not mentioned by the author. 
Table 1.1. Symptoms commonly reported in the literature 
for the premenstrual syndrome. 
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symptoms and feelings of oedema and breast discomfort. I 
Psychological symptoms, such as depression, irritability, 
lethargy and confusion, 'are undoubtedly the most important, 
although bloatedness of breasts and abdomen, and headaches, 
frequently occur. 
However many other symptoms-have been described in, the 
premenstrual phase, and Moos (1969) has found references to as 
many as 150 symptoms in the literature. Dalton (1977) has 
classified the wide variety of symptoms which may occur cyclically. 
There are psychological, neurological, respiratory, and 
dermatological symptoms, as well as orthopaedic disorders such as 
joint pains. Earlier workers had reported such symptoms as weight 
gain (Thomas, 1933) ulcerative stomatitis (Israel, 1938), increased 
thirst, insomnia, and nausea (Rees, 1953). In addition existing 
illnesses such as asthma, glaucoma, or epilepsy may be exacerbated 
cyclically (Dalton, 1964). 
The timing of the symptoms in relation to menstruation is an 
important question which can only be resolved properly by the use 
of prospective studies. In one such study Moos, Kopell, Melges, 
Yalom, Lunde, Clayton & Hamburg (1969) found that symptoms related 
to swelling or weight gain began to occur at 14 days before the 
period, reached a peak and stayed high for 4 days premenstrually. 
Feelings of anxiety and aggression also increased after ovulation, 
with aggression reaching a peak 9 days premenstrually while anxiety 
was highest one to two days before menstruation. It is interesting 
to note that they found no separate peak at ovulation for any of these 
symptoms in their subjects, who were women selected for both high 
and low premenstrual symptoms. 
Using retrospective questionnaires, other authors have usually 
stated that the symptoms last from seven to ten days and are usually, 
/6 
but not always, relieved at menstruation (Rees, 1953; Greene & 
Daltcn, 1953). 
2.3 Definition 
Studies of symptomatology have led several authors to try 
to define the syndrome. But faced with such a multiplicity of 
symptoms, Dalton (1977) has stated that the only common factor is 
the cyclical recurrence of disease with each menstrual cycle. The 
came conclusion was reached by Sutherland & Stewart (1965). Perhaps 
a more useful working definition was provided by Kessel & Coppen 
(1963) (see below), using epidemiological methods. They found a 
cluster of. symptoms which were depression, irritability, tension, 
swelling and headache, which were maximal one to two days before 
menstruation. The feelings of swelling occurred in the breast 
(80%), abdomen (50%), feet and ankles (10%), and areas such as 
face, neck and fingers in a negligible number of women. 
These symptoms closely resemble the clinical observations of 
Rees (1953) and Greene and Dalton (1953). In a recent study in 
this Department (Kerr, 1977; Taylor, 1977) of 120 women the syndrome 
was characterised by mental symptoms (70%) usually of depression or 
irritability or both while bloatedness, breast tenderness, headaches 
and lack of coordination occurred in 20 to 30% of patients (see 
Table 1.1). 
2.4 Epidemiology 
The premenstrual syndrome has been studied quite extensively 
since the 1950's. The studies have fallen into groups, where either 
whole populations or selected groups of patients have been studied. 
The former studies have helped to answer questions about the prevalence 
of the syndrome amongst all women. An early estimate was supplied 
by Bickers & Woods (1951) who found that 36% of all women in one 
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American factory applied for treatment in the premenstrual phase. 
In a well controlled and now classic study Kessel &'Coppen 
(1963) set out to look at the prevalence of premenstrual symptoms 
in British women sampled from general practices throughout Britain. 
465 women were asked in retrospect about their symptoms by postal 
questionnaire. It was found that one in nine women reported severe 
pain, irritability or headaches before or during menstruation, while 
four out of five reported some swelling. A cluster of symptoms was 
found, of irritability, depression, tension, headache, and body 
swelling, all of which were maximal one or more days before menstruation, 
and this cluster occurred to a moderate or severe extent in one in 
four women. 
These authors also found that dysmenorrhoea were present in 45% 
of all women but that those with the cluster of premenstrual symptoms 
developed pain before rather than during the menses. Thus one form 
of period pain is present with PMS, while true dysmenorrhoea occurs 
separately. 
Sutherland & Stewart (1965) studied 150 students and nurses by 
retrospective questionnaire and they found that 66% experienced some 
dysmenorrhoea and 70% experienced cyclical al: in eruptions. These 
high figures may be due to the young age group of their subjects (mean 
age 21). They also found'that about 65% of the women experienced 
depression. irritability and body swelling premenstrually. These 
three symptoms occurred together in 3956 of their sample. 
Estimates of the prevalence of the premenstrual syndrome, 
as opposed to individual symptoms, varies widely in the literature 
due to the difficulties of definition of the syndrome. 
Although figures as highs 95% have been quoted (Pennington, 
1957) there is general agreement that the cluster of emotional and 
physical symptoms usually defined as PMS occur to a marked degree in 
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30 to 40% of women (Kessel & Coppen, 1963; Dalton, 1977). 
The epidemiological approach is used in the study of the 
aetiology of many diseases, and may be helpful in the understanding 
of PMS. Dalton (1977) has noted that the syndrome tends to occur 
more frequently in women in their thirties and forties. She also 
notes that FMS is associated with high parity, indicating perhaps 
that childbirth is a precipitating factor, although parity is also 
related to age, so that it is difficult to state with certainty 
that it is associated with PMS. Another observation by Dalton 
(1964) is that PMS may persist after hysterectomy, ovariectomy, 
adrenalectomy or the menopause. However very few authors have 
studied these factors quantitatively. In one prospective study I 
(Boumont, Richards & Gelder, 1975) it was found that premenstrual 
symptoms persisted after hysterectomy,. but occurred to a lesser 
extent. 
A large amount of work has been carried out on the effects of 
oral contraceptives on PMS. While there is some evidence that women 
experience less PMS-while on the pill (Royal College General 
Practitioners, 1974) it also appears that PMS may be more frequent 
in past users of the pill (Kutner &. Brown, 1972). There also appears 
to be an increased incidence of PMS after pre-eclamptic toxaemia 
(Dalton, 19,77). 
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2. THEORIES REGARDING THE AETIOLOGY OF THE PREMENSTRUAL SYNDROME 
Frank (1931) postulated that a rise in "female sex 
hormone" (oestrogen) might be responsible for premenstrual tension. 
He irradiated the ovaries of his patients and the symptoms were 
relieved. Since that time many treatments have been employed, 
including progesterone, progestogens, diuretics, androgens, vitamins, 
lithium and tranquillizers. Some of these Treatments have been used 
empirically and success has been claimed in most cases, but in the 
few controlled studies carried out a very high placebo effect has 
been noted (Jordheim, 1972; Matteson & Van Schoultz, 1974). There- 
fore apart from some very recent studies on bromocryptine, studies 
of treatments have not been very informative and they will not be 
considered in detail in the following review. 
Before any connection can be made between any hormones 
and PMS, it must be established firstly, that specific biochemical 
changes may lead to behavioural change, and secondly, that these 
biochemical changes may be brought about directly or indirectly by 
one of the hormonal changes in the cycle. 
A great deal cf attention has been paid to the monoaminos 
and the effect of various drugs on peripheral nerve function. 
Unfortunately less is known about the central nervous system since 
by its very nature direct measurement is difficult. 
There is indirect evidence that the central monoamines 
may be deficient in depression. The drug reserpine, which depletes 
the brain of monoamines, causes depression and another group of drugs, 
the monoamine oxidase inhibitors, prevent the degradation of the 
central monoamines, and these are sometimes successful in the treatment 
of depression (Pare & Sandler, 1959). The study of cerebrospinal fluid 
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(CSF) is the closest yet reached to the study of changes in the 
human brain and it has been demonstrated that depressives have lower 
CSF concentrations of indoleamines such as 5-hydroxytryptamine (5-lIT) 
than non-depressed patients (Ashcroft, Crawford, Eccleston, Sharman, 
MacDougall, Stanton & Binns, 1966). Although it is still believed 
Uit amines are involved in depression, more recent work indicates that 
the relationship between depression and biogenic amines in the CSF 
is not straightforward (Pullar, 1973) and it is postulated that other 
factors such as receptor sensitivity are involved (Shaw, Riley, 
Tidmarsh & Blazek, 1976 ; Green, 1978). 
It is an attractive idea to relate the changes in PMS to 
changes in the central amines, although there is little evidence to 
support this. Grant & Pryse-Davies (1968) found that the cyclic 
pattern of MAO in the endometrium is abolished in women taking the 
combined progestogen-oestrogen contraceptive pill and these pills are 
also responsible for a reduction in mood swings. 
This is not of course evidence of a causative relationship. 
In a recent study Feine, Belmaker, Rimon & Ebstein (1977) looked at 
platelet MAO in women with PMS. They could find no cyclical change in a 
PMS group but in an earlier paper (Belmaker et al 1974) thece workers 
found a marked cyclical pattern in a group of asymptomatic women. 
However the two papers are not strictly comparable. 
Despite this lack of understanding of the central effects 
in PMS, several theories of aetiology have been put forward and these 
are considered below. 
3.1. The possible role of ovarian steroids 
Since the first suggestion by Frank (1931) that oestrogens 
might be a factor in PMS, attention has focussed on the ovarian steroids, 
especially the two most important steroids of the corpus luteum, 
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progesterone and oestradiol. Authors in early papers studied these 
hormones using indirect clinical means. Israel (1938) thought that 
PMS was caused not by an excess of circulating oestrogen but by a lack 
of antagonism by progesterone. He found that a majority of his patients 
had an abnormal secretory phase as indicated by endometrial biopsy, 
indicating a relative deficiency of progesterone, although he could 
not understand why PMw was not seen in anovular cycles. 
Morton (1950) found a monophasic temperature curve in 
23 of his 29 PMS patients and endometrial biopsy and vaginal smears 
suggested an excess of oestrogen to progesterone, with evidence of 
diminished luteal activity. He also gave oestrogens to two ovariecto- 
raised and one postmenopausal woman, who then suffered painful breasts, 
abdominal bloating, weight gain and "nervous tension". The general 
belief that the ratio of progesterone to oestrogen is low in PMS 
has been widely supported (Rees, 1953; Greene & Dalton, 1953). The 
support of the last two groups for. this idea came largely from the 
success in treating PMS with progesterone injections or suppositories, 
although the placebo effect was not determined. Rees (1953) did however 
compare the effects of diuretic, progesterone, progestogen and androgen, 
and he found that progesterone, progestogen, and androgen were effective 
in alleviating physical and mental symptoms. He explained these 
results in terms of antagonism towards oestrogens, since both the 
progestogen (ethisterone) and the androgen (testosterone) are diuretic 
and antag ristic to oestrogens. He thought that oestrogens might cause 
PMS symptoms such as breast changes, water retention, and possibly 
hypoglycaemia and increased glucose tolerance. 
More-direct evidence regarding the role of the ovarian 
steroids has come in recent years from studies of hormone plasma 
concentrations. Loraine & Bell (1971), could find no abnormality in 
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the excretion of pregnanediol by six women with PMMS. 
Adamoupoulos, Loraine, Lunn, Coppen & Daly (1972) 
also looked at urinary steroid levels in a group of 15 women with 
PMS. They found that seven out of fifteen cycles were apparently 
anovulatory, as pregnanediol levels were very low in the second half 
of the cycle. However urinary gonadotrophins and oestrogens were 
not markedly altered. These authors concluded that, as the symptoms 
were still present in these anovulatory cycles, progesterone per se 
was not the cause of PMS, and neither was the renin-angiotensin- 
aldosterone system likely to be involved as this does not have a 
cyclical pattern in anovulatory cycles. These results seem rather 
strange in that later studies of plasma steroids, described below, 
have not recorded anovulatory cycles. Also some plasma studies have 
recorded raised oestrogen levels in PMS (see below). However in 
another urinary study (Prill & Krüger, 1963) no difference was found 
in urinary oestrogen levels in women with PMS. It could be that. 
the plasma oestrogen differences are so small that they are not 
likely to be detectable in urinary excretion rates, since the latter 
reflect clearance rates as well as secretion. A more sophisticated 
approach was taken by Blckström & Carstensen (1974), who measured 
hormones in blood. 
These authors compared daily plasma levels of steroids in 
the last six days of the cycle from eight women with no symptoms and 
ten women with premenstrual symptoms of anxiety and irritability. 
They found that progesterone levels at one to three days before 
menstruation were the same in both groups but at 4-6 days premenstrually 
levels were significantly lower in the PMS group. Oestrogen levels 
were significantly higher in the PMS group in the two to five days 
before menstruation, resulting in a higher oestrogen/progosterone 
ratio at days 3 to 6 premenstrually. 
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In a further study BHckstrdm, Wide, Sdderg&rd & 
Carstensen (19766) looked at progesterone, oestrogens, FSH, LH 
and sex-hormone-binding globulin in the last ten days of the 
cycle and they found that at days 4 to 10 premenstrually both 
progesterone and oestrogens were low in a small group of women 
with PMS. However the oestrogen values rose to a peak above 
controls 4 days premenstrually while progesterone continued to 
be low. There were no differences in LH values or in levels of 
sex-hormone-binding globulin in the two groups. But FSH levels 
were higher in the PMS group 6 to 9 days premenstrually, then 
falling to control levels. Two other brief reports have appeared 
regarding ovarian steroids and PMS, although no details are 
supplied about methods. Smith (1975), in a study of premenstrual 
depression, found lowered progesterone levels, but no difference in 
plasma oestrogens. The one contradictory finding, by O'Brien & 
Symonds (1977) was that the progesterone peak was raised in women 
with PMS compared to controls. 
It appears that the type of symptom is important, since 
further work by BHckströms group on very small numbers has indicated 
no abnormality in sex steroid ratios of women suffering with either 
headaches (Bäckstrdm & Carstensen, 1974) or feelings of swellings 
(BUckstrdm & Matteson, 1975) as their main symptom. There is also 
evidence that women with benign breast disease may have reduced 
progesterone to oestrogen ratios (Sitruk-Ware, Sterkers, Mowszowicz 
& Mauvais-Jarvis, 1977). Unfortunately these authors do not indicate 
whether the women experience any other symptoms cyclically, indeed, 
the pattern of occurrence of breast disease is not recorded. 
Thus the classification of premenstrual symptoms is an 
important factor which may confuse the endocrine picture, For instance 
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migraine is often cited as a premenstrual symptom (Dalton, 1964), 
yet in a study of 138 women with migraine only 24 had migraine 
attacks which could be related to the cycle, or menstruation 
(Epstein, Hockaday & Hockaday, 1975). Oestradiol and progesterone 
plasma levels were studied in eight of this "cyclical migraine" 
group compared to controls, and both hormones were found to be 
higher in women with cyclical migraine. It appears that migraine, 
although it may occur premenstrually or menstrually, cannot be. 
considered as a PDT.; symptom but rather as a related but separate 
disorder. 
The theory that gonadal steroids influence behaviour has 
a general grounding in the study of the role of these hormones in 
brain function in other mammals. There is now considerable evidence 
that oestradiol and progesterone accumulate in the central nervous 
system, and that they affect brain metabolism and neural function, 
and this is reviewed by BUckstrUm (1978). 
For instance, autoradiographic studies show that selective 
accumulation of radioactive oestradiol occurs in the pituitary, 
hypothalamus, pre-optic area and brain stem of rats, cats and monkeys 
(Michael, 1965). 
The cortex, subcortex, brainstem and cerebellum in the 
rat all take up radioactivity very quickly if 
3H-progesterone is 
injected, but the radioactivity is lost much more quickly from these 
areas than from the hypothalamus (Hamburg, 1966). This is not to say 
that progesterone has no functional significance in these areas, 
since the same phenomenon occurs for the potent anaesthetic preg- 
nanolone, which still exerts anaesthesia 30 minutes after 98% of the 
steroid has disappeared from the brain in mice (Holzbauer, 1976). 
There is also evidence from animals that progesterone and 
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oestradiol affect neural activity (Barraclough & Cross, 1963; 
Sawyer & Kawakami, 1961) and that they have antagonistic effects 
on electroshock seizures threshold in rats (Woolley & Timiras, 1962). 
Gonadal steroids also influence mating behaviour in rodents - and 
such behaviour correlates with the menstrual cycle in primates 
(Goy & Resko, 1972). 
However there has been very little progress in the study 
of relationships between steroids and the human brain, due to the 
practical and ethical problems of such studies. It has been shown 
that total levels of progesterone, oestradiol and testosterone in 
human plasma are closely correlated with levels in cerebrospinal 
fluid, indicating that these steroids penetrate the central nervous 
system (BUckstrtim, Carstensen & Södergärd, 1976 ä). 
Epileptic women exhibit a cyclical pattern in the number 
of seizures, with least in the luteal phase, and an increase in the 
number at menstruation when progesterone is low (Laidlaw, 1956). 
Exogenous progesterone reduces the number of seizures and oestrogens 
increase them (Morrell, 1959). It has been known for a long time 
that progesterone is also a potent anaesthetic, and this effect is 
more marked in females (Merryman, 1954). But apart from the early 
psychoanalytical studies of Benedek & Rubenstein, (1939) correlating 
behaviour with vaginal cytology, there has been no-direct study of 
human behaviour correlated with the ovarian cycle. Even in a very" 
recent, and othorwise very thorough study, a peak in human female 
sexuality was found at midcycle, but simultaneous hormone measurements 
were not carried out to determine the exact relationship (Adams, 
Ross Gold & Burt; 1978). 
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3.2 The renin-angiotensin_nldosterone erstem 
Several investigators have put forward the theory that 
an imbalance of electrolytes may be responsible for the symptoms 
of PMS, perhaps in conjunction with ovarian steroid imbalance. 
Greenhill & Freed (1941) first suggested that ovarian activity may 
influence electrolyte and water balance. Janowsky, Berens & Davis 
(1973) elaborated upon this theory, and put forward the hypothesis 
that the renin-angiotensin-aldosterone(AA) system is involved. 
They studied eleven women on a metabolic ward on a 
controlled diet over 15 cycles and they made daily evaluations of 
weight, 'negative mood', and the urinary potassium/sodium ratio 
(K/Na)". 
They found a correlation between weight gain, negative mood and the 
urinary potassium/sodium balance, all of which reached a peak in the 
last seven days of the cycle. They also noted that the peak in K/Na 
ratio occurred two days before the peaks in weight gain and negative. 
" mood, suggesting a definite time course of events. It is known that 
the K/Na ratio in urine may reflect changes in the circulating levels 
of aldosterone (Morris & Davis,. 1974). From their indirect evidence 
Janowsky et al (1973) infer that the RAA system may be involved in 
PMS. 
The findings of Janowsky et al (1973) differ from previous 
reports in that they found"a relatively small midcycle weight gain. 
In a similar controlled study Bruce & Russell (1962) found a greateg 
and more abrupt change in weight at midcycle than in the premenstruumo 
but they did find a correlation between change in weight and sodium 
and water retention in their PMS patients. 
The pattern of aldosterone excretion and also plasma levels 
occur in parallel with weight gain, with a peak at ovulation and again 
in the luteal phase (see page 22). 
47 
Perrini & Piliego (1959) found that the premenstrual 
excretion of aldosterone was increased up to threefold the post- 
menstrual in seven women with premenstrual syndrome. They also found 
a greatly increased K/Na ratio in urine in the premenstrual compared 
to the post-menstrual phases in their PMS patients. The change in 
K/Na ratio and aldosterone excretion was not seen in three non-PMS 
controls, who tended to have lower excretion of aldosterone and K/Na 
ratios at both times in the cycle. These findings regarding aldo- 
sterone excretion were confirmed by Piliego, Rossini, del Zotti & 
Scardapane(1964) who studied 15 patients and 15 controls. 
There is apparently no other direct evidence to implicate 
aldosterone, although Greenhill & Freed (1941) found that diuretics 
relieved symptoms in 34 out of 40 patients. Rees (1953) found that 
diuretics relieved bloatedness but not depression. 
Possible mechanisms causing symptoms of PMS 
Changes in the RAA system and hence electrolyte balance is 
the obvious mechanism for the bloatedness and oedema seen in PMS. Yet 
even this relationship is in doubt. Oelkers, Marsen, Molzahn, Lohmann 
& Hammerstein (1973) studied sodium, oestrogen, aldosterono and 
potassium excretion in 3 patients with premenstrual weight gain of 
more than 3 Kg. They found that sodium was retained, yet aldosterone, 
oestrogen and renin excretion tended to be low. A salt-retaining 
P. 
factor other than aldosterone (or oestrogen) was postulated. 
The emotional and psychological changes in PMS must also 
be explained. There are two possible mechanisms whereby symptoms may 
be produced. The symptoms may be caused indirectly via the retention 
of sodium or water brought about by increased aldosterone, and the 
retention of sodium or water may directly affect brain function. There 
is some evidence that the distribution of sodium and water are altered 
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in chronically depressed patients (Coppen & Shaw, 1963), and the 
distribution returns to normal when the patients recover. 
The other possibility is that changes in aldosterone 
metabolism directly affect brain function. There is no evidence for 
effects of aldosterone on brain biochemistry or function, but angio- 
tensin appears to alter animal behaviour, central neurotransmitters 
and autonomic function (Janowsky at al., 1973). 
In summary, there is little direct evidence for the 
involvement of the RAA pathway. But as already described (p. 24) 
progesterone may be. directly responsible for the luteal increase in 
plasma aldosterone, yet progesterone itself has an antialdosterone 
effect. Oestrogens, which promote salt and water retention as 
described previously, may also alter the RAA axis. Therefore it is 
possible to imagine that an altered progesterone/aldosterone ratio 
may exaggerate the effect of some component of the RAA system, 
leading to at least some of the symptoms of PMS. 
3.3 Prolactin 
Horrobin (1973) has put forward a case for considering 
prolactin as a key factor in the syndrome. He proposed that prolactin 
causes both the mental and physical changes in the cycle, and that these 
two may be independent of each other so that a woman may have the mental 
symptoms but not the physical and vice versa. He also suggested that 
the syndrome is most likely to occur in women with an erratic pattern 
of prolactin secretion in the luteal phase of the cycle. 
Some of the evidence is provided by Horrobin himself. He 
carried out a study of electrolyte balance in one PMS patient. and he 
found that water and both sodium and potassium were retained in the 
last 7 days of the cycle. Prolactin, unlike the mineralocorticoids, 
retains water and both sodium and potassium. Retention of potassium in 
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the luteal phase has also been shown by Edwards & Bayliss (1973) 
in women in the upright position, although Bruce & Russell (1962) 
could find no change in potassium balance in PMS patients. 
More direct evidence for the prolactin theory has come 
from the measurement of prolactin in serum. This was done on 4 
occasions in the last three weeks of the cycle in 28 women with PMS 
and 21 controls (Halbreich, Ben-David, Assael, & Bornstein, 1976). 
They found that throughout the menstrual cycle the mean serum prolactin 
in the FMS group was higher than the controls. They also found that 
the average individual increase in the prolactin in the premenstrual 
period was higher in women with PMS. Despite great variability among 
the subjects, these differences were statistically significant. 
Halbreich et al (1976) may thus shed light on the controversy 
over whether a premenstrual rise in prolactin occurs (see section 
1.1.3) by the fact that previous samples of women were not classified 
by their PMS status. 
Further information about the role of prolaetin in PM 
has been obtained from the study of the effects of bromocryptine, which 
suppresses prolactin secretion by a direct action on the pituitary 
(Pasteels et al, 1971). Bromocryptine acts as an analogue to'dopamine, 
which is the prolactin inhibitory factor, so that bromocryptine is a 
dopamine receptor-agonist. In four studies bromocryptine has been 
administered to PMS patients in a double-blind crossover fashion. In 
the first study (Benedek-Jaszmann & Hearn-Sturtevant, 1976) the subjects 
were perhaps atypical in that they were patients attending an infertility 
clinic and had prolactin levels just above or below the upper normal 
limit. There was significant improvement in breast symptoms, oedema, 
weight gain and mood, and the reduction of prolactin levels, by 
bromocryptine. 
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Unfortunately these authors did not extend their double- 
blind trial to their other group of women who were not selected for 
infertility or high prolactin values. This group of women did however 
report good results after bromocryptine treatment on an empirical 
basis. 
Other controlled trials have been less encouraging. Chose 
& Coppen (1977) in a study of thirteen patients, found no significant 
improvement. In a more detailed study Andersen, Larsen, Steenstrup, 
Svendstrup & Nielsen (1977) found no improvement in any symptoms 
except 'mastodynia' in the bromocryptine-treated cycles. Of the 21 
women, in their study only five had transient high levels of prolactin 
and there was no evidence for a difference in follicular and luteal 
levels, in contrast to Halbreich et al (1976). However Andersch, 
Hahn, Wendestam, Öhman & Abrahamsson (1978b) in a study of 20 PMS 
patients and 20 controls, did find a luteal increase in prolactin in 
the PMS group, although only two samples were taken per cycle. These 
authors also reported that the women, by self-rating, were significantly 
improved in the symptdms of breast discomfort and irritability. The 
problem with comparing these studies is that different dosages and 
time schedules were employed, and different methods were used to 
evaluate improvement. Another problem is that bromocryptino, as 
dopamine agonist, may be acting on central mechanisms other than 
prolactin secretion. t 
The interaction between prolactin and the steroids of the 
menstrual cycle (p. 26) may be implicated in the aetiology of PMS. 
While frank hyperprolactinaemia leads to anovulation, slightly 
raised prolactin levels may be responsible for menstrual cycle defects 
such as the short luteal phase (Corenblum, Pairaudeau & Schewchuk 
1976). Benedek-Jaszmann & Hearn-Sturtevant (1976) have suggested 
a connection between prolactin-induced progesterone deficiency 
and PMMS, since they found evidence that many of their infertility 
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patients with "high-borderline" prolactin also had short luteal 
phases and evidence of progesterone deficiency as drown by endometrial 
biopsy. All of their patients had premenstrual syndrome, yet it is 
not clear whether the sample was in fact selected for this criterion. 
Therefore all that can be said is that the premenstrual syndrome may 
occur in conjunction with slightly raised prolactin and luteal deficiency, 
and, indeed, Andersen et al (1977) observed three cases of slight 
hyperprolactinaemia and progesterone deficiency, of which only one had 
a typical PMS. 
If prolactin is involved in PMS then some explanation of the 
symptoms must be made. Prolactin is known to promote mineral and water 
retention, which may explain the oedema seen. Moreover prolactin may be 
directly responsible for breast changes, and this would accord with the 
results of Andersen et al (1977) and Andersch et al (1978b) It is worth 
pointing out however that breast disease, such as galactorrhooa, may 
occur in spite of prolactin levels in the normal range (Kleinborg, 
Noel & Frantz, 1977), and also that many patients with hyperprolactin- 
aemia do not have galactorrhoea (SeppUlU, Lehtovirta & Ranta, 1977). 
The possible role of prolactin in mental illness is reviewed 
by Horrobin, Mtabaji, Karmali, Manku & Nassar (1976). The interest of 
these workers was first aroused by the fact that some drugs such as 
reserpine which provoke depression also stimulate prolactin 
t 
secretion. $ut the only published report of prolactin levels in 
depressive illness is that of Sachar, Frantz, Altman & Sassin (1973) 
who report that baseline prolactin levels were elevated in their 24 
patients. 
A preliminary report by Horrobin et al (1976) confirms that 
prolactin is raised above upper linits of normal in twelve patients 
with neurotic depression. These authors point out however that 
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emotional stress may give rise to high prolactin secretion and not 
vice versa. 
It seems therefore that prolactin is unlikely to be the 
primary cause of neuronal disturbance, leading to deranged behaviour, 
especially as prolactin is within limits for controls in many patients 
(Andersen et al 1977, Andersch et al., 1978" Perhaps prolactin 
reflects other changes in the neuroendocrine pathways which may be 
responsible for mood changes. 
3.4 Other hormonal theories of PMS 
Billig & Spaulding (1947) suggested that women with PMS 
have a mild degree of hyperinsulinism in the premenstrual phase, 
leading to hypoglycaemia. They carried out glucose tolerance tests 
and found that there was increased sugar tolerance immediately prior 
to menses compared to other stages of the cycle, and this was also 
found by Morton (1950). The symptoms of hypoglycaemia are hunter, 
increased peripheral nerve sensitivity, and irritability as well as 
possible headaches and loss of concentration. Easy bruising may also 
be part of this syndrome. These very early papers have not been followed 
up, although Freedman, Ramcharan, Hoag & Goldfien, (1974) in a study of 
over 4000 women, found that serum glucose was reduced in the last five 
to eight days of the cycle. 
Dalton (1977) has put forward a general concept for the 
aetiology of PMS involving a fault in a "progesterone feedback pathway". 
She postulates a feedback pathway via the hypothalamus and pituitary 
to the adrenal cortex, which when interrupted would lead to diminished 
stimulation cf the adrenal. cortex and disturbances in glucocorticoids 
and mineralocorticoids. 
Unfortunately there is no evidence for such a pathway. 
Progesterone has a synergistic effect on the negative feedback of 
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oestradiol on FSH via the hypothalamus, but no effect on the 
adrenal cortex has been reported. Progesterone does alter-glucose 
in that it promotes amino acid breakdown by the liver (Landau & 
Lugibihl 1961), but this action is independent of the adrenal cortex 
since it is maintained in hypophysectomised, adrenalectomised patients 
(Landau, Bergenstal, Lugibihl, Dimick & Rashid, 1957)" 
Similarly the natriuretic effect of progesterone, as 
discussed in section 1.1.2. is also independent of the adrenal since 
the antialdosterone action of progesterone can be reproduced in 
adrenalectomised patients given aldosterone substitution therapy 
(Landau & Lugibihl, 1961). Thus the mechanism described by Dalton 
(1977) seems very unlikely. 
There has however been no work on cortisol levels in PMS. 
There is evidence that a small increase in adrenocortical activity 
may take place in depressed patients but the disturbance is not as 
great as that seen in minor stress situations (seo Coppen, 1970, for 
review). . 
A quite different theory was suggested by Rogers (1962). 
He pointed out that the symptoms of PMS such as irritability, depression, 
and oedema are present in many allergic conditions, and that many women 
may suffer from an allergy to the steroids themselves. Many allergies, 
due to small molecules such as drugs, involve the combination in vivo 
of the drug (acting as hapten) with a body constituent to form a 
complement antigen. One example is penicillin (Levine, 1965). 
Heckel, Leahy & Pleger (1958) showed that many women with 
menstrual disorders were allergic to pregnanediol when skin tested 
with the substance, although none were allergic to oestrogens or 
progesterone. Rogers (1962) gave minute quantities (1-0.1, micrograms) 
of pregnanediol to 33 patients of whom 29 showed improvement. This in 
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itself is not remarkab] i but he claimed that the women could 
differentiate between doses of 0.1 and 1 micrograms with improvement 
at the lower dose, presumably with desensitisation, but worsening 
at the higher dose. 
No further work has been reported with regard to the 
endocrine allergy theory of PIAS, although it has been noted (Dalton, 
1977) that many allergic conditions, such as asthma, rhinitis or 
urticaria, are exacerbated premenstrually. 
Another substance implicated in the aetiology of PMS is 
pyridoxine (vitamin B6). A number of workers originally speculated 
that the depression sometimes associated with oral contraceptives 
might be related to a fünctioral deficiency of this vitamin (Rose, 
1969) and pyridoxine has been used successfully in this type of 
depression (Adams, Rose, Folkard, Wynn, Seed & Strong, 1973). 
Pyridoxine is a co-factor in the dopaminergic pathway and 
also in several steps in the metabolic pathway of tryptophan. It has 
been suggested (Brush, 1977) that a relative deficiency of B6 might 
act at several levels to induce the symptoms of PNS, through 
dopaminergic pathways and via disturbed tryptophan metabolism. The 
only evidence so far comes from the use of vitamin Bä therapy in PMS. 
An early controlled trial had disappointing results (Stokes & Mendels, 
1972), although empirical treatment of 70 women has proved successful 
in over half the cases (Kerr, 1977). c 
3.5. The psychogenic theory'of PMS 
Although it is commonly believed that the mood changes 
of the menstrual cycle have biochemical origins, there are undoubtedly 
social and psychological factors. Menstruation itself is still 
surrounded with superstition and taboo. It may be argued that the 
tension, irritability and depression seen premenstrually could be 
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socially mediated responses to the onset of menstrual flow. This 
theory can be tested by studying women taking oral contraceptives where 
menstruation itself still occurs yet without the normal endocrine 
events, although there are problems as other psychological factors 
come into play in these women. Paige (1971) found that mood swings 
were abolished in women taking combination and sequential oral 
contraceptives, confirming the work of Grant & Pryse-Davies (1968). 
Using a different approach, Berry & Md3uire (1972) related 
the womans perception of her sexual role (using a questionnaire) with 
her cyclical symptoms, and they found no evidence that the'classic 
PMS symptoms were associated with psychosocial or psychosexual 
conflicts. 
Beumont, Richards & Gelder (1975) studied premenstrual 
symptoms in 25 women with normal cycles and 7 hysterectomised women. 
The phase of the cycle was determined by menstrual dates in the 
menstruating women and by LH and progesterone values in the hysterecto- 
raised group. Using a prospective self-rating daily questionnaire they 
found that the menstruating group had more pronounced swings in mood 
than the hysterectomised group, suggesting that the level of symptoms 
is dependent on the womens awareness of the stage of the cycle. But 
one puzzling feature is that the mean scores of mood, physical and 
psychological symptoms are higher throughout the cycle in the hyster- 
ectomised group, a feature which is not commented upon by the authors. 
It is likely that women after hysterectomy are an atypical group and 
therefore not suitable as controls. 
Another commonly held belief is that PMS is associated with 
psychological ill health. According to this idea all women 
experience physiological change, but the women who complain about 
these symptoms are neurotic. It has been reported that premenstrual 
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symptoms occur in up to 95% of women (Pennington, 1957). This 
implies that PMS is intrinsic and physiological, and indeed several 
theories have been put forward which suggest a selective advantage 
to PMS in the course of evolution (Rosseinsky & Hall 1974; Morriss 
& Keverne, 1974). 
In a study df 500 randomly sampled women Coppen & Kessel 
(1963) found a positive correlation between neuroticism and severe 
premenstrual tension. However, as Clare (1977) points out, the 
symptoms on the scoring system for neuroticisn heavily overlap the 
symptoms used to score PMS, so it is not surprising that an 
association was found. 
Thus there is no conclusive evidence so far that PNMS is 
psychogenic in origin. 
3.6 Aims of Thesis 
From the discussion above it would appear that several 
hormonal theories of the cause of PMS have been pursued but none have 
been tested in a convincing manner. 
The hormones most often mentioned are progesterone, oestradiol, 
prolactin and aldosterone. It was felt that the absolute values of 
these hormones may be less important than the relationships between 
them. It was decided therefore to try to measure plasma progesterone, 
c 
oestradiol and aldosterone and serum prolactin simultaneoubly during 
the cycle in women with PMS and compare the relationships found with 
those in asymptomatic women. 
Ideally one would like to study hormone relationships at 
the local level of the tissue affected, such as brain or breast tissue, 
but these are obviously inaccessible in human subjects, and no animal 
models for PMS exist. Another biochemical approach would be to study 
monoamines and their metabolites, but the same problem is encountered 
in that only peripheral blood can be studied in the women. In addition, 
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the methodological problems of measuring substances such as 
dopamine are considerable. 
Therefore it was felt that an overall picture of hormonal 
events during the cycle was a good starting point, especially as all 
the hormones have not been studied simultaneously in women with PMS 
before. In this thesis it was also hoped to be able to study hormonal 
patterns associated with different symptoms, and also to compare some 
psychological and endocrinological approaches. The endocrinological 
studies, proposed above have only been possible in the last decade, 
thanks to advances in techniques of plasma steroid measurement. These 
advances are reviewed in the next section. 
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4. EARLY METHODS OF MEASUREMENT OF STEROIDS 
lý. lý PROGESTERONE 
Early measurement of progestational activity involved 
bioassay, the end-point of which usually included either maintenance 
of pregnancy, or changes in uterine physiology, such as hypertrophy 
of the ctromal nuclei in ovariectomised mice (Hooker & Forbes, 1947). 
Physicochemical methods of progesterone quantitation . 
were developed in the 1950s, and the first successful determination 
of progesterone in blood was the spectrophotometric method of Zander 
& Simmer (1954). Numerous extraction steps and a paper chromato- 
graphic step were required to give the necessary specificity. 
Modifications of this method were published by Short (1958), Sommerville 
& Deshpande (1958) and Oertel, Weiss & Eik-Nes (1959), but all these 
methods were only sensitive enough for pregnancy plasma. 
At about this time patterns of progesterone in the body 
were investigated by the measurement of its main metabolite, pregnane- 
diol, in urine. Using the colorimetric method of Klopper. et al (1955) 
clinically useful information was obtained about the normal menstrual 
cycle (Klopper, 1957)" 
A further improvement in assay of blood levels carne with 
the development of gas chromatographic (GLC) methods (Collins & 
Sommerville 1964), which gave slightly improved sensitivity. Other 
useful GLC methods were developed using flame ionization (Yannone, 
McComas & Goldfien, 1964), or electron capture (Van der Molen & Groen, 
1965). Another chemical method was the double derivative isotopic 
method where a radioactively labelled reagent such as 
355- thiosemi- 
carbazide is allowed to react with progesterone (Riondel, Tait, Tait, 
Gut & Little, 1965). After extensive purification steps the specific 
activity of the product is measured by liquid scintillation counting, 
and thus the mass of steroid can be determined. There is automatic 
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correction for losses as 
3H-progesterone is added initially as 
internal standard. Although the recovery of steroid was low in 
this method, the. sensitivity was higher than could be previously 
achieved. 
However all these methods were laborious, due to the 
number of purification steps involved, and they were therefore 
unsuitable for routine clinical use. 
Saturation analysis using the competitive protein binding 
technique of Murphy (1967) was first applied to progesterone by Neill, 
Johansson, Datta & Knobil (1967), using a dog corticosteroid binding 
globulin. However the binding protein was not specific enough to 
eliminate all chromatography steps, so that thin layer chromatography 
was necessary (Neill et al., 1967, Yoshimi & Lipsett, 1968). 
However Johansson (1969) reported a competitive protein 
binding (CPB) assay using one extraction with a particular petroleum 
ether which selectively extracts progesterone, making chromatography 
unnecessary. 
The first radioimmunoassay (RIA) reported (Abraham, 
Swerdloff, Tulchinsky & Odell, 1971) was employed using an antiserum 
to the 21-hemisuccinate of 11-desoxycortisol. This antiserum cross- 
reacted completely with 17-hydroxyprogesterone and 11-desoxycortisol, 
so that a column chromatography step was required. Furuyama & Nugent 
(1971) prepared an antiserum to progesterone-3-carboxymethyl-oxime-BSA, 
but they found that the results in plasma were doubled unless a column 
chromatography step was included. 
Recent RIA methods have used an antiserum to 11X-OH 
progesterone hemisuccinate BSA which is more specific (Spieler, Webb, 
Saldarini & Coppola, 1972; Youssefnajadian, Florensa, Collins & 
Sommerville, 1972). This has enabled assays to be carried out without 
chromatography, and since then many methods have been published with 
procedural improvements, enabling the rapid, routine estimation of 
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progesterone in blood. Two recent modifications have been the use 
125 
of 1-iodohistamine radioligands (Scarisbrick & Cameron, 1975) 
and enzyme-labelled progesterone (Joyce, Read & Fahmy, 1977) as the 
'labels' to be 'counted'. ' 
+. 2 OESTRADIOL 
The problem of assay of oestradiol are those associated 
with the measurement of any steroid, namely those of specificity 
and sensitivity. The oestrogens present more difficulties than most, 
however, due to the existence of several structurally similar oestrogens, 
and also due to the various forms in which oestrogens may exist, such 
as conjugates in urine and protein bound complexes in blood. The 
earliest methods of analysis were bioassays measuring total nucleated 
or cornuated epithelial cells in the vaginal smear of ovariectomisod 
mice (Allen & Doisy, 1923). This and other bioassays did however 
suffer from the usual draw-backs of tediousness, lack of reproducibility, 
and nonspecificity. 
Techniques using chemical determination were later 
developed to measure oestrogens in urine since the methods were not 
sensitive enough to measure blood levels. The detection of oestrogens 
was carried out by a -colorimetric reaction such as the Kober reaction 
where the sample is heated with aqueous sulphuric acid and phenol, 
cooled and reheated to reveal an absorption maximum at 520 nm. This 
method was used by Brown (1955b)to measure urinary oestrogens and he 
was able to assay oestrone, oestradiol and oestriol individually using 
prior chromatographic steps. 
The reaction was modified (Ittrich, 1958; Klopper & Wilson, 
1962), but problems of sensitivity were still present, especially for 
blood samples. Other chemical methods such as acid fluorescence 
(Preedy & Aitken, 1961) and gas liquid chromatography (Wotiz, 
Charransol & Smith, 1967) have been used to measure the individual 
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oestrogens in non-pregnancy plasma, but large volumes of blood are 
required, precluding studies where repeated sampling is necessary. 
When radioactive oestrogens became available these could 
be used as internal standards to determine losses during the lengthy 
purification procedures. They were also used in the double isotope 
derivative technique together with a reagent such as 
35S-p-iodobenzene 
sulfonyl chloride (Baird, 1968). These techniques were sensitive 
enough to measure oestradiol-17A in the plasma of men and non- 
pregnant women, but the procedure was still very laborious. 
Saturation analysis was soon applied to oestradiol using 
at first uterine binding proteins from rabbit (Korenman, Perrin & 
McCallum, 1969) and sheep (Shutt, 1969). These binding proteins were 
not specific enough to discriminate between the oestrogens without prior 
chromatographic separations. The Competitive protein binding assay 
et ai 
of Korenmanj(1969) which used celite columns did however show good 
agreement for mile and female follicular phase values with the 
isotope dilution method of Baird (1968). 
A recent step in the assay of plasma oestradiol has been the 
elimination of the chromatography step by using a highly specific 
antiserum. Abraham(1969) carried out the first non-chromatographic 
assay of plasma oestradiol but the antiserum was fairly nonspecific. 
Other RIA methods-described for oestradiol have had to 
include column chromatography but these assays were improved by the 
use of Sephadex LH-20 microc. umns (Emment, Collins & Sommerville, 1972) 
which speeded up the assays and reduced the assay blank effect. 
Eventually antisera were produced with a cross-reactivity of 
less than 2% with oestrone and oestriol, which meant that non- 
chromatographic assays could be performed. These antisera were produced 
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against either oestradiol-11-BSA (England, Niswender & M46dgley, 
1974) or oestradiol-6-BSA (Dean, Exley & Johnson, 1971). 
More recent assays have eliminated even the ether 
extraction step. Possible interfering substances are removed by 
adding an excess of testosterone to displace all oestradiol from 
plasma proteins (Jurjens, Pratt & Woidring, 1975). Other 
simplifications have been the use of iodinated labels for oestradiol 
for counting by gamma ray spectrometry (England et al., 1974), and 
even enzyme labels (Van Weeman & Schuurs, 1971). 
4.3 ALDOSTERONE 
The initial assays for mineralocorticoid activity were 
crude bioassays which measured changes in the level of sodium or 
potassium excretion by adrenalectomised dogs or rats. This method was 
modified by Simpson & Tait (1952) so that radioactive sodium and 
potassium were used. 
After aldosterone itself was isolated and characterised 
a number of physicochemical methods were developed. In one such 
method the end-point depends on the ability of the aldosterone ketol 
side chain to reduce tetrazolium salts which then produce soda 
fluorescence (Nowaczynski, Koiw & Genest, 1957). However many other 
groups react with the tetrazolium salts so that successive chromato- 
graphy steps were required first. The majority of the chemical methods 
were used to measure the urinary metabolite of aldosterone, aldosterone- 
18-glucuronide, which is converted to the free compound by hydrolysis. 
The secretion rate of aldosterone could be measured by the 
adminstration of 
14C-or 3H-isotopes 
and the estimation of the specific- 
activity of the metabolite aldosterone-18-glucuronide in blood. 
Estimates of aldosterone secretion rates in clinical conditions have 
confirmed the trends seen in the urinary excretion of aldosterone 
(for review see Coghian &' Blair-West, 1967). 
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An isotopic dilution method of measurement which was 
more sensitive and therefore suitable for assay in plasma was 
described in the late 60's. The methods of Peterson (1964), Coghlan 
& Scoggins (1967) and Nowaczynski, Silah & Genest (1967) involve 




aldosterone is used as internal standard. These methods are sensitive 
since the sensitivity depends only on the specific activity of the 
labelled reagents, but the specificity relies upon several purification 
steps. 
Another method, gas liquid chromatography, was also 
developed about this time (Bravo & Travis, 1967) but was only, 
sensitive enough for urinary studies. 
All these physico-chemical methods have the drawback of 
nonspecifity, which is especially important in the case of aldosterone, 
since this hormone is present in blood in very low concentrations 
together with large amounts of the other corticosteroids. The daily 
secretion rate of aldosterone by the adrenal is 50-100 pg while the 
corresponding rate for cortisol is 8-25 mg. (Catt, 1971). None of 
the above methods were therefore practical enough for routine clinical 
use, especially for plasma estimations'. 
More information became available after the application 
of competitive binding protein techniques. Unfortunately aldosterone 
is not bound to any extent by plasma proteins (Davidson, De Venuto 
& Westphal, 1962), so that intracellular binding proteins had to be used. 
However attempts to use renal receptor proteins were not successful 
owing to the instability of the proteins (Robinson & Fanestil, 1970; 
Vyzantiades, Ekins & Slater, 1970). 
The first reports of radioimmunoassays for plasma aldo- 
oterone still involved a chromatographic step (Mayes, Furuyama, Kem 
& Nugent, 1970; Bayard, Beitins, Kowarski & Migeon, 1970), since the 
antisera, to aldosterone-3-oxime BSA, were relatively nonspecific. An 
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antiserum to aldosterone-18,21-dihemisuccinate BSA has been made 
by Haning and coworkers at the Worcester Foundation (Having, 
McCracken, St. Cyr, Underwood, Williams & Abraham, 1972). This 
antiserum, although also rather nonspecific, has been widely 
distributed and has led to a large increase in the number of 
reports on aldosterone plasma levels. 
More recently several highly specific antisera have 
been developed which eliminate the chromatographic step. This 
was achieved by the careful preparation of a pure mono-oxime 
conjugate, aldosterone -3- carboxymethoxime - BSA 
(McKenzie & 
Clements, 1974; Jowett, Smith & Slater, 1975; Vetter, Freedlender 
& Haber, 1974). On theoretical grounds conjugation at the C-3 
position which exposes the 'Unique' C and Dr of aldosterone 
would produce more specific antibodies than conjugation at the C-18 





1. GENERAL METHODS 
1.1 Materials 
Steroids 
Cortiso1411/3,17oC, 21-trihydroxy-4-pregnene-3920-dione)I oestrone 
(3-hydroxy-193,5 (10)-estratriene-17-one), and 170(-hydroxyprogesterone 
(17o-hydroxy-4-pregnene-3,20-dione) were from B. D. H. Ltd., Poole, Dorset. 
Aldosterone(18 , 11-hemiacetal of 11,21-dihydroxy-3120-dioxo-4- 
pregnen-18-al), oestriol(1,3,5 (10)-estratriene-3,16oc, 17f-triol), 
pregnenalone(, -P-hydroxy-5 -pregnen-20-one), pregnanedione(54-pregnan- 
3,20-dione), dehydroepiandrosterone(3, zS-hydroxy-5-androstene-17-one), 
11a-hydroxyprogesterone(11cC-hydroxy-4-pregnene-3120-dione), 
20a-hydroxyprogesterone(20x-hydroxy-4-pregnene-3,20-"dione) and 
testosterone(17(j-hydroxy-4-androstene-3-one) were from Sigma Chemical 
Co. Ltd., Kingston, Surrey. 
Cholesterol(4-cholestene-33 -ol), corticosterone(11/3921-dihydröxy- 
4-pregnene-3,20-dione), oestradiol-17p (1,3,5 (10)-estratrietie-3,17jS - 
diol), and progesterone(4-pregnene-3,20-dione) were from Koch-Light 
Laboratories, Ltd., Colnbrook, Bucks.. 
11-Debxycorticosterone, DOC(21 hydroxy-4-pregnene-3,20-dione), 
tetrahydrocortisol(3cX, I1/3,170(, 21-tetrahydroxy-5f -pregnan-20-one) *- 
18 -hydroxydeoxytorticosterone, 18-DOC(18121-dihydroxy-4-pregnene-3,20- 
dione) and aldosterone, was from the MRC Reference Collection, Westfield 
College, Tondon NW3. 
DHD (20&hydroxy-9/3,10oc-pregna-4,6 -diene-3-one) and dydrogesterone 
(9/d, 10d-pregna-1t, 6 -diene-3,20-dione) were from Philips Duphat, BV, Weesp,, 
Hollandr, 
Radioactive Steroids 
(1o2-, 3H) progesterone, 58 Ci/mmol, (1,2,6,7 3H) progesterone, 87Ci/mmol, '. 
(1,2 3H) aldosterone, 50Ci/mmol, (2,4,6,7 




cortisol, 82 Ci/mmol, and 
3H-hexadecane 
standard were from 
the Radiochemical Centre, Aanershani, Bucks. 
Antisera 
An antiserum to progesterone-11a-hemisuccinyl-BSA, raised in goats, , 
was a gift to Dr. M. G. Brüsk from Dr. B. J. A. Furr, National Institute 
for Reaearch in Dairying, Reading. 
An antiserum(088) to aldosterone-18,21-dihemisuccinate-BSA, raised 
in sheep, was a gift tp Dr. M. G. Brush from-the National Institute 
of Arthritis, Metabolic & Digestive Diseases, Bethesda, U. S. A 
Antisera to 17/3-oesbradiol-6(-o-carboxymethyl)-oxime-BSA, raised 
in rabbits, was given by Dr. P. G. Dean, Department of Biochemistry, "= 
University of Liverpool. 
Progesterone 11a-hemisuccinate and progesterone-1la-henisuccinyt-BSA 
were kindly provided by Dr. M. W. Johnson, Chelsea Hospital for Women, 
and the latter was used to raise antisera in our laboratory (see below). 
General Reagents 
Light petroleum(petroleum ether), bp 40°-60°C and bp 80°-100°C, 
ethyl acetate, toluene, chloroform, boric acid, sodium hydroxide, 
sodium dihydrogen brthophosphato(2H20) and disodium hydrogen 
orthophosphate(anhydrous), and isatin, were all Analar grade, from 
B. D. H. Ltd. 
1,4-diamiroanthroquinonet, sodium azide, gelatin, Dextran Grade C 
mol wt. 60,000-90,000, and Decon 90 were also from B. D. H. Ltd. 
Zimrnermans reagent (2.5M potassium hydroxide in ethanol and 
2% (w/v) m-dinitrobenzene in. ethanol), prepared freshly before use, was 
also from B. D. H. Ltd. 
Charcoal Norit A, Bovine Serum Albumin and Trig buffer, pH 8.5 
were'from Sigma Chemical Co. Ltd. 
Other reagents were methanol, Analar(Hopkins & Williams, Chadwell 
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Heath, Essex), ethanol, Analar, (Burroughri &Wellcome, London S. E. 11), 
dichloromethane, Pronalys (May & Baker, Dagenham, Essex), PPO, 
(2,5-diphenyloxazole) and dimethyl POPOP (114-(2-(4-methyl-5- 
phenoxazolyl))-benzene)'from Koch-Light Laboratories,. Ltd. 
Sephadex LH-20 was from Pharmacia Fine Chemicals, Uppsala, Sweden. 
Also used were Triton X-100(Rohm &Haas, Croydon, Surrey), Freunds 
adjuvant(Difco, Surrey) and butane/heliixm, 1.3/98.7(B. O. C., London S. W. 19) 
Glassware and pipettes 
10, -13 and 30 ml capacity Quickfit tubes and stoppers were obtained 
from Corning Ltd., Stone, Staffs. 
Volumes of 10 pl and 25 pl were dispensed using Eppendorf automatic 
pipettes (Eppendorf. GN, Hamburg, Germany) and volumes of 0.05,0.1, 
0.2 and 0.5 ml were dispensed using Oxford Samplers (Boehringer 
Corporation Ltd., London). 
Volumes of 0.4 to 1.0 ml were also dispensed with an adjustable 
Pipetman 1000 (Gilson, Villiers-le-Bel, France) or i Solectapette 
(Clay Adams, N. J., U. S. A) which proved useful in deep narrow tubes. 
For repeat dispensing of solvents, volumes of less than 1 ml were 
dispensed from an Oxford Pipettor (Boehringer Corpn. Ltd. )and above this 
volume a BB pipette was used (Bie & Bernsten, Ltd., Copenhagen) was used. 
Volumes of scintillant were dispensed with a 10 ml Zippette (Jencons 
Hemel Hempstead, Herts. ); and other scintillation equipment was glass 
vials (Packard Instruments Ltd., Caversharn, Berks) and plastic insect 
vials (Sterilin, Teddington, Middx. ) 
3 ml capacity tubes for plasma storage were from Luckhams, Sussex. 
Apparatus 
Lithium heparin 10 ml tubes for blood samples (Tekiab, Durham) 
were centrifuged in an MSE Super Minor. All other centrifugations were 
carried out in the MSE Mistral 4L (MSE, Crawley, Sussex). 
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A vacuum oven(size 1, Gallenkamp) was attached to a vacuum pump, 
2SC? CC (2,; wards, Crawley, Sussex) for the evaporation of solvents*in 
the assay tubes. 
All other drying down procedures were using comjressed'air (on 
tap) and a manifold incorporated into a Perspex frame containing 
syringe needles which slotted on toý of`a Perspex rack to fit 
12 x 100 mm tubes. This piece of equipment was made in the Medical 
Unit Workshop, St. Thomas's Hospital Medical School. 
A Corumatic"200 liquid scintillation spectrometel, in use before 
October 1975, a'4ir scanner (both from Tracerlab, Surrey), and an 
Intertechnique SL33 liquid scintillation spectrometer (Intertechnique, 
' 
Brighton, Sussex), were used for radioactive counting. 
A scanning spectrometer, Unicam SP800 was used in the Biochemistry 
Dept., St. Thomas's Hospital Medical School. 
Tubes were vdrtexed using a Rotamixer de luxe (Hook & Tacker, 
London S. W. 9) and for short periods they were kept at 4° C on a 
Cooltray(Chemlab Instruments Ltd., Hornchurch, Essex). 
The calculators were a Compucorp 344 Statistician (Sunlock, 
California, U. S. A) and an HP55 (Hewlett Packard, Slough, Berks). 
Other equipment was ; silica gel layer plates 60F254( Merck$ 
Darmstadt, Germany), chromatography paper (Whatman, Maidstone, Kent), 
paper chromatography. tanks (32 x 20 x 57 cm), thin layer chromat- 
ography tanks (22 x 7x21 cm) and a microlitre glass syringe to 
apply chromatographic samples (Hamilton Bonaduz AG, Switzerland). 
Cleaning glassware 
Glassware was rinsed with water several times before immersion 
in 5% Decon 90 for 8- 24 hours. It was then rinsed in tap water at least 
12 times and in distilled water 10' times, and dried at'75°C. Extraction 
tubes were p4erinsed, with 1-3'ml of the solvent to be'used. 
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Plastic insert vials, Pasteur pipettes and automatic sampler 
tips were used once and discarded. 
t. 2. ScintilliAtion counting 
A quench curve was constructed for different volumes of 
buffer, using 
3H-hexadecane 
as internal standard. A regression 
analysis was performed for channels ratio (CR) and automatic 
external standards channels ratio (AESCR) curves using the 
Compucorp calculator. Regression analyses were linear (r = . 98) 
for efficiences up to 309 on the Tracerlab. Regression equations 
for channels ratios in this range were used to calculate 
efficiencies and hence dpm. For the Intertechnique coefficients 
from the quench curve were read into a computational unit via 
the Multimat Teletype of the SL33 before counting. A programme 
would then calculate a non-linear quench curve and automatically 
correct each vial so that both cpm and dpm were printed. 
Triton X-100 detergent Triton X-100, a polyoxyethylene ether, 
is a detergent which has proved most useful in the counting of 
aqueous solutions, as it forms stable solutions with up to 14% 
water (Turner, 1971). 5g PPO and 0.1 g dimethyl POPOP were 
dissolved, with stirring, in 667 ml. toluene, and 333 ml. Triton 
X-100 was added. Up to 15% of buffer could be mixed with the 
scintillant to form a clear solution. 
The use of polythene insert counting vials 
When large numbers of vials are in use, for instance, in radio- 
assay, the cost and practicability of the counting system lust 
be considered. Polyethylene vials of 5 ml capacity which fit 
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into the standard glass vials may be of advantage for two 
reasons. Firstly, the vials are cheaper than the glass ones, 
so that they may be thrown away after use, which eliminates 
the problem of washing and decontamination. Secondly, less 
scintillant is needed, (and this may partly offset the 
increased cost of the disposable vials! ). 
It was noticed on the Intertechnique, if the same insert 
vials are recounted, that there was an increase in the computed 
dpm of approximately 130% over 15 hours if the AESCR quench 
curve was used. However if the CR quench curve was used 
changes with time did not occur, so that this method of quench 
correction was used in subsequent assays. Nevertheless, to 
counteract any possible changes with time, standard curve 
vials were placed both before and after unknowns symmetrically 
about an axis, thus: 1,3,5 .... '6,412. 
The final counting system was 3.5 ml Triton mixture in 
polyethylene insert vials, and efficiency under these conditions, 
using 0.5 ml of 0.1 M Phosphate buffer as quencher, was about 
19% on the Tracerlab (compared to an efficiency of 23% in all 
glass vials) and 26% on the Intertechnique. 
1.3 Purification of reagents 
1.3.1 Radioactive steroids 
Although the half-life of 
3H is twelve years, it is important 
to use a pure steroid tracer especially if the tracer is to be 
added as an internal standard to determine recovery. Radioactive 
steroids should be purified at regular intervals; this should be monthly 
for tetra-labelled steroids, such as (2,4,6,7-3H) 1713 -oestradiol, and 
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every two months for other compounds (Brenner, Guerrero, Cekan 
& Diczfalusy, 1973). 
(1,2-3H) Progesterone 
Paper chroratograohyv 
1 ml of the stock solution of 25 iCi/ml in ethanol was 
purified by a Bush P10 paper chromatography system of petroleum 
ether (800 - 100°C)/ methanol/ water (100/70/30). The paper 
(Whatman No. 1) was spotted with 50 vg of unlabelled progesterone 
and with the labelled steroid. The chromatogram was left to 
equilibrate overnight and was run for 3-4 hours at room temperature. 
The strip containing unlabelled steroid was stained using 
the Zimmermanns reagent and the strip containing the radioactive 
band was passed through the Tracerlab 41r scanner, with butane; helium; 
1.3; 98.7 used at 5 lbf/in2. The radioactive scan was aligned with 
the paper strip and the corresponding radioactive band removed, cut 
into small pieces and eluted with 10 ml ethanol. The ethanol was 
decanted and the paper was further washed with 5 ml ethanol. 
The Rf value for progesterone was 0.84, and the estimated mean 
recovery was 71% (n = 5). A solution of 
3H 
progesterone purified by 
paper chromatography 14 weeks previously was repurified using the 
same system. On the scan there were no apparent peaks due to impurity. 
This could mean that there was no deterioration in the label, or that 
the impurities were non-radioactive and therefore not detected. 
Column chromatography using Sephadex LH-20 
Since 1970 Sephadex LH-20 has come into use as a separation 
medium for steroids (Murphy, 1970). Sephadex LH-20 is a dextran 
gel with both hydrophilic and lipophilic properties, and separation 
depends upon gel filtration, adsorption and partition. 
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Although benzene/niethanal (95/5) is the usual solvent 
system for progesterone (Youssefnajadian et al., 1972) it was 
decided on safety grounds to avoid benzene wherever possible. 
About lg of Sephadex was soaked in approximately 10 ml of the 
solvent system (dichloromethane/methanol, 95/5) overnight. The 
excess solvent was then decanted and the remaining slurry poured 
into a Pasteur pipette which had been prerinsed with the solvent 
system and blocked at the narrow end with a glass bead (3mm diam). 
When the gel had reached a height of 7.5 cm. it was washed with 
solvent and a glass wool disc (the diameter of cork-borer size 3) 
inserted on top. The columns were kept on the cool-tray during 
use since separation deteriorates above 20- 
0C (Murphy & d'Aux, 1975) 
3H-progesterone (10iCi") was added to the column in 0.2 ml of 
solvent mixture and allowed to drain into the column. Elution was 
set up by adding set volumes of solvent to the column, allowing 
this to drain through the column into a collecting tube, then 
transferring the whole column to the next collecting tube and 
repeating the process. The advantage of this method is that 
expensive columns with stopcocks or fraction collectors are not 
necessary. 
10 ul of each fraction was counted on a scintillation 
counter. The fractions corresponding to the peak of 
3H-progesterone 
were pooled, evaporated, and redissolved in 10 ml of ethanol. The 
column was discarded after one use. 




Both systems, paper and column chromatography, provided a 
purified label which was sufficiently pure to use in internal 
standard recovery experiments and in radioimmunoassay. However, 








Fig. 2.1 The elution pattern of (1,2- 
3H) 
progesterone 
from a column 7.5 cm in length, packed with Sephadex LH-20 
in the solvent system dichloromethane/methanol, 95/5. 
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can be seen in the final eluate, indicating possible interfering 
substances, and in the length of the chromatography and detection 
procedures. Columns of LH-20 require about two hours and the product is 
free of apparent imputities since assays using this label were 
satisfactory. In the dichloromethane/methanol system the progesterone 
is eluted very quickly, which raises a few doubts as tö the separating 
powers of the system. 
(1,2-3H) aldosterone 
Although paper chromatography is the usual method for the 
purification of 
3H-labelled 
aldosterone, (Ito et al., 1972) a-. separation 
system on Sephadex LH-20 columns has been suggested by Murphy(1971) 
and such a method has now been used to purify the label (Waldhausl, 
Haydl & Frischauf, 1972). Both methods were compared. 
Paper chromatography 
The chromatography paper, Whatman no. 1, was washed overnight 
in a chromatography tank by eluting the paper with 200 ml redistilled 
methanol, and 10 iCi of 
3H-aldosterone (0.7 ug) was applied, in 0.1 ml 
ethanol to paper strips together with 50 µg unlabelled aldosterone. 
The solvents, benzene/water/methanol, 2/1/1, were equilibrated and the 
chromatograph run according to the method of Bush(1961), keeping the 
tank in darkness throughout the procedure. The radioactive band was 
located as described for 
3H-progesterone 
and the purified (1,2- H) 
aldosterone was eluted from the paper overnight with methanol, then 
with 2 ml of 906 methanol and finally with 3 ml methanol. 
the P. f value for aldosterone 
(labelled and unlabelled) was 
0.33 which compares with a value of 0.3 quoted by Gray, Greenaway & 
Holness, 1961) The recovery of radioactivity from the aldosterone 
band, as determined by scintillation counting, was 80%, 82% and 22% 
on three separate occasions, and since there was no evidence in the last 
run of high impurity, apparently the aldosterone was lost, underlining 
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one of the disadvantages of paper chromatography, in that the 
lengthy procedure tends to promote losses of labile steroids. 
Another disadvantage is the health hazard of using benzene, although 
toluene is a possible alternative. 
Column chromatography 
It was decided to try miniature columns in Pasteur pipettes 
for the chromatography step, and one gram of Sephadex LH-20 was 
soaked in 20 ml of dichloromethane/methanol, 98/2 (Murphy, 1971) and 
a column prepared to a height of 7.5 cm as described on page 73 . 
10 JiCi (0.7 mg) of (1,2 
3H) 
aldosterone was applied to the column 
and fractions collected as described on page 73 . The fraction 
showing the peak of radioactivity, i. e. the fractions from 2.0-2.5 ml 
were redissolved in ethanol, and pooled to a volume of 10 ml. The 
recovery of radioactivity was 82% from this peak and the only impurity 
eluted was at 8-10 ml. 
Wheh the steroid from the column was used subsequently in an 
assay it gave initial binding of 65%, sensitivity of 5 pg(see 
page 80 ) and a blank of zero. When labelled steroid from a 
paper chromatographic purification was used in the same way the 
initial binding was 60% and the sensitivity was again 5 pg but the 
blank was not tested. It seems therefore that both methods provide a 
satisfactory label for the assay. 
311-labelled-oestradiol-l7ß 
(2,4,6,7 3H)-oestradiol-174 was stored in a solution of 25 pCi/ml 
in redistilled ethanol and repurified every four weeks on a Sephadex LH-20 
LH-20 column, 7.5 x 0.5 cm, using dichloromethane/methanol, 95/5 
(Murphy, 1971). The fractions containing the main radioactive peak 
were pooled, evaporated to dryness, and redissolved in ethanol to 
give a solution of about 1 pCi/ml, which was stored at 4°C. 
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1.3.2. Unlabelled steroids 
Progesterone 
A standard solution of 1.00 mg/ml progesterone in ethanol was 
prepared and the purity checked by thin layer chromatography on a' 
silica gel plate 60F254 in the solvent system acetone/chloroform 
5/95. The least amount of steroid detectable, when viewed at 
254 nm, was 0.2 ug. The system gave good separation from other 
steroids such as 17-hydroxyprogesterone, and progesterone was' 
apparently pure, but the same solution was retested one year later and 
two impurities were seen, which is fairly surprising as progesterone 
is rather unreactive, with the most likely reactions occurring as 
hydroxylations at the C-3 or C-20 positions (Klyne, 1965). 
Another feature of progesterone is its poor solubility in aqueous 
media, even when protein is present (Clark & Gurpide, 1972). Thus 
it is important that the initial standard stlutions are in ethanol 
or toluene, both of which we found to dissolve progesterone equally 
well. 
Aldosterone 
The purity of aldosterone, obtained from Sigma and from the 
ANC Reference collection was checked by thin layer chromatography 
as above, using the system ethanol/chloroform, 8/92. The chromat- 
ographs were repeated after aldosterone had been in solution for 
6 months and 9 months. At 6 months two s: yall impurities were seen 
on the chromatographs of the MRC standard, with Rf values of 0.08 
and 0.16, compared to the value of 0.23 for aldosterone. After this the 
Sigma standard was used and it was still apparently pure at 9 months, 
but subsequently new stock solutions were prepared every 6 months and 
stored at -20°C in ethanol. 
Oestradiol-17f3 
17/-oestradiol was dissdved in redistilled methanol to form a 
stock solution of 1.00 mg/ml and stored at -20dC iör up to 6 months. 
2. RADIOIMMUNOASSAY 
2.1 General Considerations 
The technique of radioimmunoassay (RIA) was first 
reported by Berson & Yalow (1959) for the measurement of insulin, 
and it has since been applied to the measurement of many proteins 
and also low molecular weight haptenic substances such as digoxin, 
cyclic, ANP and the steroids. As already described (Chapter 1) 
immunoassay is now the method of choice for most steroids, 
especially now that specific antisera are available and 
chromatography steps are largely eliminated and since only 
immunoassays can provide the necessary specificity, sensitivity 
and convenience for rapid repeated sampling.. 
As a liquid scintillation spectrometer was already 
available in this Department tritium-labelled antigens were 
chosen for all the assays. RIA is however a deceptively simple 
'a - technique and great care must be taken to assess performance if 
the results are to compare with other methods (Fraser, Guest, 
Holmes, Mason, Wilson & Young, 1975). 
As it has been necessary to produce radioimmunoassays 
for progesterone and aldosterone for this project, an outline of 
the principles and reliability criteria of radioimmunoassay are 
given, followed by a detailed account of the development of the 
assays for these two hormones. The radioimmunoassay methods used 
to measure other hormones in this project are given more briefly. 
Principles of RIA 
RIA is only one of many techniques involving the principle 
of saturation analysis, that is: 
p+q= pq +p 
where p is the substance to be measured, q is the binding reagent 
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(such as an antibody) and pq is the bound portion. If some labelled 
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antigen, p*, is present in the incubation, there is competition for 
the available binding sites on the binding reagent, and the amount of 
labelled p* present as pq will be a function of the concentration of 
unlabelled p. The proportion of labelled p" in either bound or free 
fractions can be determined and plotted as a function of p (the 
standard curve). The three basic requirements for saturation analysis 
are therefore: (1) a labelled version of p which is stable and which 
can be easily measured, such as an isotope or enzyme-label (Engvall & 
Perlmann, 1971); (2) a specific binding reagent, usually an antibody, 
as in immunoassay, or a plasma protein, as in CPB; and (3) a quick and 
convenient method to separate the free and bound fractions. 
One of the problems arising from immunoassay has been the 
lack of agreement regarding the kinetics of the reaction. The anti- 
body-ligand interaction is complex and the standard curve obtained is 
nonlinear. The abscissa of the curve is in most cases the dose variable 
(unlabelled p) plotted on a linear or logarithmic ecale. The ordinate 
may be the bound fraction, the free fraction, or a combination of both. 
The bound to free ratio (R) is a linear function of the concentration 
of bound antigen (B). This, the Scatchard plot, may be used to estimate 
the concentration of binding sites on the antibody (via the intercept) 
and the affinity constant via the slope (Feldman & Rodbard, 1971). 
Other commonly used ordinates are the bound to total ratio,, 
(B/T), and the ratio of bound to bound at zero dose of p, B/B 0, 
although these two curves are nonlinear. For the assays in this 
department it was decided to use the B/B 0 response variable against 
the logarithmic dose-variable for most applications. This has the 
advant -ages of being simple to calculate; of being linear over most 
of the curve; and having a fixed range of 0 to 1.0 for B/Bo, which 
simplifies comparisons between-assays. 
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Criteria for the Assessment of the Assay 
The reliability of the assay is determined by the criteria 
of the standard curve, and by purifications procedures carried out 
prior to the RIA. The criteria of the standard curve are in turn 
largely determined by the quality of the antiserum. An antiserum 
is characterised by titre, (optimal dilution), by affinity (or 
avidity) which is expressed as the affinity constantt and by 
specificity, which is determined by cross reactivity studies. 
The chief reliability criteria of the assay are described below. 
W Precision 
Precision is the amount of variation in the estimation of 
unlabelled hormone, X, and is dependent on the precision of the 
standard curve at each point. 
For straight lines the standard deviation of the response 
B/Bo can be used (Feldman & Rodbard, 1971). With nonlinear curves 
the precision is not consistent over the whole range of the curve, 
and for this reason the precision of plasma duplicates will vary 
depending on the point of interpolation on the standard curve. Hence 
when the precision is quoted the range of hormone concentrations 
should also be mentioned. 
The precision of the assay is also dependent on the error in 
the estimation of recovery of the hormone after extraction. Precision 
is usually expressed as the coefficient of variation of duplicate 
plasma measurements. 
(ii) Sensitivity 
The sensitivity of the assay is determined by three variables . 
(Abraham, 1974). 
a) The least detectable dose on the standard curve, or detection limit. 
This approximates to twice the standard deviation of the zero dose 
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response (Midgley et al., 1969). The least detectable dose will 
depend upon the error in the determination of Bo and also upon the 
slope at Bo, although as pointed out by Ekirs (1975) the slope is to 
some extent an artefact of the variables plotted. 
b) The blank values. These are indicated by a decrease (positive 
blank) or increase (negative blank) in binding in samples with zero 
dose of unknown, for instance water blanks, The blank value should 
ideally be less than the least detectable dose. Negative blanks are 
perhaps more of a problem as they are difficult to quantitate. 
c) The recovery of steroid after purification. 
Nonequilibrium assays: It has been sho%m (Rodbard, Ruder, Vaitukaitis 
& Jacobs, 1971) that if equilibrium is not reached the sensitivity 
of the assay may be improved by delayed addition of labelled antigen 
after a preincubation of unlabelled antigen and antibody. 
This may be especially useful in some steroid assays 
where sensitivity is of prime importance, and in practice a pre- 
incubation step is widely used (Cameron & Scarisbrick, 1973; Emment, 
Collins & Sommerville, 1972). 
(iii) Accuracy 
Accuracy may be defined as the extent to which the mean of an 
infinite number of measurements agrees with the exact amount of the 
substance which is present (Midgley et al., 1969). In the case of 
steroid assay this is measured by adding known amounts of steroids 
to water blanks or ideally to plasma containing no endogenous 
steroid. 
Other methods of testing accuracy involve exchange of samples 
between assay laboratories and also the comparison of results by 
different methods. 
(iv) Specificity 
Specificity may be defined as the extent of freedom from 
interference by substances other than those intended to be measured 
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(Midgley et al., 1969). In the RIA of steroids a particular 
problem affecting specificity may be cross-reacting steroids, and 
this depends upon the characteristics of the antiserum. The 
specificity of the antiserum is tested by cross-reaction studies 
and if necessary, interfering steroids may be removed by selective 
solvent extraction or chromatography. 
Nonspecific binding may also occur due to lipids or plasma 
proteins. If a solvent extraction is not necessary to remove cross- 
reacting steroidss then heating the plasma prior to assay may 
remove non-specific interfering proteins (Hennarn, Collins & Sommerville, 
(1973)" 
2.2 Development of the assay for progesterone 
2.2.1 The production of antisera 
Although some antiserum was kindly provided by Dr. B. J. A. Furr 
it was decided to raise some antisera in our own laboratory. This 
was facilitated by a kind gift of conjugate to progesterone- lJot 
-hemisuccinyl BSA from Dr. M. W. Johnson at Chelsea Hospital for Women. 
Antisera raised with conjugates of progesterone coupled to BSA at 
position 11 show less crosc-reactivity than those coupled at other 
sites (Kohen, Bauminger & Lindner, 1975) and are now widely used. 
Characterisation of the conjugate: The method used was that of 
Erlanger, Borek, Beiser & Lieberman (1957)- 
Progesterone-'lloc-hemisuccinate (P-HS) was dissolved in Tris 
buffer, pH 8.4 (Sigma) to a concentration of 3.5 x 10-7M and 
progesterone-110ý-hemisuccinyl BSA (P-BSA) and BSA were made up to 
concentrations of 6x 10-7M. The ultraviolet spectra of the 
compounds was investigated on a scanning spectrometer (Unicam SP800) 
at wavelengths from 400 nm to 200 nm for all the solutions. 
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The spectra were plotted (see Fig. 2.2), correction was made 
for the baseline absorbance at 325 nmq and this value was, subtracted 
from the maxima at 246nm . The resulting maxima were 0.16 for 
P-BSA and 0. ýq for P-HS. The steroid/BSA ratio was thencalculated 
according to Erlanger et a! (1957). The resulting ratio was 26 
molecules of progesterone to 1 molecule of BSA. This conjugate with 
a molar ratio of 26 fulfills the criteria of Midgley & Niswender (1970) 
-han 20 ensures a high titre. who suggested that a ratio of greater 4. 
The theoretical maximum is 60, the number of free amino groups 
available on the BSA molecule for condensation reactions. 
Purification of the conjugate 
30 mg of the conjugate was dissolved in sufficient water 
and introduced into a wetted dialysis tube. The tube was sealed 
at one end and dialysed against distilled water overnight. The c1614$'ý 
V'eSICILkf- was then freeze-dried (in the Chemicaý Pathology Department, 
St. Thomas's Hospital Medical School) and the lyophilised conjugate 
was kept at 40C before use. 
Immunisation 
There is no generally agreed method for the successful 
production of steroid antisera. nor for the animal species to be 
used, although the rabbit is the preferred animal in most cases 
(Nieschlag, Kley & Usadel, 1975). Rabbits are cheap, fairly easy 
to handle and a convenient size for the regular collection of serum. 
Many different sites of immunisation have been described (Nieschlag 
et al., 1975), but one of the most common routes of administration 
is subcutaneous injection at multiple sites with booster injections 
at regular intervals (Youssefhajadi6n, Florensa, Collins & 
I Sommerville, 1972). Antibody response is enhanced by the use of 
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several weeks, although the dose of immunogen may be less 
important (Hurn & Landon, 1971)- 
Four male New Zealand rabbits, one year old, were obtained 
several days before immunisation and kept in theanimal houseq 
St. Thomas's Hospital Medical School.. 
Eight mg of the conjugate was dissolved in 2 ml distilled 
water and 6 ml of complete Freunds adjuvant was added. The mixture 
was emulsified by vortexing for 10 min. Each rabbit was injected 
with a total of 2 ml solution (2 mg P-BSA) subcutaneously and 
intra- 
dermally on 10 sites over the back and haunches. 
Booster injections of 1.5 to 2 mg conjugate in 1.5 to 2 ml 
of 50% incomplete Freunds adjuvant wore given in the same mann er 
at 8,20,28,33 and 50 weeks. 
Small test bleeds (1 - 2ml) were obtained from the marginal 
vein of the rabbits ear, which had been shaved, coated with a thin 
layer of vaseline, and nicked lightly with a needle. The blood wa3 
allowed to clot and then centrifuged at 1400 g for 10 min. The 
serum obtained was kept at 40C before testing the titre and cross- 
reactivity with 17a-hydroxy-pi-ogesterone (see below). 
Larger volumes of blood were obtained by puncture of theear 
vein in a similar manner except that a scalpel blade was used to 
incise the voin. Bleeds of 15 ml were collected at 18,239 32,40 
aand 49 weeks. Half of the serum was kept at 40C with 0.1% sodium 
azide, and the rest was frozen at -20 
0C in small aliquots. Rabbit 
no. 1 died at 42 weeks but the other rabbits were anaesthetised and 
the blood harvested at 60 weeks, either by incision of the jugular 
vein (Rabbit 4) or by catheterisation of the carotid artery (rabbits 
2& 3), when 40 ml and 60-70 ml were obtained, respectively. 
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2.2.2. Assessment of the antiserum 
The titre, cross-reactivity and affinity of the Furr 
antiserum (no. 465/5) and the St. Thomasl antisera were tested. 
Titre: The titre is performed by incubating various 
dilutions of the antibody with a fixed mass of radioactively 
labelled steroid, in stated incubation conditions. The optimal 
dilution (titre) is likely to change if any assay parameters 
are changed, and for this reason the Furr antiserum (465/5) was 
re-tested, although details had been provided by Dr. Furr. 
Working solutions of each antibody bleed were serially 
diluted in assay buffer, and incubated in the presence or absence 
of 500 pg unlabelled progesterone. The assay conditions are 
described in section 2-3-1- 
The titre curve for the Furr antiserum 465/5 indicated that 
the 115000 working dilution gave 53% initial binding and a steep 
decline in counts if 500 pg progesterone was added, and this was 
taken as the optimal titre. As 0.25 ml of this solution is taken 
for each incubatio. n, and diluted to 0.5 ml for the final assay 
volume, it is difficult to compare the titre with that of other 
workers who uso different assay volumes. 
The titre of the bleeds from the rabbits immunised with 11C(- 
OH-progesterone-BSA was tested and the change in titre is shown 
in Fig. 2.3. The working titre of the bleed finally chose (B2S2) 
was 113000, equivalent to a final dilution of 1/6000. 
Specificity: As an index of specificity the cross-reactivity 
of the test bleeds of the St. Thomas' antisera were tested using 
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Taýle 2.1. 
Cross-reactivity with 17a-OH progesterono 
Rabbit Cross-reactivity % 
6 weeks 15 weeks 
7.9 8.5 
2 1.1 1.0 
3 6-3 1.8 
4 1-5 5.4 
Furrs (from goat) - 0.8 (8 weeks) 
Rabbit 2 gave the highest specificity and a good titre at 
15 weeks, and a further bleed from this animal at 23 weeks (B2S2) 
was tested with eight other steroids. The antiserum of Furr was also 
checked for cross-reactivity. The incubation conditions are described in 
2.3-1. The results for B2S2 are shown in Fig. 2.4. The cross-reaction 
was calculated as: - 
pg progesterone causing 50% drop in binding x 100 
pg cross-reactant causing 50% drop in binding 
The main cross-reactivities found were for lloc-hydroxy- 
progesterone, 33%, pregrianedione 3.6%, 17a -hydroxyprogesterone 0.3%, 
pregnanolone, 0.31,161 and 200k-hyd'ýxqprogesterone 0.2%. Other steroids 
had cross-reactivities in tho order of 0.005% (cortisol and cholesterol) 
and 0.1% (oestradiol and testosterone). The specificity of the antiser= 
is similar to that of Furr (1973) and Spieler et al. (1972), who also 
used a conjugate to progesterone-llcK-hemicucci. nyl-BSA. 
Cross-reactivities for synthetic progestogens were also low 
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Affinity Constant: The affinity constanta of tho Furr antiserum 
and B2S2 were calculated using a Scatchard plot (see General 
Considerations). The affinity constant for B2S2 was derived from 
the linear portion of the curve (Fig 2-5), from the vertical intercept 
until an R value of about 1.0, since the effective affinity constant 
(K) governing the system is thought to be the K at Bog that is the 
K at the vertical intercept (Ekins, 1971). 
The K values obtained by this method were 3-7 x 10 
9 1/mol for 
B2S2 and 3-0 x 109 1/mol for the Furr antiscr=, which is in the mid- 
range of K values found by Midgley & Niswender (1970) for a variety of 
steroid antisera. 
2.2.3 Purification of Plasma Prior to Assay 
The objectives of a solvent extraction are to free progesterone 
from non-steroidal substances which may interfere frn the ausay, and A 7- 
S UM to remove arV natural stero4 ds which cross-react -with the anti er 
(such as 170ý-hydroxyprogesterone)'or which occur in high levels in 
plasma (such as the corticosteroids). These conditions are met by the 
batch of petroleum ether with boiling point 300 - 600C and hoxane, 
which is preferred by some workers (Furuyama & Nugent, 1971). 
Petroleum ether, bp 400 - 600C, and hexane were rodistilled, 
and 15 ml glass stoppered centrifuge tubes and 10 ml conical tubes were 
prerinsed with 1 ml of the solvent to be used. (1,2_3H) progesterone, 
5000 dpm/50 ul in ethanol was used as internal standard. 
Plasma from non-pregnant women was thawed at room temperature, 
and fibrinous matter was removed by centrifuging the samples for 5 min 
at 1000g. It is thought that removal of 1his material increases final 
precision (D. Fahmy, personal communication). 
0.1 to 0.4 ml of plasma were added to the tubes and diluted 
with waLer to a volume of 0.5 ml. 5000 dpm of 
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ethanol) was added to all the tubes and to scintillation vials in 
triplicate to estimate recovery. 
This step preceded the extraction by 30 min. to allow the 
added steroid in the tracer to equilibrate with the steroids already 
present. It is thought that this step is necessary as most steroids 
are bound to plasma proteins and will be extracted less readily than 
the free tracer, leading to an overestimate of the endogenous steroid 
extracted. Indeed, an equilibrium time o. I at least four hours has 
been recommended (Abraham, 1975). - 
After this incubation steP 5 ml of solvent was added to the 
tubes and the tubes were vortexed for 30 seconds. They wero then 
dipped into a mixture of carbon dioxide ice chips and ethanol for a 
few seconds. This froze the lower, squeous layer, and enabled the 
solvent layer to be poured off into 5 ml tubes. The solvent was 
evaporated to dryness at 50 0C in a water bath in a stream of compressod 
air. The extract was then redissolved in 0.4 ml-ethanol and vortexed 
briefly, before aliquots were taken for scintillation counting. 
No emulsions were formed using either of the solvents. The 
recovery of progesterone was 78 + ý% (n = 4) using hexane and 85. t 2% 
(n 4) using petroleum ether. This was a significant difference 
(P<0.01) when tested by Students It' test. However there was no 
difference in the variability of extraction for the two solvents 
(Variance ratio test). 
There was, very little difference between the two solvents, 
either chemically or in their ability to extract progesterone. There- 
fore petroleum etherg which is much cheaper, was the preferred solvent 
in future assays. The equilibrium time for tracer and plasma was 
changed to 16 hours at 40C. The average recovery of steroid in the 
subsequent assays is discussed in the section describing assay criteria. 
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2.2.4 Incubation with antiserum 
Preparation and storage of reagents 
Buffer: The RIA buffer was 0.1 M phosphate, pH 7.0 
containing 0.1% gelatin according to the method of Furr (1973), 
although it was not found necessary to add sodium azide as the 
buffer was kept at 40C and used within six weeks. 
Labelled progesterone: (1,2- 
3H) 
progesterone (58 ci/=ol) 
and after December 1976, (1,2,6,7-3H) progestorono (87 Ci/mmol)-were 
purified as described above. A working solution of label was prepared 
about weekly by evaporating label in ethanol at 50 0C in compressed 
air and adding buffer to give a solution of 20,000 dpm Of 
3H- *' 
progesterone (32-48 pg) per 0.25 ml buffer. 
Standards and Unknowns: The stock solution of 1 mg/ml was 
stored at -20 
0C for up to a year (see Section 1.3-2). Dilutions were 
made in ethanol at about six weekly intervals aild kept at 40C in glass 
stoppered tubes. The standards for assay were 0,25,50,100,2509 
500,1000 and 2000 pg in 0.1 ml volumes from the appropriate ethanolic 
solution, and these standards were added in triplicate to glass tubes, 
10 x 75 =. The standards were evaporated to dryness at 40 
0C in a 
vacuum oven attached to a vacuum pump prior to incubation. 
The unknown steroid samples were treated in an identical 
way in that 0.4 ml ethanol was added to the dried extracts after 
petroleum ether extraction, as described, and 0.1 ml volumes were 
transferred to 10 x 75 mm tubes in duplicate and evaporated to dryness 
as abovo . Incubation then proceeded in the tubes. 
Antiserum: Stock solutions of antisera were kept at 2-40C 
in 0.1% sodium azide and 1/100 dilutions in buffer were prepared for 
regular use. For the preliminary experiments antiserum no. 465/5 was 
used at a working dilution of 115000 in buffer. For assays after 1975 
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antiserum No. B2S2 from this department was used at a working dilution 
of 113000 in buffer. The antisera were diluted immediately before use 
and volumes of 0.25 ml were used in the incubation. 
Incubation Procedure 
Exact conditions of incubation time, temperature and assay 
volume vary widely in the literature, although the pH is relatively 
noncritical (Rosa, Malvano & Rolleri, 1974). The incubation procedure 
used inthis department was based on that of Furr (1973) but it was 
hoped to be able to shorten the overnight incubation and possibiy to 
improve the sensitivity. 
Standards, buffer, labelled progesterone, and antiserum 
465/5 are described above. A series of six standard curves cont&ining 
0,500 and 1000 pg were set up. The antiserum and labelled progestorono 
solutions were mixed (1/1) before use. 0.5 ml of this solution was added 
to the standard tubes and mixed briefly on the vortex mixer, and the 
tubes were incubated for a range of times and temperatures. After each' 
incubation 0.2 ml of dextran-coated charcoal (see 2.2-5) was addedl and 
vortexed for 4 seconds. After 20 min at 40C the tubes were centrifuged 
and 0.5 ml was taken for scintillation counting. 
Fig. 2.6 shows the standard curves for incubations at room 
temperature (20 0 C) for 60 min., and at 40C forf2O min. up to 16 hours. 
There appears to be a 'family' of curves with incubations over 2 hours, 
with no statistical difference (Students It' test) between the points, 
except the zero dose. However, comparison of the overnight (4 
0 C) and 1 
hour (20 0 C) incubations reveals statistical differences at all points. 
The B0 value increases with time, although-a steady state does appear 
to be reached after 2 hours, which is presumably equilibrium. This is 
in agreement with the work of Rosa, et al. (1974) who found that equi- 
librum was reached within one to four hours for progesterone, oestradiol 
and aldosterone. Unfortunately the experiment in Figure 2.6. gave no 












Fig. 2.6 Standard curve (+ S. D. )(n 3) for progesterone 
at different temperatures and incubation times. 
0 500 1000 
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One to two hours is the most convenient incubation 
time, although it may be necessary to reduce this on occasions. 
Although a pre-incubation step was not tested in the present experiment 
it was decided to add the antiserum separately, marginally before the 
tracerg for incubations of less than two hours, in the hope of improving 
the sensitivity. 
There seems little effect of temperature in this assay, so 
that the only possible advantage of increased temperature would be to 
increase solubility of the dried extracts, and as this did not appear 
to happen in this assay it was decided to carry out further assays at 
40C for one or preferably two hours* 
2.2.5 Separation of antibody-bound and free steroid 
Dextran is commonly used with charcoal for the separation- 
of free and bound steroid as it is thought that dextran might act as 
a molecular sieve, excluding the )Dound complex from the charcoal 
0 
(Herbert, Lau, Gottlieb & Bleicher, 1965). However Binoux & Odell 
(1973) have shown that dextran is unnecessary in some assays, but 
they recommend that conditions should be optimised for each assay 
method. 
.an 
The effect of dextran in the separation of free and bound prorestero e 
A solution of 5% charcoal (C) in buffer was made up and 
dilutions were prepared, shaking the solutions thoroughly before 
pipetting, and using a wide bore pipette. The dextran-coated charcoal 
(DCC) was made up in a similar manner, starting with a stock solution 
of 5% charcoal, 0.05% dextran buffer. Before use all solutions were 
shaken thoroughly and they were stirred continually at 40C while in 
use. 
The assay solution was prepared by mixing equal volumes of 
465/5 antiserum dilution and 
3H-progesterone 
solution to give a volume 
97 
of 0.. 5 ml, in 10 x 75 mn. assay tubes ("bound" progesterone, PAS) 
and also solutions of 
3H-progesterone 
only were added to a series 
of tubes and diluted to 0.5 ml with buffer ("free" progesterone, 
or antibody blank). 0.2 ml volumes of C and DCC were pipetted, 
using a Pipetman P1000, into tubes containing both free and bound 
steroid. The tubes were vortexed briefly and kept at 40C for 20 min. 
and then centrifuged at 40C for 10 min. at 2000 rev/min (1200 g) in 
a Mistral 4L. 
Supernatant volumes of 0-5 ml were removed using a 
Selectapette not more than 10 minutes after contrifugation, and 
placed in scintillation vials. The vials were counted on the Packard 
counter. The total counts in the supernatant of both 'free' and 'PAS' 
solutions was counted. The percentage of counts in the supernatant 
could then be calculated, and the percentage of counts adsorbed by 
the charcoal obtained by subtraction. 
Results: (a)'Adsor-ption of free steroid 
Dextran-coated charcoal adsorbs more than 95% of the ' 
free steroid at concentrations of 0.1% or more (Fig. 2-7). Charcoal 
alone is not'efficient until a concentration of 0.25% is reached. 
(b) Separation of bound and free steroid 
Fig. 2.7 shows the percentage of free 
3H 
adsorbed by the 
charcoal where bound steroid is also present. DCC adsorbs 40% of the 
label, indicating that 60% is bound to the antiserum. However at 
concentrations above 1% the level of 
3H 
adsorbed by DCC rises, 
indicating that the bound steroid is being 'stripped' from the anti- 
body complex. If C alone is used at concentrations where it adsorbs 
more than 90% free steroid, i. e. above 0.6% the level of apparent free 
steroid adsorbed increases more sharply. 
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Z The effect of increasing concentrations of 
charcoal (C) and dextran-coated charcoal (DCC) upon the 
percentage of 
3 H-progesterone adsorbed, in the presence 
(A, * ) and absence 010 ) of antibody. 
of Binoux & Odell (1973) since they were studying a protein-hormono 
assay with much higher protein content than is provided by additives 
in the buffer, such as BSA or gelatin. Indeed, it seems that the 
presence of dextran in the separation is advantageous for several 
reasons. Firstly, although both systems adsorb 97% or more of the 
free steroid (i. e. &n antibody blank of 3%), DCC is efficient at 
99 
lower concentrations, and over a greater range. This may be important 
as charcoal solutions are very heterogenous and fluctuations in 
concentration will occur during pipetting. Secondly, it appears that 
charcoal alone 'strips' the bound steroid more readily. This might 
give rise to several anomalies in the assay, such as positive blank. 
The effect of incubation time with DCC 
The incubation and separation procedures are described above. 
The only change was an increase in the concentration of label to 105 
dpm/tube, because very low counts'were expected tn the cupernatant of 
some tubes. The concentration of DCC was 0.625% charcoal, 0.00625% 
dextran (w/v) in buffer. All the incubations took place at 40C. 
Fig. 2.8 shows that in the antibody blank. tubes the 
concentration of 
3H 
adsorbed rose from 98% at 5 min to 99.2% at 
25 inin, with a plateau after this. When bound counts were present a 
similar pattern was seen but counts in the DCC started to rise after 
45 minutes. All the free steroid is adsorbed by this time, as 
-ed by the antibody blank-, so I indical. that any increase in adcorption 
represents stripping of the bound complex. Therefore the incubation 
time for DCC with progesterone chould be bet, ýeen 25 and 45 minutes. 
2.2.6 Experiments to remove blank effects 
From time to time both negative and positive blanks were 











Fig. 2.8 The percentage (+ S. D. ) of 
3H-progesterone 
adsorbed 
by dextran-coated charcoal as a function of time, in the presence 
0) or absence of antibody. (n=3 at all points)* 
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Effect of Detroleum ether on the standard curve 
Two standard curves were set up (see above). In the 
second set 5 ml of petroleum ether (40-60 0 C) was added to the tubes 
and evaporated to dryness in the vacuum oven before addition of the 
standards. The two curves are shown in Fig. 2.9. It appears that 
petroleum ether suppresses binding at up to 100 pg standard but it 
has the reverse effect at higher concentrations. Indeed, when this 
experiment was repeated petroleum ether caused higher binding at tho 
doses of steroid below 100 pg and no effect at higher temperatures. 
This demonstrates the unpredictable and variablo effect 
of petroleum ether residues on the standard curve, which may give 
rise to either positive or negative blanks. As the effect may not be 
consistent over the whole standard curve, the blank (if positive) 
should not be subtracted from all the readings, although some authors 
have advocated this (Abraham, 1974). If the blank effect was less than 
the detection limit of the curve it was ignored. If blanks were a 
persistent problem for a while (probably due to a particular solvent 
batch), then some petroleum ether was added to the standards to 
compensate. 
Investigation of negative blank 
It is possible that a negative blank is caused by an 
substance which interferes with the adsorption of free steroid by 
the charcoal to give a high 'antibody blank'. This can be tested by 
measuring the adsorption of 
3H-progesterone by'charcoal after mixing 
with plasma residues. 
Assay conditions have been described previously. Volumes 
of non-pregnancy plasma (0.4 & 0.2 ml) were diluted to 0.5 ml with 
water, and extracted as described above. Extract residues were re- 
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o--o standard curve 
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Fig. 2.9 The effect of the addition of 1 ml of petroleum 
-erone ether, 400-600C, on the standard curve (+ S. D) for progest 
(n=3 for all points). 
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dissolved in ethanol and 0.1 ml volumes transferred to assay tubes 
. 11 
and evaporated to dryness. 0.5 ml of a buffer solution containing 
20,000 dpm of 
3H-progesterone 
was added to the tubes and DCC was 
added as above. 
The level of antibody blank was 0.8% (n = 3) in the tubes 
containing 2 ng standard, and it was 0.75% (n = 3) in the tubes 
containing the plasma extracts. It seems that interference with 
the separation system is not' a cause of the negative blank. Many 
other mechanisms have been suggested which may account for the 
apparently higher binding in these blanks, such as interference 
with the tertiary structure of the binding protein (Pizarro & 
Kolanowski, 1972). This seems quite likely as the steroid-protein 
binding may be hydrophobic in nature (Rosa et al., 1974) and 
would therefore be susceptible to non-polar substances, such as 
1--pids, left in the dried residues of organic solvents. However 
blanks were rarely a problem (see page105)and when they did occur 
they were raraly outside the confidence limits of the B0 values 
2.3 The Final Progesterone Assay 
2.3-1. Summary of procedure 
The final working assay is summarised in the form of 
a flow sheet in Fig. 2.10. - The detailed procedures have already 
been described: - 
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0.2-0.5 ml plasma thawed at room temperature 
I Wo different dilutions added to tubes* 
Add 0.05 ml 
3H-progesterone (5000 dpm) 
in ethanol. Leave overnight at 40C. 
I 
Extract with 5 ml petroleum ether, 40-600C 
Vortex, freeze lower layer. Decant solvent 
Evaporate to dryness at 40 
0C in air. (rACLA(fOI4) 
Add 0.35 ml ethanol and vortex 
2x0.1 ml in 0.1 ml into insert vials to 
estimate recovery. Count 
for 10 min. or 10,000 counts 
3x0.1 ml of standard; 
0,25,50,100,250,500, 
1000,2000 pg in assay tubes 
Z. Vapul-mbe to dryness 
at 40 0C in. vacuum oven 
I 
Add ml of 113000 antiserum (B2S2) 
Add 0.25 m, 
3H-progesterone (20,000 dpm) (25-50 Pg) 
Incubate 1-2 hours at 40C. 
Add 0.2 ml of 0.62% DCC. Incubate at 
40C for 25. min. 
_D at 
1200 g for 10 min. at 40C. 
Decant 0.5 ml supernatant into insert vials 
Add 3-5 ml scintillation fluid. 




0) values for standard curve and 
interpolate 
unknowns. Correct for recovery. 
Fig. 2.10 Flow sheet for final progesterone assay 
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2-3-g Assay criteria 
The Standard Curve 
The initial binding was a mean of 54 + 10 (SD) % (n - 34) 
3 
in the presence of 35 pg of H-progesterone, and the mean B 50 value 
was 341 + 90 pg. The non-specific binding (antibody blank) was 
ccnstantly less than 2% of the total counts. 
Blank: Out of a total of 105 assays, there were 10 water blanks 
values that were higher than the initial binding B0 plus one standard 
deviation. These were classified as 'negative blanks'. In these 
assays the mean quality control was 6.9 1 1.8 ng/ml, which is not 
significantly different from the mean quality control of the 'positive, 
blanks (7-1 + 1.4 ng/ml). However negative waterilanks were 
reflected in negative plasma blanks, indicating that the effect of 
the negative blank was not parallel throughout the whole assays and 
this would be expected (see Fig. 2.9). There were also 54 water 
blank values within one standard deviation of the B0 value and 41 
water blanks reading between 25 and 50 pg on the standard curve, 
although there were no blanks higher than this. 
Sensitivity: The detection limit of the progeaterone standard 
curve was taken as twice the SD of the B0 value on the curvel and this 
value was a mean of 10 pg in our curves. In theory this means that 
the lower limit of sensitivity, taking 0.4 ml of plasma and an aliquot 
for assay of 25%, is 100 pg/ml. In practice the blank values were 
sometimes higher than 10 pg and the detection limit was usually 
taken as 25 pg. The corresponding sensitivity in plasma is 250 Pg/ml- 
Most authors quote a detection limit of 20 to 25 pg (Furr, 
1973; Furuyama & Nugent, 1971; Brenner et al., 1973), although 
Youssefnajadian et al (1972) could detect 10 pg on the standard curve. 
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Precision: The interassay precision was a coefficient of 
variation (CV) of-19% for a plasma pool of 7.0 ng/ml (n = 52) and 
a CV of 13%. for a pregnancy pool (n = 31). This compares with CV values 
of 15% (Brenner et al., 1973) and 13-7% (Furuyama & Nugent, 1971) 
for female luteal plasma pools. 
The intraassay precision was 15.0% (CV), (n = 5) for 
values less than 2 ng/ml, 9.5% (n = 5) for a value of 4.5 ng/ml, 
and 8.0%, (n = 5) for a value of 12.5 ng/ml. The corresponding 
precision by Furr (10,73) is 5.1% for a value of 0.8 ng/ml and 6.8% 
for a value of 3.2 nglml. 
For the entire method the mean CV was calculated for all 
the plasma values obtained. As each plasma sample was taken at two 
dilutions the pairs were not strictly duplicates, and it is difficult 
to make comparisons with other papers. Using a competitive binding 
protein assay and measuring duplicate pairs, Johansson (1969) found 
a CV of 14.5% for values of 5-10 ng/ml, which was calculated using 
the formula: 
CV dý 'j 
(2nL 
where d is the percentage difference between duplicate values and 
n is the number of duplicate paira (based on Snedecor, 1956). 
According to this formula the mean coefficient of variation of our 
values was 18% in the range 0-2.0 ng/ml (n = 28), 1M, in the rango 
2.0-10.0 ng/ml (n = 46) and 15% in the range 10.0-20.0 ng/ml 
(n = 38). 
Accuracy: Known amounts of steroid were added to water and 
to follicular phase plasma. The result is shown in Table 2.2. The 
endogenous steroid in the plasma was subtracted from the result, 
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Table 2.2. The recovery of progesterone added to water 
and to follicular phase i)lasma, corrected for endogenous levels. 
(X) 
Added steroid WATER (y ) 
A 
PLASMA (z) 
ng steroid SD n steroid SD n 
measured measured 
ng ng 
0.25 - - - 0.262 . 034 5 
0.5 0.505 . 12 7 o. 481 . 071 5 
1.0 1.05 . 22 52 1.059 . 065 5 
2.0 2.18 . 42 8 1.920 o. 168 2 
4.0 3.76 j - 11 1- I-I -I 
These values gave a regression equation for the water samples of: 
y=1.07X + 0.93 r=0.995 
and for the plasma samples: -" = 0-97X + 0.02 r=0.99 
Another measure of accuracy was to exchange samples with another 
laboratory. This was arranged with Dr. Margar6t Swain at the Imperial 
Cancer Research Fund, who used a compotitive protein binding assay. 
The following equation was obtained for pregnancy plasmas: - 
(our result) = 1.10, (Dr. Swains result) + 6.82 (n = 11) 
0.89 
An exchange was also carried out with Dr. D. Fahmy at Cardiff who 
was using an RIA similar to our own. The equation obtained for a 
comparison of female luteal phase bloods was: - 
our result = 1-03 (D. Fahmys result) + 1.78 (n = 13) 
0.92. 
Recovery: The procedural losses were estimated by calcdlating 
the recovery of some internal standard added to the samples before 
extraction. The mean recovery in one typical assay was 71-7 ±. 2.5% 
(n = 4ý). This compares with the mean recoverylound by Furr (1973) 
of 74.5 + 3.1%, although it may bo possible to obtain recoveries 
consistently above 90% if the right batch of petroleum ether is found 
0 . 03 
(Cameron & Scarisbrickl 19? 3). 
2.4 Development of the Assay for Aldosterone 
2.4.1 Antiserum 
The antiserum to aldosterone- 18,21-dihemisuccinato 
BSA was originally prepared by Dr. R. Haning in the laboratories 
of Dr. & Mrs. J. F. Tait. The conjugate was prepared by the method 
of Erlanger et al. (1957), and the conjugation and immunisation 
procedures are described by Haning, McCracken, St. Cyr, Underwood, 
Williams & Abraham (1972). The antiserum, batch No. 088, was 
already diluted 1/100 when received, and 1 ml. aliquots were 
frozen except for the working solu'tion, which was kept at 4oC 
with 0.1% sodium azi-de (BDH) added. The titre was tested using the 
I assay conditions and reagents described in I. atqr sections. 
Titre: A titre of 1/(5 x 105) was found to bind 50% of 50 P9 A 
of labelled aldosterone, and to give aB 50 value of 50 pg. 
Specificity: Haning et al (1972) found that there was less 
than 10,61 cross-reactivity with cortisol, corticosteronel cortisone, 
testosterone, dehydroepiandrosterone, progesterone, and oestradiol -17ý- 
It has been shown by Haning and co-workers (1972) that the cross- 
reactivity does not alter with different assay condithns, at least 
for this antiserum. 
However some of the cross-reactivities were retested by us 
and the following values were found: cortidol . 002%; corticosteroneg 
0.2%; dehydroepiandrosterone, . 005iAl; DOC . 06% tetrahydrocortisol 
. 001% and 18 -DOC . 01%. 
It was found that if ' the chromatography step in the assay 
was excluded the apparent value in the sample was 214 + 32% 
(n = 2) of the value found after LH-20 chromatography. The value 
I 
found after a charcoal purification, as described on P-1159was 121 + 
log 
23% (n = 3) of the value found after chromatography. Although this 
is not an absolute test of specificity it does show that a purification 
' step is necessary and that the chromatography step is preferable to 
other methods. 
Affinity Constant: The affinity constant was calculated from 
'a Scatchard curve and found to be 2x 10 
10 1/mol with a second slope 
at higher concentrations of bound antigen. 
2.4.2. Purification of plasma prior to assay 
While there is disagreement about chromatographic procedures 
for the purification of plasma, most authors employ an initial 
extraction step with dichloromethane(DCM). 
Extraction ste_p: Glass-stoppered tubesl of 30 ml and 15 ml 
capacity, were pre-rinsed with 5 ml dichloromethane before use. 
0.05 ml of internal standard containing 9000 dpm of (112- 
3H) 
aldosterone was added to the tubes and the voluma made up to 2 ml 
with glass distilled water. Total counts were estimated by adding 
0.05 ml of internal standard directly to the counting vials. Either 
8 ml (to the 15 ml capacity tubes) or 20 ml (to the 30 ml capacity 
tubes) of dichloromethane was added and the tubes were Vortexed for 
one min. The aqueous layer was removed using a Pasteur pipette 
attachdd to a small suction pump. The dichloromethane was 
evaporated to dryness in an'air stream at 400C in a water bath. 
W hen just a trace of solvent remained, the residue was dissolved 
in 0.2 ml of DOMethanol, 98/2 (this was to be the solvent system 
for the next stage in the purification). The recovery of labelled 
steroid was measured by counting volumes of the extracts by liquid 
scintillation spectrometry. 
Recovery of internal standard after 30 minutes pre-incubation 
with the plasma was 67 + 4% (n = 2) with 20 ml solvent and 55 1 11% 
110 
(n = 4) with 8 mi solvent. If the pre-incubation step was omitted 
%, he recovery was 60 + 1% (n t 
These recoveries are low in comparison to those of other 
workers; Poulsen et al (1974) found a recovery of 8ý+ 5% using 10 ml 
DCM with 1-3 ml serum. The poor recovery in this experime. nt could 
be due to inadvertent removal of DCM while aspirating the upper 
layer, or it could be due to losses in the blowing down process as 
Poulsen et al (1974) used nitrogen and not air. 
There was no statistical difference between recoveries with 
and without preincubation suggesting either that endogenous aldo- 
sterone is not bound to plasma proteins or that 30 minutes pre- 
incubation is not sufficient. There is some recent evidence for a 
specific a1dosterone-binding protein in human plasma (Richardson, 
Nowaczynski & Genest, 1976) but the importance of this is not yet 
known. 
It was decided to use 8-10 ml solvent (as the smaller tubes 
were more convenient) and to use nitrogen if at all possible in the 
blowing down of aldosterone solutions. 
Further purifications of the Dlasma extracts 
As most antisera are not specific enough to discriminate between 
aldosterone and the corticosteroids in a thousandfold excess, (see 
Chapter 1) it has been necessary until recently to perform a 
clu, omatographic step in the assay. 
The first RIA reports used paper chromatography for purification 
of plasma extracts with antisera crossreactihg in the order of 0,01% 
for cortisol. Bayard et al (1970) used the B5 system on Whatman 
No. 2 paper and Mayes et al. (1970) added an extra silica gel column 
after this. Ekins, Newman, Piyasena, Banks & Slater (1972) used 
the B5 system with SG81 paper, 
ill 
Ito et al. (1972) first described a purification step using 
Sephadex LH - 20 on a 60 x1 cm-., glass column and using dichloro- 
methane/n. ethanol as the-solvent. They reported that blank values 
were negligible. LH - 20 chromatography has been reported for other 
applications such as urine extracts (Waldhhusl et al., 1972) or to 
measure aldosterone and deoxycorticosterone in the same sample 
(Castro, Kutas, Jelen & Bartos, 1974). LH - 20 columns using water 
as the solvent have been described (Nowaczynski et al., 1974). 
1 
Other workers have tried to avoid the chromatography step. 
Farmer, Brown, Howard and Fabre (1973) oxidised aldosterone to the 
lactone and used an antibody specific to the lactone itself. Other 
workers have taken an immunological approach and have used an anti- 
body twice, firstly to remove the aldosterone from the solutions in 
the bound form, then to re-extract and assay it (Gomez-Sanchozl. 
Kem & Kaplan, 1973; Martin & Nugent, 1973). However these methods 
were tedious, and the only possible advantage over chromatography is 
the possibility of automating these techniques. 
Highly specific antisera have bpdextensive purification . 
ý) 
unnecessary (see Chapter 1) but these antisera were not easily 
available to us. It was decided to try Sephadex LH - 20 first since 
it had already proved convenient, and also to test non-chromatographic 
methodsof purification. 
LH - 20 columns 
Coliunns were prepared using dichloromethane/methanol, 98/2, 
as described in section 1.3-1. except that, to allow for a reservoir 
of 1 ml capacity, the columns were only 6.5 cm in height. Columns 
containing Sephadex LH - 20 which had been soaked in distilled water 
were also prepared. Volumes of (192-3H) aldosterone containing 0.1 pCi 
(630 pg) were evaporated to dryness and redissolved in 0,2 ml 
of the solvent to be used on the column. The steroids were applied 
112 
to the columns and 0.5 ml fractions were collected until 1.5 ml. 
solvent had been eluted. (1,2- 
3H) 
progesterone (0.6 pCi, '3.. 2 ng) 
and (1,2_3H) cortisol (0.1 PCij 0.4 ng) were also added to the 
columns to determine the elution pattern. They were mixed with 
3H 
aldosterone and run on the columns as before. 
The flow rate for DCMAIeOH was 10 ml /h and for water it 
was about 5 ml/h. The elution pattern for both systems is shown 
in Fig. 2.11. These graphs are a composite of three different 
columns running aldosterone, aldosterone plus cortisol and aldo- 
sterone plus progesterone. No separate peak could be obtained for 
cortisol or progesterone on the water column, at least in the first 
ml eluate. A sharp peak for aldosterone was obtained at 2.25 - 
3.25 ml eluate on the DCM/MeOH column, with a peak for progesterone 
at 1 ml and for cortisol at 5 ml. The peak for aldosterone on the 
water columns was at 2.5 - 3.5 ml. on the column, and at 3-4.5 ml on 
the second. 
It is difficult to compare the elution patterns of other 
authors with our own as the column dimensions are all different. 
However an attempt was made to do this, assuming the principle of 
gel filtrationsand calculating the volvne of each column from the 
dimensions mpplied in the papers by applying the formula (volume 
=r2x height ). The comjparison is shown in Table 2.3. 
TABLE 2.3. The elution pattern of steroids 
using the DCMPeOH (98/2) sjstem and-different 
column sizes 
Author Vol ým 
cm 
conversion 
factor (10- Prog 
PEAK oil 
Aldo Corticol 
This study 1-3 1 1 2-7 5 
Ichikawa et al (1974) 7.5 5.8 - 2.6 4.2 
Daniel et al (1974) 15.1 11.6 1 2.0 3.1 
Waldhausl et al(1972) 19-7 15.1 - 2-3 3-7 

























FiR. 2.11 Elution patterns of Aldosterone (Al) (-'- '19 
aldosterone plus progesterone (P) (---i, and aldosterone plus 
cortisol (CO) (-) from columns 6.5 cm in length, packed with 
Sephadex LH-20 in two solvent systems; A, dichlorcmethane/methanol, 
(9812) and B, distilled water. A small peak (I) was eluting in 
the same position as progesterone in solvent sy#em A when 
aldosterone was run. 
vi 
This is a very crude comparison, as other factors such as 
temperature and flow rate were not taken into account. But 
columns of different volume seem comparable in this way, and if 
anythingg the smaller columns allow a. relatively better separation. 
This encouraged us to proceed with the 'mini' columns further. ' As 
to the better solvent system, the dichloromethane/methanol system 
was preferable on two theoretical and two practical counts. 
1. The separation between cortisol and aldosterone using the water 
system was not proved to be satisfactory despite the results of , 
Nowaczynski et al (1974). There was no apparent reason for this. 
Piles of the water columns were not reproducible. 2. The column pro-A 
This is especially important if large batches of coliimrrare to be 
run without checking the peak each time. 
3. The water columns were slower to run, and nonpolar steroids such 
as progesterone were eluted rather late. This would mean that columns 
would require. washing with very large volumes of'water between runs. 
4. An eluate in water would be difficult to evaporate to dryness in 
a short time. 
Therefore, rather reluctantly in view of the unpleasantness 
of DCM, the DCM/MeOH columns were used in future assays and the water 
columns were discarded. 
Calibration of the columns 
The reproducibility of the elution pattern was tested, from 
column to column, and marker dyes which help to locate the steroid 
peak (Drewes & Kowalski, 1974) were investigated. 
Columns were prepared as in Section 1.3-1. except that 
columns were 6.5 cm. in height. Three columns (A-C) were made 4 
days before use and kept in a tightly sealed jar containing some 
solvent, at 40C. Three weeks later another column (D) was made up 
freshly and run on the same day. The dyes were isatin and 1,4, 
diaminoanthroquinone which had been recommended by Ichikawa, Murata 
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Shigiya. (1974). Columns A-C were run simultaneously after 
20, OCO dpm 3H-aldosterone in 0.2 ml eluate had been added to each 
column. ' The crystalline dyes were dissolved in a few drops of the 
solvent and added to the columns with the 
3H-aldosterone. 
The elution pattern for the four columns can be seen in 
Fig. 2.12. Although column D was prepared and run three weeks 
after A-C the fraction eluting aldosterone remains constant. The 
flattened peak and long 'tail' of column C could be due to 
Sephadex escaping from the column, since some of the gel was found 
in the collected fractions. 
Isatin did not appear until after the main peak of aldo- 
sterone (Fig. 2.12). 1,4diaminoanthroquinone itself separated into 
two dyes on the column. The stronger purple dye eluted at the same 
place as isatin, and weaker pink dye was eluted before the main 
peak of the aldosterone. 
As the columns are reproducible from column to column and 
over time, it seems safe to use the columns without dye, so long 
as prior calibration of a few columns from the batch has been 
carried out. The recovery of 
3H-aldosterone 
from the columns is 
described in section 2.5.2. 
Evaluation of charcoal precipitation technique to separate aldosterone 
from (bound) cortisol 
Cortisol is largely bound to cortisol binding globulin, while. 
aldosterone is largely free or bound loosely to albumin (Sandberg, 
Rosenthal, Schneider & Slaunwhite, 1966). Aldosterone can be 
partially purified by separating bound and free steroids in plasma, 
and Varsano-Aharon & Ulick (1974) have used charcoal to do this 
before assay with antiserum No. 088. We attempted this method in 
















FiE. 2.12 Reproducibility of elution patterns from Sephadex 
LH-20 (DCM/methanol, 08/2); columns A'Q(---ý, B (A-)j and - 
C (0---), packed and eluted together, and column D (05--) packed 
and eluted three weeks later. The position at which the dye 
isatin "is eluted is indicated. 
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MIS eluate 
The charcoal method of purification was adapted from the 
method of Varsano-Aharon & Ulick (1974). 3 gm of Norit A was 
'waphed' by vigorous Shaking with 20 ml O. lM phosphate buffer, 
and then centrifuged for 15 min at 1400 g. The buffer layer was 
removed and 50 ml buffer containing 60 mg dextran C was added. 
This was the DCC solution used to purify the plasma (solution A). 
Plasma samples from pregnancy, and water samples containing known 
amounts of steroid, were assayed. The plasma (0.2 ml) was diluted 
to 2 ml with water in 15 ml capacity stoppered centrifuge tubes, 
mixed with 6000 dpm 
3H-aldosterone, then left for 30 min at 40C. 
Charcoal purification: -0.5 ml of solution A was added to the 
samples and the tubes vortexed for 4 seconds- The tubes were 
centrifuged at 40C at 1200 g for 10. min and 1. -he supernatant was 
removed and a1 ml fraction taken for counting. The charcoal 
precipitate was washed with 5 ml buffer, the tubes vortexed and 
centrifuged again, and the buffer removed. The aldosterone in the 
charcoal was resuspended using 0.5 ml DCM, vortexed briefly, and a 
further 7 m! DCM added. It was found that only by this two stage 
process was the charcoal resuspended. The tubes were finally 
centrifuged as above and the DCM poured off. It was found that 
the charcoal did not precipitate as expected from the solvent, but 
that the DCM could be poured off cleanly. The DCM was evaporated 
to dryness at 40 0C and the residue redissolved in 1 ml ethanol. 
Fractions were taken for assay and to estimate recovery by liquid 
scintillation counting. 
LH - 20 columns: Identical samples were purified by dichlorOmethane 
extraction and column chromatography as described previously. 
Assay,: All the samples were assayed as described in 2.5.1. 
The recovery of internal standard was a mean of 61 + 6% 
(n = 18) for c-ýOrcomt purification. The amount of aldosterone lost 
in the initial charcoal separation is low as less than 1% of the 
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radioactivity was found in the initial supernatant. Therefore the 
losses must occur because not all the free aldosterone is re- 
dissolved in the DCM. 
The very low recovery of aldosterone in the bound fraction in 
the pregnancy samples is surprising since Varsano-Aharon & Ulick 
(1974) found that 15-30% of 
3H-aldosterone 
may be present in the 
supernatant and these figures may be higher in pregnancy when CBG 
is increased. The amount of aldosterone bound to CBG, although 
small, is variable and may be altered by changes in temperature and 
CBG concentration (Westphal, 1970). 
The plasma values found after charcoal and column purification 
are shown in Table 2.4.. 
TABLE 2.4. Values found in the same plasma extracts 
after column or charcoal purification 
Sample COLUMNS ' 
-- 
CHARCOAL Mean Charcoal 
duplicates mean CV,; mean CV% Mean Columns 5ro 
pg1m, pg1ml 
Non pregnancy 243 26 343 29 141 
Pregnancy (1) 474 10 595 20 126 
Pregnancy (2) 588 4 567 19 96 
50 pg 78 11 41 52 
250 pg 234 26 62 26 
blank 2-5 6. o 240 
The blank values for both systems are satisfactory, but there 
is a worrying over-estimate in the plasma samples measured by 
charcoal purification in two cases, indicating some cross-reactivity 
still remaining. It is inferred that it is an overestimate by the 
charcoal method rather than an underestimate by the column method 




were a systematic error in the column method causing an under- 
estimate it would show up in all the samples presumably, whereas 
an overestimate due to crossreactivity will naturally be seen only 
in samples containing plasma. 
Another consideration is the speed and convenience of the 
purification method. Although the charcoal method could be speeded 
up, at present, with three centrifugation steps, it is scarcely 
easier than the miniature columns. 
In general the LH-20 Iminicolumns' are a satisfactory and 
fairly convenient form of purification of. the plasma extracts, especially 
as expensive columns and fraction collectors are unnecessary. 
2.4.3 Incubation with antiserum 
Preparation and Storage of Reagents 
Buffer: Although the National Institutes of Health recommend borate 
buffer for this antiserup, phosphate buffer would be more convenient, 
and so the two buffers were compared. 
0.1 M phosphat -e buffer (buffer p) pH 7-0 was prepared containing 
0.1% gelatin. Borate buffer, (B)-pH 8.0, was prepared by dissolving 
boric acid in 250 ml water with 1.35 gm sodium hydroxide. 15 ml conc. 
HU was added and the solution made up to 500 ml with water. The pH 
was adjusted to 8.0 with drops of conc. HCI. To 100 ml of this 
solution B was added 0.24 gm BSA to give a borate buffer with 0.24% 
BSA(buffer BBSA). 
Three standard curves were prepared and incubated with the 
three buffers with conditions described in section 2.5.1. The DCC 
solutions were identical except that they were prepared in the three 
buffers. 
The standard curves are shown in Fig. 2.13. The non-specific 


















Fig. 2.13 The effect of phosphate (P)l borate (B) and 
borate plus BSA (BBSA) buffers on the standaý-d curve (+ S. D, n=3) 
for aldosterone. 
4t-o P buffer 
o-----o B+BSA tuffer 
B alone 
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detectable dose was 7 P9 for P and 15 pg for BBSA. The omission 
of BSA from the borate buffer led to an almost complete decline in 
binding, which could be due to either the, 
3H-steroid 
or the anti- 
body coming out of solution. 
Phosphate buffer in the incubation led to higher initial 
binding and a steeper curve, and less non-specific binding than 
occurs with the buffer containing BSA. Although borate bufferl 
pH 8.0, with BSA is mentioned in most published methods it seems 
thai the phosphate buffer with gelatin provides a better standard 
curve and is also cheaper. 
Labelled Aldosterone: (192_3 H) aldosterone was purified as 
described in 1.3-1. and the purified solution was kept in ethanol. 
A-working solution of 80,000 dpm 
3H-aldosterone/nl in PH 7-0 
phosphate buffer was prepared at weekly intervals (250 Pg/ml)* 
Standards & Unknowns: The standard stock solution (see Section 1-3.2) 
was diluted in ethanol to give solutions containing 5,10,25,50, 
100,250,500 and 1000 pg/0.1 ml, and these were kept for up to two 
weeks at 40C in glass stoppered tubes. For the standard curve 
triplicate 0.1 ml volumes of the above dilutions were added to 
10 x 75 mm glass assay tubes. 
The eluates from the columns were evaporated to dryness at 
40C in a stream of air, using the manifold described in the method 
for progesterone. They were redissolved in 0.35 ml ethanol. Two 
0.1 ml volumes were added to assay tubes and 0.1 ml was also added 
to insert vials to estimate the recovery. 
The standards and unknowns were evaporated to dryness in a 
vacuum oven before the addition of the antiserum and label. 
Antiserum,: The 1/100 dilution of antiserum was further diluted to 
give a working solution of 1/250000- 0.25 ml of this was added to 
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each assay tube. 
Incubation Prodedure 
The effect of the sequence in which reagents are added: 
Four standard curves were set up. The antibody working 
solution (see above) was mixed with an equal volume of the working 
solution of 
3H-aldosterone, 
and 0.5 ml of this mixture was added to 
two standard curves, and incubated for 1 hour and 24 hours at 40C. 
To the two other standard curves the antibody solution (0.25 ml) 
was added separately firstj and 0.25 ml of the 
3H 
solution was added 
after 10 mins. Incubations of 1 hour and 24 hours at 40C wore 
followed by the addition of DCC as described below. 
The data are rather scanty but the standard curves are shown 
in Fig. 2.14. There is a steeper curve at 1 hour if the unlabelled 
steroid and antibody are preincubated, but this difference disappears 
at 24 hours, when presumab'j'. y equilibrium occurs.. Rodbard et al (1971) 
predict that a preincubation will make the assay more sensitive under 
non-equilibrium conditions, and although this was not proved 
conclusively on this occasion, a preincubation step was included in 
further aldosterone assays. 
The effect of temperature 
Some standard curves were incubated for 5 min. at 37 0C before 
further incubation at 40C for 1 hour and 3 hours. When these curves 
were compared with those in which no warming occurred, there was no 
significant difference between the initial binding (BO) and the 
detection limits of the curves. 
2.4.4. Separation of antibody-bound and free steroid 
Dext. -an coated charcoal is the preferred separation medi= for 
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even for the same antiserum (WaldhaUsl et al., 1972; Vetter et al., 
1973). Other methods of separation have been used, such as Florisil 
(Ito et al., 1972). A novel method has been described by Jowett, 
Slater, Piyasena & Ekins (1973), in which they extract thefree 
aldosterone directly into a toluene based scintillant. Although 
this-method was reliable, careful control of the timing of the 
extractions is needed, and another problem is that each separation 
would require an extraction tube with stopper, which in an average 
assay would be more than a hundred tubes. Taking these points into 
account, the toluene based method was not attempted, and the DCC 
solution from the progesterone assay was tried first, 
Effect of incubation time 
A 'bound' solution of 
3H-aldosterone 
with 1000 pg of un- 
labelled steroid ardantibody was prepared as described abovet and 
3 
a 'free' solution of H-aldosterone alone was also prepared. After 
incubation for 1 hour at 40C, 0.2 ml of 0.6259o charcoal (Norit A), 
0.00625Y6 dextran in buffer was added to all the tubes. After various 
incubation times at 40C the tubes were centrifuged at 1200 g for 
10 min. at 40C. 0.5 ml of the supernatant was removed and added to 
insert vials for liquid scintillation counting. 
In the antibody blank more than 99% of the counts are 
adsorbed by the DCC after 5 minutes. When bound counts are present 
equilibrium is reached by 10 minutes, and there is no increase in 
counts after this, indicating that Istripping"of the steroid from 
the antibody does not occur. This is perhaps a reflection of the 
high avidity of this antiserum. 
2-4-5 Investigation of blank effects 
Negative blanks were not a problem in this assay, although 
positive water blanks did occur sometimes (see 2-5.2). The origin 
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chromatography step, and both these were investigated. 
The assay procedure is cbscribed in earlier sections. In 
the first experiment 1 ml of DCM (not redistilled) was added to 
the standard curve, evaporated to dryness, and the standards 
assayed. In the second experiment 1 ml of eluate from a fresh 
Sephadex LH-20 column was added to the standard curve and d: fted. 
In the first experiment the DCM residue had no effect on the 
standard curve (see Fig. 2.15). Although there was a slight fall 
in binding at the point B0 this was not significant. In the second 
experiment there was a significant fall in binding at 0,25,50 and 
100 pg (see Fig. 2.15). On the basis of these findings it was. 
decided to add 1 ml of column eluate to the assay standards, a 
procedure also adopted by Ito et al. (1972). 
2.5 The Final Aldosterone assav 
2.5.1. Summary of procedure 
The assay procedure for aldosterone is summarised below. 
1 
Extraction: 15 ml glass stoppered tubes were prerinsed with DCM. 
One ml of plasma was mixed with 5000 dpm (16 pg) of (112_ 
3H) 
al. dosterone. in the tubes and left for 30 min. at 20 0 C. 
10 ml of DCM (redistilled) was added and the tubes were 
vortexed for 30 seconds. The supernatant was removed, using a 
gi lass pipette attached to a vacuum line. The dichloromethane was 
evaporated to dryness in air at 50 0C and the extracts redissolved 
in 0.3 ml of DCM/M. ethanol, 98/2, prior to chromatography. 
Columns: Columns 6.5 cm in height were prepared in prerinsed Pasteur 
pipettes, using a3 mm glass bead as a support. The Sephadex LH-20 
was soaked for 4'hours in DCM/Methanol, 98/2, and the resulting 
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slurry was packed into the columns, using a glass fibre disc 
(cork borer size 3 in diameter) at the top of the columns. Fractions 
were collected by adding 0.5 ml volumes of solvent mixture to the 
drained columns (using a Boehringer IRI pipettor), allowing all 
the solvent to run through, and transferring the column to a fresh 
collecting tube before adding the next volume. The first 2 ml 
were discarded, and the next 1.5 ml collected. This fraction was 
evaporated to dryness at 50 0C in air. 0.33 ml of ethanol was added 
and the tubes vortexed, then 0.1 ml was taken for recovery and two 
0.1 ml fractions were taken for assay. The columns were rinsed 
through with at least 10 ml of solvent, and kept in a screw-capped 
jar containing solvent at 40C, to be used again. 
Assay: Standards in 0.1 ml ethanol of 0,5,10,25,50,100,250 and 500 P9 
and unknowns were added to 10 x 75 nim glass tubes and evaporated to 
dryness at 400 C in a vacuum oven. A dilution of 1/250,000 of 
antiserum (no. 088) was prepared in 0.1 M phocp hate buffer, pH 7-0 
with 0.1% gelatin. A solution of (112-3H) aldosterone containing 
15,000 dpm/0.25 ml was prepared. 0-25 ml of the antiserum was added 
to the tubes in random order, and after 10 min. at 40C 0.25 ml(48 pg) of 
labelled aldosterone was added to the tubes in the same order. The 
tubes were mixed gently and left for 1h at 40C. 0.2 ml of 0.625% 
charcoal, 0.00625% dextran in buffer was added to the tubes and after 
15 min. at 40C they were centrifuged for 10 min. at 1200 g at 40C. 
0.5 ml of the supernatant was transferred to an insert counting 
vial and 3.5 ml of Triton/toluene scintillant added. The vials were 
counted for 10 min. or 10,000 counts and the assay values were 
calculated as described in Section 
2-5.2. Assay criteria 
Standard Curve: The mean B0 value for 21 assays was 55-3% 
+, 7.9%. and the mean B 50 value was 75 pg. The mean non-specific 
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binding was 2+1.5% of the tctal counts. 
Blank: The blank was in the range of 0-5 pg in 18 out of 21' 
curves, with blanks of 5 to 10 pg on 3 occasions. The mean blank 
was 2+3 pg. The values found in methods using LH-20 chro. mato- 
graphy are generally within twice the standard deviation of B09 
i. e. from 0 to 6 pg (Ito et al., 1972). The blank may still be 
appreciable in non-chromatographic methods owing to factors in the 
methylene chloride (Poulsen et al., 1974). McKenzie & Clements 
(1974) avoided the problem by taking the standard curve through the 
extraction procedure. 
Sensitivity: The detection limit of the standard curve was 3 pg 
and the corresponding plasma value is 17 pg/ml aldosterone 
when 1 ml of plasma is taken. Detection limits using the same 
antiserum as our own (088) have varied from 6 pg (Ito et al., 1972) 
to 15 Pg (Nowaczynski et al., 1974), although values as low as 1.7 P9 
Wowett et al., 1973) have been recorded for other antisera. The 
equivalent sensitivity for a double isotope derivative assay is 
140 pg/20 ml (Nowaczynski et al., 1967). 
Precisim: The interassay precision was tested by means of a quality 
control sample and the coefficient of variation was 11% (n = 16) 
for a value of 249 pg/ml. The value found by Ito et al (197? ) is 
11% and the precision of Daniel et al. (1974) varied from 3 to 14%, 
with both groups using similar assays to our own. However a C. V. of 
22% has been reported for low plasma levels even when chromatography 
is omitted (McKenzie & Clements, 1974). 
The intraassay variability was calculated as described for 
progesterone. The coefficient of variation for values of 0-100 pgj 
100-250 pg/ml and 250-500 pg/ml were 10.1%' (n = 16), 10.6% (n = 45) 
and 8.2% (n = 17) respectively. These are close to the figure of 9.2% 
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found by McKenzie & Clements (1974). 
Accuracy: 50 to 1000 pg of aldosterone was added to water and 
assayed. The values obtained can be represented by the equation: 
y=0.998x - . 73 r=0.998 (n = 41) 
An accuracy study was not carried out in plasma, but the 
results in water shown no apparent systematic error. An accuracy 
study was carried out with adrenalectomised plasma using the 
same antiserum as our own after LH - 20 columns, and the accuracy 
was 102 + 2.6% (Ito et al., 1972) 
Recovery: The recovery of 
3H-aldosterone 
added to plasma was 
58 + 9% in 18 assays. Recoveries in this range are found for 
paper chromatography (Migeon et al., 1973) and LH - 20 chromato- 
graphy (Ito et al., 1973) but recoveries after silica gel column 
chromatography are slightly higher at 77 ± 5% (Mayes et al., 1970). 
Recoveries after solvent extraction alone may be 85 - 90% 
(McKenzie & Clements, 1974; Poulsen et al., 1974). 
Conclusions: 
Although this method has now been superseded by methods 
using more specific antisera, the reliability criteria are 
comparable with these newer methods in all respects apart from 
the sensitivity and speed. 
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2.6 OESTRA6IOL 
An assay for 17p-cestradiol was developed by other members of 
this Department, particularly by Mr S Ord. 
2.6.1. Antiserum 
The antisera (R3 & R4)kindly provided by Dr. P. D. G. Dean, 
were raised against 17fi-oestradiol-6(-o-carboxymethyl)-oxime BSA 
in rabbits. 
Titre: The titre of the first batcb7, R4, was found to be 115000 
when 0.1 ml of this solution was added to the assay. The titre of 
the -second batcN R3, was 1/15,000 under similar conditions. 
Specificity: The cross-reaciivity of the antisera. are described 
by Exley, Johnson & Dean (1971). The cross-reactions with oestriol 
andcnstrone are in the order of 1%, and very low cross-reactions 
(0.01%) are evident for non-oestrogenic steroids. Other oestrogens 
such as oestrone are present to an equal or lesser extent than 
oestradiol in menstrual cycles, so that cross-reactions of 1% or so 
should not create problems. 
Affinity-Constant: The affinity constant was calculated from a 
Scatchard curve and was found to be 2x 10 
10 i/mol. 
2.6.2. Summary of Procedure 
Thanks to the highly specific antisera, described aboveg the 
assay did not require purification of the plasma beyond a simple 
extraction to remove non-specific factors. The procedure is outlined 
below; details of the reagents used will be iound in preceding sections. 
Extraction 
The solvent most commonly used for the extracticn, ofoestradiol 
is diethyl ether (Abraham, 1969; Mikhail, Wu, Ferin & Vande Wiele, 
1970), although Dr-. P. Hurt in this Department found that extraction 
0 
was, as good with dichloromethane. Dichloromethane is non-flammable, 
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yet with a low boiling point for rapid evaporation, and it was 
chosen for the extractions until assay No. 15. However after this 
the accuracy in the next few assays was very low, and it was found 
that diethyl ether extractions were preferable, so that ether was 
used in assays after this. 
15 ml glass stoppered tubes were rinsed with 1 ml of the 
solvent to be used, and 2000 dpm (3 Pg) of 
3H 
- labelled 170- 
oestradiol was added to each tube, together with 0.5 - 1.0 ml. 
of the plasma samples, in duplicate. The mixture was left for 
1h at 20 0 C. 
If dichloromethamwas used; 10 ml of redistilled dichloromethane 
was added, the tubes vortexed for one min. and the aqueous layer 
removed by suction. The solvent was evaporated to dryness at 50 
oc 
in air. 
If diethyl etýer was used; 5 ml. of ether was added to the tubes and 
vortexed for one min. The bottom layer was frozen in a mixture of 
solid carbon dioxide chips in ethanol, and the ether layer was 
decanted and evaporated to dryness at 400C in air. 
The residues from both extractions were redissolved overnight 
in 0.35 ml. buffer and vortexed the'next day. Two 0.1 volumes were 
added to assay tubes and Oil ml. was added to scintillation vials 
to determine recovery. 
Assay 
A solution of 
3H-labelled 170 -oestradiol of 150,000 dpm/ml 
in 0.1 M phosphate buffer was prepared weekly from the repurified 
stock solution. Standard solutions of 17/3 -oestradiol were prepared 
weekly in buffer from the stock solution of 1 mg/ml in ethanol, and 
volumes of 0.1 ml of buffer containing 012.5,5,10,25,50,100 and 
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250-pg of 17/3 -oestradiol were added in triplicate to assay tubes. 
0.1 ml of the anti-serum (see above) was added to the standards 
and unknowns and aftei an incubation for 30 min at 40C, 0.1 ml (20 pg) 
of the label solution was added, the tubes were incubated at 40C 
for a further hour. 
1 0.5 ml of O.. Ia'charcoal, 0.05% dextran in buffer was added to, 
all the tubes, vortexed briefly, and incubated at 40C for 20 mi-n. 
The tubes were centrifuged at 1200g for 10 min. at 40C. 0.5 ml. 
of the supernatant was removed, using a Selectapettel and placed into 
insert vizils for liquid scintillation counting, as described in 
Section 1.2. 
2.6., 3. Assay Criteria 
Standard Curve 
The mean B0 for R4 was 72 + 8% (n 8) and R3 wx 69 + 6% (n 2). 
The detection limits of the curve were 3 pg for-R4 and 1.5 P9 for 
It . 
the-other antiserum, R3. Kushinsky & Anderson (1974) reported a 
detection limit of 1 pg, but other quoted limits have been as high 
as 10 pg (Powell & Stevens 1973). High sensitivity for mstradiol 
is important as. the plasma levels are especially low in most 
circumstances. The B 50 values were 50 pg for R4 and 22 pg for R3. 
The mean non-specific binding was 3. t 1.8% for R4 and 7-5 + 2% for 
R3. 
Blanksl:. The water blank was within the standard deviation of the 
zero point in all but 3 assays. Two assays had 'negative blarA,. ' 
and in one assay there was a positive blank of 25 pg. This assay 
was discarded. The mean positive bloaLk was 1-5 ±1 pg (n = 10). 
In earlier column chromatographic methods, 'the blank could 
be 8+6 pg (Ermnent et al., 1972), or even 11 pg (Mikhail et al., 
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19,70)9 which meant volumes of plasma of up to 5 ml, had to be 
used to overcome this effect. In non-chromatographic assays 
England et al., (1974), using benzene to extract, found a blanie. 
of 4 pg, while Aso et al. 9 (1975), using ether, found a value of 
0.2 pg. 
Sensitivity: The detection limit was taken as 3 pg, which meant 
that if 1 ml of plasma was assayed and 20% of this extracted, then 
the sensitivity was 15 pg/ml plasma. 
Precision: The intra-assay precision of the sample measured in 
duplicate, for the values 10-100,100 - 200, and 200 pg/ml, were 
9.9% (n = 31), 11.0% (n = 43) and 9,19of (n = 20) respectively. Aso 
et al (1975) found the mean coefficient of variation for a whole 
range of duplicates was 7.4% but values of up to 19% havo been 
recorded, even when the extraction step is omitted (Jurjens et al., 
1975). 
The inter-assay precision (quality control) was estimated from 
two plasma pools to be 10% (n = 4) for a mean of 88 pg/ml and 17% 
(n 5) for a mean ofý120 pg/mi. England et al. (1974) obtained 
an inter-assay precision of 6- 7%, while the corresponding figure 
for Aso et al. (1975) was 18% (n = '16). 
Accuracy: The"-accuracy was tested by adding standard amounts of 
oestradiol to water blanks. The recovery of 100 pg was 118% (n = 2) 
and the recovery of 250 pg was 94% (n = 8). The accuracy was also 
tested by assaying four dilutions of the same plasma pool. The 
regression coefficient was 0.99 and the results obtained are 
described by the equation; 
(observed) = 1.10 (expected) - 12.4 pg/mi. 
An exchange of samples was carried out with the Chemical Pathology 
Department and the following equation was obtained: 
(Gynae. Dept. results) = 0.84 (Chem. Path. results) + 9.4 r=0.99 
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Recovery: The recovery of 
3H-oestradiol 
added to plasma before 
assay was 70 + 11% (n = 60) when dich. 1oromethane was used and 
74 + 9P56 (n = 48) with diethyl ether. These results are rather low 
compared to 97% found by Aso et al. (1975) after a single ether 
extraction. These authors do however vortex mix the extracts for 
at least one minute, which is twice as long as the procedure usual 
in this department. 
Conclusions 
The oestradiol assay was difficult to run in that periodically 
the assay broke down, and the standard curve or accuracy went 
wrong for no apparent reason. However the assay finally stabilised 
and the assay criteria are comparable with other authors. 
2.7 Prolactin 
I 
Prolactin determinations were carried out by Dr. M. %T. Wheeler, 
Department of Chemical Pathology and Metabolic Disorders, St. Thomas' 
Hospital, using a radioimmunoassay. 
Antiserum 
Antiserumv batch 7110, was supplied by Dr. G. Groom, Tenovus 
Institute, Cardiff. Although it was recommended that this antiserum 
was used at a working dilution of 1/6000, it was found that the assay 
protocol employed allowed a working dilution of 1/10,000, equivalent 
to a final dilution of 1/70,000. There was no significant cross- 
reaction with growth hormone (< 3,166), although it is unlikely that any 
of the patients studied would have had significant growth hormone 
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levels as there were not acromegalic, had not eaten for several 
hours and were not unduly stressed. 
Material for iodination 
Highly purified prolactin was obtained free from the 
National institutes of Health, Bethesda, Maryland, USA. 2 pg 
hormone were iodinated either by using the chloramine - T. method 
or the lactoperoxidase method. After iodination, the iodinated 
hormone was separated from free 125-Iodine by column chromato- 
graphy, using &-phadex G-100 in a 100 cm column. 1.5 ml aliquots 
wer. e collected with the iodinated hormone being eluted in fractions 
47-53. The middle fractions of the prolactin peak, fractions 
49 -51, were bulked, aliquoted as 500 pl amounts and stored at 
-20 
0 C. No further purification was c arried out before use'. When 
fresh this preparation gave a zero binding of 45%, dropping to 
25% over six weeks but without any loss in assay performance as 
determined ýy the assay quality control samples. 
Radioimmunoassay 
50 )11 standard or sample were adde4 with 450 jil 2.5% horse 
serum in phosphate-buffered saline, PH 7.2, to 75 cmx 12 cm 
polystyrene I tubes (RT30, Sterilin Ltd) using an LKB Autodilutor. 
100 V1 antiserum was added, the tubes mixed and the assay stored 
at 40C. Zero tubes containing no standard aný blank tubes 
containing no antiserum were prepared at the same time. 
After 18-24 hours incubation 100 pl prolactin, equivalent to 
between 10,000 and 15,000 cpm was added to each tubes, with 100 P1 
being added to two empty tubes - the total count tubes. 
After a further incubation of 18-24 hours at 40C, 100)ai 
of a solution of rabbit serum and donkey anti-rabbit gammaglobulin, 
at dilutions of 1/20 and 1/200 respectively was added to all tubes 
except the total tubes. 
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The tubes were incubated for at least a further 18 hours, 
centrifuged at 3,000 rpm and the supernatant aspirated. The amount 
of radioactivity in the precipitate remaining, equivalent to the 
anti-body bound labelled hormone was determined using a Gan. maset 
500 (Tracerlab Instruments Ltd). Unknowns were read from the 
I standard curve subsequently produced. 
Assay Performance 
Theýroutine assay used had a sensitivity, determined as the 
10% drop from the zero binding, of about 100 miu/1 (using MRC 
standard 71/222). This meant that the lowest values of the normal 
population could not be measured and therefore the normal range 
is quoted as <48o miu/1. 
The intra-assay variability is 5.4% with an interassay 
variabi - lity of 9.3%6 
3. ANALYSIS OF DATA 
General Statistics 
In the calculations the mean (R) and standard deviation (SD) 
are usually given as (x + SD) followed by (n), the number of 
observations. In some cases the standard error (SE)of the mean is given; 
this is defined as SD . The coefficient of variation 
(CV) is SD . 100% 
rn 
x 
It has been shown (Kletzky, Nakamura, Thorneycroft & Mishell, 
1975) that progestercne and oestradiol, in the menstrual cycle tend 
to follow a logarithmic normal rather than a normal distribution. 
Accordingly steroid values were transformed logarithmically and 
the grouped values calculated as the log mean and log standard 
devia ti on. However the antilog of the standard deviation cannot 
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be derived directly but is calculated as (antilog. mean - antilog 
(log. mean- log. SD))for the SD below the mean and (antilbg. (log. 
mean + log. SD) -antilog. mean)) for the SD above the mean. As 
these two values are not equal, the mean and standard deviations 
of plasma values are expressed as R (SD uI 
SD 1) where SD U 
is the 
upper standard deviation and SD 2 is the lower one. 
Statistical treatment of the normalised data was, unless 
otherwise stated, comparison of unpaired means (Students It' test) 




The plotting of the standard 6urve for all theassays was the 
B/Bo or the B/T vs log. dose, as described on page 79 - 
6 Standards were assayed in triplicate and 'unknown' plasma 
extracts in duplicate. The mean dpm valýe for each 'standard or 
unknown was-calculated and the standard curve wAs plotted as 
(dpm / dpm at B0)X 100% vslog. pg standard. Values for unknowns 
were interpolated on the curve and the final result calculated as 
follows; - 
X= 100 xX- value in pg / ml plasma 
rVX- value interpolated from 
S. C of 0.1 ml extract (pg) 
r- percentage recovery of I. S. in 
0.1 ml extract 
V- volume plasma assayed (ml) 
Values of pg/ml or ng/ml of plasma were then converted to 
S. I. units of nmol/l. 
Arranging the Plasma values 
One of the problems associated with the collection of data 
in the menstrual cycle is the adjustment of different cycle 
lengths. This can be done on an absolute basis, counting from 
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ovulation as the reference point. Ideally the day of the LH peak 
should be used, but as daily LH determinations were not available 
in our study the day of the rise in body basal temperature (BBT) 
was the reference point. However the problems of determining the 
exact day of ovulation from the BBT are well known. 
As the second half of the cycle is less variable than the 
first (Marshall, 1963) it would seem reasonable also to use the 
onset of the next menses as the reference point. Accordingly the 
data were arranged both ways, around the onset of the next periQd 
and also around the day of the first increase in body basal temperature 
where this was known (for instance, in Group I, see page 144). 
The computer model 
the cycle can also be divided into proportional units for 
comparison between different women (Redgrove, 1971). As progesterone 
values are really only of interest in the luteal phase (the levels 
are approaching the sensitivity of the assay in the follicular phase) 
it was decided to attempt such a comýarison of luteal progesterone 
values. 
Proge, ýIterone values appear to fit a periodic or wave-like 
shape, and a computer programme was devised by Dr. S. C. Darby using 
a sine wave model. The luteal phase was divided into proportional 
units (radians) and the corresponding progesterone values fitted to 
the sine wave programme, which calculates the goodness-of-fit of 
the sine curve and the maximum progesterone values at the mid-point- 
in the luteal phase. This maximum amplitude of the sine wave is 
referred to as the progesterone 'index'. 
Validation of the computer model 
One problem with determining a progesterone index by the 
computer model is that the luteal phase length should be known. 
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As this information was not available for all of the women it was 
decided to take an arbitrary luteal phase length of 14 days where 
the true figure was not known. The effect of such an approximation 
was tested by calculating the indices for the first group (see Ch-3 
in both ways; with the true (known) luteal phase and with an arbitrary 
luteal phase. The results are shown in Table 2.5. 
Table 2.5 Computer indices of progesterone secretion calcuiated 
using either the true luteal phase length, or an arbitrary length 
of 14 days. 
Actual luteal phase Arbitrary luteal phase 
Index S. D. Index S. D. 
nmol/l nmolll 
Controls (10) 48-7 7.7 43-1 7*4 
PMS group 1 (20) 37-3 8.7 36.8 9.4 
p< 0.05 ns. 
Apparently therefore, using an arbitrary luteal phase may-give 
I 
anomalous results and may obscure differences between groups. 
One'test of the model is to compare the index values obtained 
by computer with the estimdL-s of 'low' and 'normal' progesterono 
obtained by comparing each progesterone curve graphically with the 
90P/6 confidence limits of the controls (see Ch. 4 ). In. Fig,. 2.. 16 it 
appears that the computer modell obtained via an arbitrary luteal 
phase length, is a good discriminator between normal and low 
progeAerone curves. 
Anothentest of the model was to compare. the computer 'peak' 
(y) with the true progesterone peak (X) obtained on daY 7 before 
menstruation, where this was available. The correlation between the 
two is described by the equation: 
13.8 + 0.6x ,r=0.83 (n = 39) 















Fig. 2.16 Test of the computer model of the 
progesterone peak; the progesterone index obtained 
by the computer programme for each individual is 
compared with an independent, graphical classification 
of each patients progesterone curve, whetýer 'normal' 
or 'low' (below 90% confidence limits of a control 
group). 
, low, 'normal' 
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estimate high peak values and to overestimate low ones. This is 
not surprising in view of the flattened shape of the sine wave peak, 
and it may also be a consequence of the logarithmic distribution of 
progesterone values (see above) which is not taken into account by 
the computer model, 
However it may be an advantage since an integrated value may 
be a better indicator of luteal fundtion; Abraham et al., (1974) 
have shown that one high value may be misleading with regard to 
luteal function. Computer indices were calculated for all women in 
Group I and III, using the true luteal phase length in each case, but 
an arbitary luteal phase of 14 days had to be used in the calculation 
for group II. 
CLINICAL METHODS 
The patients chosen for the study all attended the special 
research clinic for the premenstrual syndrome, and they were seen by 
Professor R. W. Taylor or one of his colleagues for clinical asses&ment. 
Although some patients weie referred following articles in the press, * 
in every case the G. P was informed and hia or her consent obtained 
before the study. - 
Details of the patients and the protocol followed for each 
study (for instance the timing of blood samples) are given in the 
appropriate Results Chapters. 
Blood Samples 
20 ml of blood. (usually for progesterone and oestradiol. 
determination)wad taken from the antecubital vein between 9-30 am 
and 15-30 pm, placed in heparinised tubes and centrifuged as soon as 
possible at 10009 for 10 min. For prolactin estimations 10 ml blood 
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was placed in glass tubes, allowed to clot for 30 min at 20 0 C, and 
centrifuged as above. All samples were frozen at -20 
0C before assay. 
Research DesiSn 
The endocrine investigations were carried out in three parts, 
governed to some extent by the patiente. available at each stage. 
These studies may be sumMarised below. 
Group 1. There was a comparison of symptomatology and menstrual 
cycle details in 20 women complaining of the premenstrual syndrome 
and seven women who were not. Plasma levels of progesterone, 
oestradiol and aldosterone were studied frequently during the 
cycle. These results are given in Chapter 3. 
Group II. Progesterone levels were studied within a heterogenous 
group of 105 PMS patients, especially with regard to symptoms and 
psychological criteria. The relationship between prolactin and 
progesterone was also studied (Chapter 4). 
Group III. In 67 PMS patients treated with dydrogesterone in a 
single-blind trial pr6-treatment levels of progesterone were compared 
with levels during treatment, and both values were correlated with 
response to the therapy. (Chapter 5). 
1 LI-3 
CHAPTER I 
Plasma steroid profiles in women 




Seven volunteers aged 22 to 34, without premenstrual 
symptoms were recruited from the hospital staff and were studied 
over ten cycles, with three women contributing two cycles each. 
These ten cycles. acted as the controls. 
Twenty women with premenstrual syndrome (Group 1) were 
selected for the investigation. Seven of these were referred from 
the Gynaecology Out-Patients clinic, while the otherswere self- 
referred following a magazine article which called for volunteers. 
Although the latter patients were chosen from, a much larger group of 
volunteers (see Chapter 4), they were chosen in chronological order 
of their appearance at the clinic, so that bias in selection should 
not occur. 
All. the women fulfilled the following'criteria: - 
1) The women were aged 22 to 45, with regular cycles, and they were 
taking no medications, apart from simple painkillerss during the 
period of study. 
2. They were available for at least four blood samples in the luteal 
phase and these were taken between February 1975 and August 1976, so 
that plasma samples from both PMS and control groups were assayed in 
the same batches. 
3. The subjects had a complete daily record of basal body temperature 
(BBT), weight and symptoms during the cycle under study. 
4. In the case O"L' the women with PMS, it was established that the 
symptoms were cyclical and that they ended at or soon after the 
onset of menses. 
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Thus the details of ovulation(by BBT), weight and' 
symptoms were available together with progesterone and oestradiol 
analyses during the luteal phase. 
All the controls and a subgroup of the PMS series (the 
first eight) had blood taken for aldosterone estimations. Most 
studies of aldosterone in the menstrual cycle have been carried out 
on patients who have been supine overnight (Michelakis et al., 1975; 
Katz & Romfh, 1972) but overnight admissions were not possible for 
our study due to the shortage of hospital beds. In other out- 
patient studies, for instance in pregnancy, subjects remain 
recumbent for 30 minutes (Weir, Brown, Fraser, Lever, Logang 
McIlwaine, Morton, Robertson & Tree, 1975). It was decided there- 
fore to adopt a protocol of 30 minutes recumbency with sampling 
between 10.00 and 15-30 h. To check that recumbency did not alter 
gonadal steroids, the progesterone index of 'recumbent' and Inon- 
recumbent' subjects in the PMS group were compared. The mean index 
of the 'recumbent' group (10) was 30-3±5-1 nmol/l and that of the 
non-recumbent group (12) was 35.7±4.8 nmol/l, (not significant). 
No attempt was made to control the diet of these patients. 
Details of the menstrual cycle and s3mptoms 
I 
The symptoms experienced by the PMS subjects and the 
controls after the rise in body basal temperature are shown in 
Table 3.1. Only symptoms that were rated as 'moderate' or 'severe' 
or that occurred on more than one day of the cycle were included. 
It is interesting from this table*that breast tenderness 
occurred in almost half the control cycles, and that the most 
striking differences between the groups are in the emotional 
symptoms, although the ratings are . very subjective. It is also 
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be6n asked aVout the duration of their symptoms, and thoy reported 
that symptoms occurred from 2 to 19 days, with a mean of 9 days, 
which is longer than the actual duration of most of the symptoms 
listed in Table 3.1. This underlines the problems in dealing with 
retrospective questionnaires. 
Some of the symptoms were maintained after menstruation 
had begun, and an indication of the timing of symptoms in the PMS 
group is shown in Fig. 3.1, which was obtained by adding the scores 
for each premenstrual day. 
Details of the menstrual cycles during the study are shown 
in Table 3.2. The length of the luteal phase was calculated from the 
day of the rise in body basal temperature, and as this method is 
rather unreliable, the estimation must be regarded as approximate. 
Table 3.2. The mean age, cycle length, luteal phase 
and flow in PMS group and controls. 
PMS group (20) C ontrols (10) P 
Mean + SD Range Mean + SD Range 
Age (years) 31 +6 22-45 28 +3 22-34 ns 
Length cycle 
(days) 
27.3 ±2 25-32 29.4 +2 26-32 . 01 
Length luteal 
phase (days) 














There was a slight but non-significant difference in the 
age distribution of the two groupsq although some effort was made to 
overcome this by selecting younger PMS patients for study. It would 
have been better to select older controls, to match the age range of 
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Figure 3.1. The daily pattern of total self-rated symptom scores 
from 20 women with premenstrual syndarnme. ' 
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the PMS group, but this proved difficult as the controls were 
drawn from a population of students, nurses nnd technicians. There 
may also be a true age effect since the syndrome is most often seen 
in women over 30 (Dalton, 1977). Indeed, it was extremely difficult 
to 'Lind subjects in their late twenties and over who were asymptomatic 
and who were not taking oral contraceptives. 
The difference in menstrual cycle length may be an effect 
of the difference in age distributiong since it has been shown on a 
statistical basis that cycles become progressively shorter (Treloar 
et al., 1967; Chiazze et al., 1968). In a study of 3,300 regular 
cycles Chiazze et al. (1968) found that the average cycle length 
for women aged'25 to 29 was 28.5 days, which is slightly shorter than 
the average for our controls. The average cycle for women aged 30 to 
34 was 28.0 years, which ip slightly longer than that found in our 
PMS group. 
It has been'shown by Sherman, West & Korenman (1976) that 
although cycles tend to become shorter in older women, it is the 
follicular phase and not the luteal phase that is decreased, and the 
same phenomenom would appear to occur in Group I, as there was no 
statistically significant difference in luteal phase length. 
2. PLASMA STEROID PROFILES' 
Progesterone 
Controls: The progesterone values obtained in the control patients 
are compared with values found by other workers in Table 3.3. The 
follicular phase values are slightly lower than those of most workers, 
although all reported levels are below 2 rimol/l. The luteal phase 
values are within the range found by other workers. Although the 
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symptoms it can be assumed from the age ranges that severe PMS 
was uncommon. 
However, a more accurate comparison of the control values 
(for the luteal phase only) can be obtained with the composite graph 
of Bdckstrdm, et al (1976b)who were also selecting controls for a 
PMS survey. The comparison in Fig. 3.2., indicates lower values in 
our control group, although the same pattern is seen. The discrepancy 
probably reflects methodological differences. 
PMS Group 
The progesterone levels of the PMS and control group were 
arranged around the day of the onset of the next period and the log. 
means were calculated. A comparison of the curves for the PMS and 
controls are shown in Fig-3-3. The progesterone levels of the PMS 
group were lower in the midluteal phase, that is, from -10 to -5 days 
premenstrually. As fairly small numbers of eamples were available 
per daX in bot h the groups, the data was grouped into two day intervals 
around the onset of menses (Table 3.4), but even with this arrangement 
the difference in the two groups only reached significance at 7-8 days 
premenstrually, although the PMS group had lower values from 5-10 days. 
When the data are further pooled into four day intervals (Table 3.4) 
the PMS group have significantly lower progesterone levels during the 
mid-luteal plateau at 5-8 days premenstrually (M-5 to -8). There 
was no significant difference between the progesterone levels on the 
last four days of the cycle, and a valid comparison is difficult 
from day -11 to -14 owing to the different luteal phase lengths, 
and this is reflected in the high variability at this time. 
The values were also arranged around the estimated days 
of ovulation and the log. means calculated (Fig. 3.4), since more 























Days before menstruation 
Figure 3.2. Daily mean(t S. E. )plasma progesterone 
and oestradiol levels in ten control patients in 
this study compared with mean values found 
for controls 















'1001 1 -1 ,,,, 9, 
*21 
12 10 86420 +1 
Days before menstruation 
Figure 3-3- Logarithmic mean (I S. E. 5 plasma progesterone 
and oestradiol levels prior to menstruation in 20 women 









91 % .0 0 
si 0 
Cd ri 
. rj .) 
t> Cd 
rzi = 





















to Co to Co 
p 
m 2 2 N 2 4 iz 93 0 93 93 0 10 (5 %-. 1. * cý 
(Z m; lýA 
j 
cý 00 00 Co 4 Co 
00 cm KN r-i %D a) H r-i P. 4 
91 
Co 4-3 1 
Cd 
2 
r-i LN 0 el 0 -t 0 ni "0 %0 (U 00 z u; t Lz cý cu r-1 cm r-i 
zo 0 
l'- c> % p 
r i t m 
0 
: 
0 i c 




H - -- 
0 r-4 94 
42 
9> 
cm 0 %Z r-i 00 -d- CM t- A mi r. 00 
fý cý ý 
tiD r- Co oo c> r-- r- rý 
0 - (M -t 14D 0c) r-i * -t 00 H + 
j c; 
155 
to ovulation itself. In Fig. 3.4, the initial rise in 
progesterone after ovulation seems unimpaired in the PMS group, 
although secretion seems to decrease 5 days after ovulation, so 
that the luteal peak is smaller and the fall in levels occurs 
slightly earlier. Menses occur in both groups when levels of 
progesterone reach about 4 nmol/l. 
Oestradiol 
Controls: The oestradiol plasma values of the controls were 
compared with other workers (Table 3-5) and found to show good 
agreement with values for the menstrual cycle obtained by both 
RIA and CPB. The midcycle peak is rather low but very few sample*B 
were obtained at that time in our study. 
The oestradiol levels in the controls showed the characteristic 
pattern of low follicular phase levels, a sharp preovulatory peak and 
a nadir at ovulation. The luteal phase levels rbse again to a plateau 
which was maintained until 11 days after ovulation, when the values 
fell sharply to follicular phase levels. This pattern can be seen in 
Figure. 3.4. 
Our control group was also compared with that of BackstrUm 
I 
et al (1976bý The curve for our control group was more 'spiky', indicating 
the small sample, but the basic shape is the same (Fig- 3.2). The chief 
difference is the higher level found by Backstr6ms group at the two low 
points of oestradiol synthesis, after the mid-cycle peak and at 
menstruation. As the ir assay was not specific for oestradiol, the 
oestrogen levels that they measure will also include oestrone and 
possibly other oestrogbns. The amount of oestrone produced by 
peripheral conversion of androstenedione is relatively constant 
throughout the cycles so that oestrone will make a relatively larger 
700 
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-10 -6 -2 02468 10 12 14 16 
- Days of the cycle (from ovulation) 
Figure 3.4. Daily log. mean(18. E. ) plasma aldosterone, progesterone 
and oestradiol levels , arranged around the day of the rise 
in 
basal body temperature, in 20 P14S cycles (, &- - -A ) and in ten 
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contribution to total oestrcgen levels at times of low ovarian 
activity (Edman & MacDonald, 1976). This might explain the higher 
levels found by Bdckstr6m et al (1976b)at these times. 
PMS group: The pattern in the PMS group was similar to that of the 
controls (Fig. 3.4) but there were slightly higher levels especially 
at the times when oestradiol secretion is falling, that isl after 
the midcycle peak and at menstruation. The latter difference can be 
seen more clearly when the logarithmic means are arranged around the 
day of the next menstrual period (Fig. 3-3). When the data were 
pooled into two day intervals the mean levels are significantly 
higher from four days before menstruation until one day after(Table 3.6). 
The ratio of progesterone to oestradiol was also calculated 
for PMS patients and controls and the results are shown in Table 3.7- 
The ratio was significantly higher W-0-05) for the last eight days 
of the cycle in the controls. 
Table 3.7 Ratio of progesterone to oestradiol in PMS patients 
and controls, dated from menstruation (M) and Ovulation(Ov) 
Day 
M- Controls PMS p 
n mean SD n mean SD 
1,2 6 52 30 8 23 17 <0.05 
314 7 72 37 3.4 46 26 ns 
5,6 6 97 29 14 78 28 ns 
7,18 8 103 41 10 78 27 ns 
9,110 6 102 55 9 50 20 <0.05 
11 t12 5 72 42 91 88 90 ns 
1-4 13 61. 35 22 38, 25 < . 05 
5-8 14 100 36 24 78 27 < -05 
9-12 11 86 49 18 64 59 ns 
+ Ov 
+192 6 81 69 6 31 13 ns 
394 6 69 42 5 62 44 ns 
160 
Aldosterone 
Con'trols: Aldosterone estimations were carried out on the control 
cycles and the results compared with those from other authors (Table 3.8). 
The values show good accord with other published methods, although the 
standard deviation is somewhat higher. The values are particularly 
comparable to those of rirýlich et al (1976), which is perhaps not 
surprising as the clinical conditions were similar. 
The pattern of aldosterone values during the menstrual 
cycle showed raised periovulatory and luteal values (Fig. 3.4), but 
no definite pre-ovulatory peak was seen, in contrast to the findings 
of others (Fr6lich et al., 1976). The point of ovulation was not 
determined accurately via the LH peak in our patients, which may partly 
explain the discrepancy. Figure 3.4 also shows that aldosterone levelc 
in the controls at menstruation are above the vaiues found in the early 
follicular'phase, with a high degree of variability. 
IINAIS Group 
The aldosterone values throughout the cycles were not 
fferent from the controls (Fig- 3.4) except that values markedly di. 
were higher in the pre-o%mlatory phase. However tho observations at 
this point were few and the difference was not statistically 
significant. 
As there were few samples 1per day the data were grouped 
into two-day intervals around the onset of the next period (Fig- 3-5)- 
At 12 to 14 days premenstrually aldosterone levels are declining, 
presumably after the peri-ovulatory peak. A second peak is seen at 
5-9 days premenstrually in both PMS subjects and controls, with no 
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are still highly variable at the end of the cycle, and although 
no statistical differences were found, there were unfortunately 
rather few PMS samples at this stage of the cycle upon which to 




Firstly it is important to show that systematic errors, 
such as nyctohemeral rhythms, are not affecting the results. There 
is now evidence that proges , terone has such a rhythm (Florensa et 
al., 1976), with higher values at 8.00 to 16.00 hours and a decline 
at 20.00 hours, although this is unlikely to influence our results 
I 
as the samplep were taken between 10.00 and 15.00. hours. 
Lenton, Cooke, Sampson & Sexton (1978) have performed a 
more intensive study of oestradiol variation, under controlled 
conditions at 15 minute intervals throughout the day. They found 
that oestradiol levels were markedly raised between 8.00 and 10.00 
hours, although this was also the time at which their study started, 
so that a stress effect cannot be ruled out. In our series one subject, 
a controll had samples taken before 10-30 h, which should not bias 
the differences we have observed. 
Lenton & coworkers also found a high variability between 
consecutive samples - up to 57% in the luteal phase - which could not 
be accountdfor by intraassay variability alone, suggesting that 
oestradiol is secreted in a pulsatile manner. This might explain 
the high variability seen in the oestradiol values in the luteal 
phase in our study, which tends to give a 'spiky' appearance to 
Figs- 3.3 and 3.4. 
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Despite these, problems the results for progesterone 
and oestradiol are comparable to those obtained during tho 
menstrual cycle by other authors. Furthermore in a study of 
women with premenstrual syndrome and controls, Bdckstrdm et al 
(1976D), studying the last ten days of the cycle, found that 
progesterone was lower in their PMS group from day 10 to day 4 
premenstrually, which is in close agreement with our findings. 
They also found that oestrogen levels were lower in the PMS group 
eight and nine days premenstrually but that they became significantly 
higher than the controls from one to five days premenstrually. There 
was some indication that this 'shift' in oestradiol levels was 
occurring in our PMS group. The significance levels for the 
difference-s are less marked in our work compared to that of the 
Mckstr6m's group, and this is probably due to their greater number 
of daily samples, and also due to the Swedish group measuring 
oestrogen rather than oestradiol which may mean that they are high- 
lighting differences in other steroids as well. 
It is perhaps not surprising, in view of the very slight 
differences that we have seen, that Loraine & Bell (1971) Prill & 
KrUger (1963) and Adamopoulos et al. (1972) could find no striking 
al, normalities in urinary oestrogens and pregnanediol. Some plasma, 
studies have also produced inconclusive or contrary findings. For 
instance, O'Brien and Symonds (1977), in a very brief report, found 
that the luteal progqsterone peak in a symptomatic group was greater 
thanin an asymptomatic group, and Smith (1975), in a preliminary studyq 
found that progesterone was lower in the last nine days of the cyclo 
in women with premenstrual depression, but oestradiol levels wer3 
unchanged. There were however no details about methods, so it is 
difficult to evaluate these two reports. Smith stresses that there 
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was considerable overlap between the two groups, and casts some 
doubt as to whether the hormonal changes are aetiologically 
important. The results that we have found for Group I do to some 
extent confirm this view. Although the mean values of progesterone 
and oestradiol were significantly different, overlap occurred at 
all stages of the cycle between the PMS and control series* 
There are several possible reasons for these equivocal 
results. The first, and most obvious explanation would be method 
variability. An interassay coefficient of variability of 19% in 
the case of progesterone and 10% for oestradiol means that differences 
between the groups must be greater than 38% and 20% respectively-to 
become at all meaningful. An added difficulty is that there are large 
episodic fluctuations of plasma levels within the individual during 
the luteal phase, which makes it difficult to pool data from different 
days of the cyclej although this would be desirable sometimes when 
the numbers for each day are too small for statistical analysis. 
Several physiological explanations may possibly account 
for the widely variable values found within the PMS groups For 
instance, there may be, within the sample of PMS sufferers, two or 
more separate groups, which may be hormonally dependent in different 
ways. One hormone-dependent group will tend to have the now 
classical decrease in the progesterone/oestradiol ratio premenstrually, 
which was seen in our group in the last eight days of the cycle and 
which occurs to a variable extent in other published studies 
(B&ckstr6m. & Carstensen, 1974; Mckstr6m et al., 197&-, Smith, 1975). 
If there are two or more aetiologies within PMS the dividing factor 
may be the symptoms. In fact, apart from one woman who complained 
chiefly of headaches and one complaining of gross oedema, all the 
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patients in Group I complained chiefly of irritability and 
depression, but Group II were rather more heterogoncous and 
the question of symptomatology is therefore discussed with regard 
to the latter group in the next Chapter. 
It is also possible that the same changes are occurring 
Jn all the women, and that subtle changes in the ovarian steroids 
I 
detectable in some women in peripheral blood but not in otherssmay 
lead to a 'cascade' effect on other hormones, which will in turn lead 
to the symptoms. Aldosterone could be such a Isocondary' hormone. 
Aldosterone 
Aldosterone levels in plasma are subject to acute changes 
I 
brought about by changes in diet and posture, so that stan. dardisation 
of these two factors is very important. The queation of posture is 
critical as different control mechanisms of aldostorone secretion seem 
to take place in the upright and supine positions- In subjects who 
are supine overnight the nyctohemeral rhythm of aldosterone follows 
that of cortisol and the correspondence with renin activity is weak 
(Katz, Romfh & Smith, 1975) although suppression of ACTH and cortisol 
does not suppress the aldosterone pattern. The increase in aldo- 
sterone upon upright posture is thought to be due to increased renin 
activity, controlled by the redistribution of the circulating blood 
volume (Sassard, Vincent, Annat & Bizollon, 1976). 
Thus while supinel it appears that aldosterone is under the 
control of a central ACTII-like control, with perhaps a role for 
potassium; while upon orthostatism, renin becomc,., the important 
controlling factor. This disparity is underlined by the different 
patterns obtained in the menstrual cycle, in that a mid-cycle peak 
of aldosterone occurs under upright but not supine conditions, (see 
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Chapter 1). 
Unfortunately our results are not strictly comparable 
with either the 'upright' or Isupincl groups of other studies. How- 
ever Sassard et al (1976) showed that aldosterone is markedly 
I 
increased in the upright position and that the levels do not decrease 
after 30 minutes' recumbency, which would tend to class our studies 
in the 'upright' group. These workers also found that renin activity 
in plasma was s-, gnificantly decreased after 30 minutes' recumbency, 
and they explain these findings in terms of the lower metabolic 
clearance rate of aldosterone and also the possibility of a persistent 
stimulus such as potassium. 
It appears quite valid to compare our results with those of 
workers studying 'upright' subjects, and indeed the values agree quite 
closely (see Table 3.8). 
However we did not see a well defined pre-ovulatory peak, 
as described by Fr6lich et al. (1976) although aldosterone levelb 
in both PMS and control subjects rose one or two days bafore ovulation 
and fell again after ovulation. In this respect the pattern is closer 
tý that of Sundsfjord & Aakvaag (1973) who found a gradual pre- 
ovulatory increase in aldosterone levels. 
Plasma aldosterone levels in the luteal phase of both 
groups were raised for five to ten days after ovulation, and this 
increase, which is about double the levels in the early follicular 
phase, is close to the findings of others (Table 3.8). In the 
control group aldosterone levels were still higher than follicular 
levels at menstruation (rigs 3.4 & 3-5). There is no mention of this. 
by other authors, perhaps because most attention has focussed on the 
ovulatory phase of the cycle. Reich (1962) did however note an 
increase in aldosterone excretion on certain days of menstruation in 
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some of her subjects, and she mentioned that this could be an ACTH- 
evoked response to stress. 
It is perhaps not surprising, in view of the complexity of. 
the control of plasma aldosterone, that no statistically significant 
differences were found between the PMS and control subjects under 
these relatively uncontrolled conditions. In a study of one patient 
with premenstrual oedema (Schwartz & Abraham, 1975) the patient had 
very high luteal phase aldosterone levels, although follicular phase 
levels were quite low, and this fits well with the hypothesia of 
Janowsky et al., (1973), that aldosterone is responsible for water 
retention in PMS. Yet the one patient in our series with premenstrual 
weight gain of six kg with oedema did not have a marked luteal increase 
in aldosterone. Oelkers et al (1973) studied three women with 
cyclical oedema of more than three kg and found decreased aldosterone 
with renin excretion, despite sodium retention. They postulated that 
another salt-retaining factor is responsible, although it is perhaps 
also likely that the excretion rates are not reflecting serum levels 
due to decreased clearance or increased conversion to other metabolites. 
However, cyclical oedema may be a special case in that most patients 
With 'classical' PMS only gain 1.4 kg or less premenstrually (Bruce 
& Russell, 1962). 
Indeed, in our series with 'classical' PMS we could find no 
abnormalities in aldosterone levels, in agreement with a preliminary 
report by O'Brien & Symonds (1977). These workers did however find that 
Sp4ronolactone, a steroid analogue of aldosterone and hence an 
inhibitor of aldosterone action, alleviated symptoms in a double- 
blind trial. Spironolactone does have other endocrine effects, such 
as the elevation of progesterone levels, possibly via the adrenals 
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(Stripp, Taylor, Bartterl Gillette, Loriaux, Easley & Menard, 
1975). 
It is interesting that the only marked increase in 
aldosterone levels in the PMS group cccurred prior to ovulation, 
although this difference was not significant. The origin of the 
pre-ovulatory increase is uncertain. Both plasma renin activity 
and substrate are unchanged at this time, (Sundsfjord & Aakvaag, 
1973) suggesting that if oestrogen is responsible, it is acting. 
outside the renin-angiotensin axis, possibly by direct action on 
the adrenals. It has been suggested that 17oc-OH progesterone, 
which also has a midcycle peak (Strott et al., 1969), may be 
involved although a natriuretic effect has not been demonstrated 
for this hormone (Iandaul Lugibihl & Dimick, 1958). 
A recent study of fasting supine aldooteroneg renin 
activity, renin substrate, oestra7diolq progesterone, gonadotrophins 
and prolactin in seven women throughout the menstrual cycle (Kaul- 
hausen, Leyendecker, Benker & Breuer, 1978) has identified a pre- 
ovulatory peak in aldosterone and renin activity even in a few supine 
individuals, but changes were on the whole inconsistentj and no clear 
relationships emerged, which is disappointing. 
It is possible that ACTH, which increases around tho day 
of ovulation (Genazzani, Lemarchand-Beraud, Aubert & Felber, 1975) 
may be involved in a pre-ovulatory peak. 
The result6 for the luteal phase do not point to any 
conclusive role of aldosterone in the aetiology of PMS. It is possible 
though that absolute levels of aldosterone in plasma are less important 
than the ratio between aldosterone and progesterone, which acts as an 
aldosterone antagonist in the luteal phase (see Chapter 1). The 
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progesterone/aldosterone, ratios for PMS subjects and controls are 
shown in Table 3-9 
Table 3-9, 
Ratio of Progesterone to aldosterone in PVZ and controls dated from 
menstruation (M) and ovulation (ov). 
M- (8) Controls PMS p 
days of . 
cycle No. Mean SD No. Mean 
SD 
ratio ratio 
1-4 12 42 25 11 47 32 no 
5-8 13 116 71 11 63 19 ý-05 
9-12 11 67 38 9 51 36 ns 
OV+ 
192 6 41 62 4 28 13 ns 
314 5 59 1 44. 4 62 1 56 ns 
I It might be expected that if the ratio is an important factor, the 
degree of statistical significance in the differences between groups 
will be greater for the ratio than for either hormone alone. However 
this is not the case. I 
There is another element to the study of aldosterone plasma 
levels which has recently come to light. It has been shown that oral 
contracept -ives increase the binding of aldosterone to a specific binding 
protein, aldosterone binding globulin (ABG), and that the degree of 
binding is related to the oestrogen content of the combination 
(Nowaczynski, Murakamil Richardson & Genest, 1978). As our method 
measures total steroid, any changes in binding would not be seen, 




Even if aldosterone levels in peripheral plasma are not 
important, there could still be effects of the luteal rise in 
aldosterone occurring at the tissue level. The retention of sodium 
or water or both may directly affect brain function. There is some 
evidence that the distribution of sodium and water are altered in 
chronically depressed patients (Coppen & Shaw, 1963) although the 
distribution returns to normal when the patients recover. The 
other possibility is that aldosterone mettaboliom directly affects 
brain function, and although there is no evidence for aldosterone 
itself being involved, angiotensin does appear to alter animal 
behaviour and autonomic function. For instance it affects the 
uptake and release of norepinephrine by the brain in rats and it 
counteracts the anaesthetic effects'of aýobarbitol (Palaic 
Khairallah, 1967)- 
Thus the findings for Group I although not ruling out the 
involvement of the renin-angiotensin-aldosteronp system, would tend 
to make a major role seem unlikely. A role for ovarian steroids 
I seems probable 
in view of the altered progesterone/oestradiol ratio 





Plasma progesterone in relation to 
prolacting symptow and psychological 
profiles in P14S. 
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1. GROUP II PATIENTS 
Protocol 
A large group (105) of women aged 19 - 47 years came 
to the clinic after reading a magazine article about the research 
into PMS in our Department. At the first clinic visit each woman 
was asked to record details of her menstrual cycle and any 
medications taken, to rate which were her 'most troublesome' 
symptoms, and to record any other symptoms noticed. From this 
self-rating the symptoins from each woman were grouped into tho 
clusters seen by Moos (1968) in his survey, and modified by 
Clare (1977)(see Table 4.1. ). These ratings were checked as far as 
possible with the womans daily symptom records. 
In addition 58 of these women, chlose4 at random, wero 
asked to complete the General Health Questionnaire, which identifies 
non-psychotic psychiatric ill-health and is a general indication of 
psychiatric distress (Clare, 1977). The completed questionnaires 
were analysed by Dr A. W. Clare of the Institute of Psychiatry. 
At least three blood samples were taken during the luteal 
phase, on about days 18, -21 and 25 of a 28 day cycle, with a shorter 
or longer interval for cyc . les of less than or more than 28 days 
respectively. The blood samples were taken under conditions described 
in Chapter 2, section 4, and analysed for progesterone. During the 
course of this study we became interested in the role of prolactin 
in PMS, and as a consequence 77 women had serum prolactin levels 
measured. A computer estimate of the progesterone index was also 
made in these 77 women, using an arbitrary luteal phase of 14 days. 
174 
Characteristics of the patients 
The mean age of the women was 34.1 + 6.2 ybars and 
the mean length of menstrual cycle'was 28.0 + ; %7 days (range 24 to 
33 days). The symptoms reported by the women were grouped into 
clusters of symptoms and the incidence of each cluster is shown 
in Figure 4.1. Most women experienced symptoms from more than one 
cluster, and a few women had symptoms in up to four clusters. 
Table 4.1 Symptom clusters (see Clare, 1977) 
experienced by 105 women complaining 
of premenstrual syndrome 
Symptom cluster Example of complaint No. women with 
cluster M 
Pain Headache, tiredness 48 
Concentration Confusion, Clumsiness 20 
Behavioural'ahange Loss of efficiency 
Autonomic reaction Dizziness, Cold sweats 12 
Water_retention Painful breasts, bloating 70 
Negative affect Irritability, Depression 95 
Arousal Feeling of well-being 0 
Control. Chest pains, tingling 1 
The onset of PMS was reported by the women to have 
occurred at puberty in 28%, after childbirth in ý5%9 and spontaneously 
in the previous two to ten years in 30%, Six women (6%) mentioned the 
contraceptive pill as a precipitating factor, and 3 other mentioned 
miscellaneous factors such as sterilisation, abol-tion and marriage. 
The time of onset was not recorded in 
The mean duration of symptoms was 10 4 days with a range 
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of 2 to 14 days, as recorded on the retrospective questionnaire. 
In 103 women the symptoms ended by day 3 of the next cycle, so that 
in only two were the symptoms prolonged beyond this. 59% of the 
women were parous. 
2. HORIONE LEVELS IN GROUP II 
Plasma progesterone levels 
The progesterone values for 92 subjects (excluding the 13 
already studied in Group I) were arranged into daily log means around 
the onset of the next period, and the results are shown. in Fig. 4.1. 
There was no statistical difference between Group II and the controls 
for Group I, although the values for the PMS group are slightly lower. 
The progesterone values for each individual were also 
plotted and the general curve for each woman compared with the- 
composite curve for the controls, with confidence limits, seen in 
Fig. 4.1. It was found that 30%"Of the subjects had a 'low' 
progesterone curve, which is defined as a curve where two or more 
points fall below the 90% confidence limits of the control curve. 
55 (60%) had a progesterone curve vithin the normal limits, and 9 
had values above the confidence limits of the controls, 
In the 77 women with a computer index o. f the progesterone 
peak the mean value was 38-9. t 9.1 (SD) nmol/l, while that of the 
Group I controls was 43.1 + 7.4 (SD) nmol/l (not significant). 
Serum Prolactin Levels 
Prolactin estimations were carried out in the luteal 
phase in 77 patients from this group, of whom eight had more than 
one sample assayed from the luteal phase and 20 had an additional 
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Figure 4.1. Log. mean plasma progesteroný levels in Group 
II MS patients ( ooeoooooo ) compared with the log, mean 
curve 1 909 confidence limits for 10 control cycles( - ). 
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patient in the luteal phase was 244 + 100 (S. D) miU/1, (range 80- 
500 miU/1) excluding two patients with values of 800 and 900 miU/1. 
The range for normal women in this assay is 0-48.0 miU/1, so that the 
majority of PMS patients have apparently 'normal' prolactin levels. 
Prolactin estimations were made throughout the luteal 
phase, so that a spread of values was obtained for the lasttwo weeks 
of the cycle, although there were few values to represent each 
individual day. The pattern of values for the cycle (Fig. 4.2) shows 
apparently no marked increase in the second half of the cycle, at 
least not until the last day before menses. The data represented in 
this way did not show a marked mid-cycle peak, but there were rather 
few samples around this time of the cycle. 
The relationship between progesterone and prolactin levels 
Prolactin estimations were carried out in 42 women with 
'normal' progesterone and in 33 women with 'low' progesterone, as 
defined above. In Figure 4-3 there is a comparison of levels of luteal 
phase prolactin in patients with 'low' and 'normal' progesterone. The 
mean prolactin value was 279 ± 104 miU/1 (SD) (n = 33) for the low 
progesterone group and 215 ± 104 miU/l (n = 42) for the normai 
progesterone group. xnub the low progesterone group tended to have 
higher prolactin levels (p <0.01) in the luteal phase. The two patients 
in Group II with hyperprolactinaemia (*>500 miU/1) both had regular 
cycles I although one patient had a low progesterone'peak, as defined 
above, and the other had a peak value of 38 nmol/l progesterone but a 
short luteal phase of ten days. 
The distribution of prolactin throughout the cycle also 
appeared to differ in relation to progelsterone status (Fig. 4.4), 
although there were not enough values to separate the follicular phase 
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Figure 4.4 was not significant in the periovulatory or late 
luteal phase (from M-5 to MO), although this may be partly due 
to the small numbers of samples at this stage of the cycle. However 
prolactin levels were markedly raised from M-13 to 11-6, which is the time 
of luteal development. Thus raised prolactin occurs at the same time 
as or slightly before the depression in progesterone seen in some 
PMS patients (Figure 3-3) which points to a causal relationship. 
The apparent inverse relationship between prolactin and 
progesterone was further studied using computer estimates of the 
progesterone peak. The correlation between prolactin values at 
between M-13 and 11-6 and the progesterone index was calculated by 
regression analysis. The regression coefficient was -0.27 which is 
not statistically significant. 
PROGESTERIONE VALUES WITHIN THE GROUP 
As there was not a suitable control group, and as the PMS 
group were highly variable in terms of symptomatology, it was decided 
to divide the women on the basis of various parameters and to examine 
the hormonal patterns. 
Symptom clusters of water retention and negative affect 
The group was divided on the basis of work by Cullberg 
(1972), who suggested that there might be different mechanisms involved 
in the symptoms of mood change, and those of breast tenderness and oedema. 
Accordingly our group was classified according to the 
symptom clusters that t. he women reported, and the groupings were 
checked by a colleague unaware of the hormone results. 
1.70 women (67%) complained chiefly of 'negative effect' pre- 
menstrually. This symptom cluster includes crying spells, anxiety, 
restlessness, irritability, mood swings, depression and tension. 
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However 51 of these women also reported water retention symptoms. 
2.27 women (26%) complained chiefly of the%%nter retention cluster, 
usually breast tenderness, gain in weight, or feelings of bloatedness 
(and also skin disorders). Again, 24 of these women also experienced 
negative affect. 
There were eight women who fitted into neither category, either 
because their records were unclear or because they recorded a multi- 
plicity of symptoms. 
There was no difference in mean age or the length of the 
menstrual cycle in the two groups. The log mean. progesterone values 
for each day, dated from the onset of the next period as beforel. was 
plotted for both groups, and the results can be seen in Fig. 4-5- 
Progesterone levels were lower in the 'negative affect' group from 
M-3 to M-10 in the figure but this difference was statiatically 
significant only from days M-7 tc> M-8 (P <0.01). 
When the mean value from the control group are compared 
(see Fig. 4.1) the 'negative affect' curve falls below the control 
curve, while the 'water retention' curve is above its 
No other difference could be seen for the 'water retention' 
and 'negative affect' groups apart from a slightly different pattern 
in the onset of the symptoms (Table 4.2). 1 
, 
Table 4.2 Characteristics of women complaining chiefly of 'negative 
affect' (N. A. ) and 'water retention' (W, R, ) 
group(70) R. group(27) 
mean age (years) 34 +6 36 ±7 
Duration symptoms (days) 10-7 4 10 +3 
Onset: childbirth 20 (29%) 3 (1vo) 
(no. ) Puberty 21 (30%) 7 (26%) 
Other 25 (36%) 16 (59%) 
Unknown 4 (6%) 1 (4%) 
No. parous 45 (62%) 16 (55%) 
Mean parity 1.2 1.3 
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Unfortunately it was not possible to examine the 
relationship of progesterone to the absence or presence of any 
particular symptom, such as breast tenderness or headaches, as 
specific questions were not asked about these. 
PsycholoCical profiles using the General Health Questionnaire 
Not surprisingly all the women (58) recorded a positive 
PMS value on a menstrual distressquestionnaire provided by Dr. COlaro 
(Clare, 1977). 26 women (45% of those who completed the questionnaire) 
had a positive score on the General Health Questionnaire, indicating 
some neurotic illness, while the incidence found for all women of this 
age group attending a general practice is about a third (Clare, 1977). 
The mean progesterone values for the Ineurotic I and 'non-neurotic' 
groups were calculated as above but no differences could be seen 
(Fig. 4.6). 
The stage of the cycle at which the dHQ was completed did 
not seem to influence the score on the questionnaire. 27% of the 
GHQ positive group completed the GHQ during days 20 to day 3 of the 
cycle, compared to 28% of the GHQ-negative group. Thus being 
'premenstrual' at the time of answering did not seem to influence 
the response. 
Other aspects of these patients were compared, such as 
age, menstrual cycle3ength, and onset of symptoms, but no significant 
differences were seen. The pattern of symptoms experienced by the 
women was also similar in both groups. 
Prolactin estimationswere available in 33 of the women who 
had undergone this psychiatric assessment. The mean prolactin value 
for the 'non-neurotic' women was 272 + 104 miU/l (n = 17), and the* 
mean level for the 'neurotic' group was 265 1339 miU/l (n = 16). 
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Figure 4.6. Log mean (I S. E. ) plasma progesterone priot 
to menstruation in PMS subjects with a negative (m 
and positive 43- - -13 ) GHQ. 
n is a mean of 6+2 for all points in both Croups. 
I 
of 900 miU/19 and if this figure is excluded, the mean for the 
GHQ positive group becomes 183 + 63 miU/1, which is significantly 
lower (p <0.01) than the GHQ negative group. 
DISCUSSION 
Our group was slightly younger than a sample of 100 
. 
patients described by Dalton (1977); 34% of our group were aged 21- 
30 compared to 19% of Daltons group. The source of referral may be 
relevantt since Daltons group were difficult cases referred by G. P. 's. 
Although there is no generally agreed symptomatology, it 
is believed that the symptoms of depression, irritability and tension 
Ir. are almost always presents and this is confirmed in 
Group II where 
95% complained of mood changes. The incidence of 70% for water 
retention, which includes breast tenderness, agrees with other 
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recorded series (see Table 1.1). The onset of PMS has not been recorded 
in most studies although some data have been obtained by Greene & 
Dalton (1953) which seems to agree with our results* 
In summary, although Group II came to us in an unusual 
way, via a magazine article, there is no reason to believe that they 
were atypical of PMS sufferers in general. The social class distribution 
was probably' skewed towards classes I and II, reflecting the reader- 
ship of the magazine, but there is no published study of the effect of 
social class on PMS. 
Progesterone and prolactin 
Although the progesterone levels of Group II were slightly 
lower than those in the controls this difference did not approach 
187 
statistical significance, as it did in Group I. One reason for 
this may be that the samples in Group II were assayed in much later 
batches so that inter-assay variability may bias the results. How- 
ever it is interesting that 30% of Group II had a progesterone peak 
value lower than the 90% confidence limits of the controls, while 
only 10% would be expected statistically (P <0.01). The expected 
proportion (10%) of patients had progesterone peaks above the 90% 
confidence limits of the controls. The lower WIL' confidence limit 
of the peak (at day -7 premenstrually) was 32.6 nmol/l which shows 
good agreement with the 10 ng/ml (32 nmol/1) level regarded by 
Johansson (1969) as the criterion of a normal progesterone peak. 
It is very difficult to make any conclusions about general 
levels of prolactin in PMS from Group II as a suitable control group 
was not available. It may even by misleading to draw conclusions 
from the pattern of prolactin levels throughout the cycle, as each 
day is represented by samples from different women. However it can 
be stated that the vast majority of PMS patients have prolactin levels 
within the range for 'normal' women - that is, women without any 
obvious pituitary or ovarian disease. From Fig. 4.2 it appears that 
prolactin levels are higher in the luteal phase than in the follicular 
phase and that there is a sharp increase 2-3 days premenstrually. This 
latter change is more uncertain as very small numbers were involved at 
this stage of the cycle and a few patients with high prolactin levels 
throughout could bias the results if they had sanples taken only at 
this time. 
McNeilly & Chard (1974) found highly variable patterns 
of daily prolactin in their group of eight women, with some showing 
An ovulatory and luteal increase, and others showing no change at all. 
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It is tempting to speculate that the differences may be due in 
part to the presence or absence of PMS in the%,, omen, and to attach 
some aetiological significance to the luteal increase seen in our 
group. Halbreich et al. (1976) in a similar study to our own, did 
look at a PMS and a control group, and they concluded that the 
luteal rise of prolactin was more marked in Vie PWS group (28% 
compared to 17%). Their design was slightly better than our own 
in that each patient contributed one follicular and two luteal 
phase samples, although this is still nowhere near the ideal of 
daily samples (or more) which would give a far more accurate 
picture. 
In our group there appears to be a mean increase of 34% 
in the mid-luteal (M-9 to -6) compared to the follicular phase 
(Figure 4.2).. Without a control group this does not confirm the 
findings of Halbreich and co-workers although it might add a little 
weight to his findings. 
As already described, gross hyperprolactinaemia leads 
to amenorrhoea and there have also been several recent papers 
linking prolactin with impaired luteal function, although in few 
patients. Hyperprolactinaemia has been linked with the short luteal 
phase (Corenblum et al., 1976) and progressively shorter luteal 
phases, with associated low progesterone secretions have been found 
to precede amenorrhoea when hyperprolactinaemia recurs after 
bromocryptine therapy (Seppa'la" et al., 1976). *There is some evidence 
that even slightly raised prolactin levels are associated with luteal 
phases of 12 days or less in infertile women although there was no 
corresponding reduction in progesterone secretion (Fredriccson, 
Bjo*rk, & Carlstro**m, 1977). ' 
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We were able to show that there is a tendency for sligHly 
raised prolactin levels to precede or coincide with low 
progesterone secretions although there was no apparent 
shortening of the luteal phase. Benedek-Jaszmann & Hearn- 
Sturtevant (1976) found a similar association between high 
prolactin and low progesterone (from endometrial biopsy) in 
a PMS group. These results euggest an inhibitory role of 
prolactin on progesterone secretion, but it is not possible to 
conclude whether prolactin is acting directly on the ovary or 
whether it is inhibiting the luteotrophic effect of the gonado- 
trophins. The only evidence so: fhr for the direct action of 
prolactin on ovarian, function comes from the in vitro work of 
McNatty et al. (1974), alreadydýscribed in Chapter 1. It has 
also been suggested that such a mechanism occurs in vivo (Glass, 
Shaw, Butt, Logan Edwards & London, 1975; Editorial, 1977)- 
However in a recent paper McGarrigle, Sarris, Little, 
Lawrence, Radwanska & Swyer (1978) treated 17 hyperprolactinaemic, 
amenorrhoeic women with clomiphene citrate and HCG, and obtained 
progesterone and oestradiol levels indicative of a normal corpus 
luteum, followed by pregnancy in most cases. Assnming that prolactin 
levels remained high during and after treatment (although this is not 
stated by the authors) it appears that corpus luteum formation is not 
inhibited by hyperprolactinaemia provided that gonadotrophic 
stimulation is sufficient. 
It is already known that high prolactin abolishes the LH 
surge in response to oestradiol administration (Glass et al., 1975; 
Aono, Miyakeq Shiojij Kinugasa, Onishi & Kurachi, 1976). Yet the 
pituitary response to LHRH is unimpaired in women with hyperprolact- 
inaemia ( Zarate, Jacobs, Canalesl Schally, de la Cruz, Soria & 
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Daughaday, 1973; Mortimer', Besserg McNeilly, Marshall, Harsoulis, 
Tunbridge, Gomez-Pan & Hall, 1973). This implies that the po, -Iive 
feedback of oestradiol to the hypothalamus is blocked in hyper- 
prolactinaemia, and the work of McGarrigle and cQ-workers confirms 
that this is the chief mechanism, since their succes3with Clomiphene 
in promoting follicular development as part of their therapy suggests 
that the negative feedback mechanism is intact. Others have found 
that Clomid alone is ineffective in hyperprolactinaemia (Bohnet,. 
Dahlen, Wuttke, & Schneiderl 1975). 
According to these findings, the prolactin-associated 
low progesterone secretion in our group would be due to an inadequate 
LH peak and consequently a poor corpus luteum, and a direct luteolytic 
action of prolactin would be unlikely. 
However the situation of hyperprolactinaemic anovulation 
is rather different to the situati6h in our patientst where ovulation 
was occurring and the prolactin levels were chiefly within the normal 
range. Prolactin has biphasic effects human granulosa cells in vitro, 
depending on the dose, and the binding of prolactin to these cells 
varies during the menstrual cycle (McNatty et al., 1974). Therefore 
it is still possible that prolactin has direct effects on the ovary, 
depending on tissue levels and the time of the cycle. 
Progesterone and symptom groupings 
Most authors studying hormonal parameters in PMS have 
not specifically stated their selective criteria for the symptoms. 
Bgckstro"m et al (1974) studied women suffering from anxiety, irritability 
and headaches, but the diagnostic criteria were not defined, nor were 
they defined in a later paper (Býckxtr8m et al. 9 1976b)*Smith (1975) 
selected women with depression as the main symptom. Although these 
two authors found similar results for progesterone, Býckstr'dlms group 
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found raised oestradiol levels while Smith did not. Among many other 
explanations for this, it is just possible that anxiety and depression 
have different aetiologies. 
The majority of studies have tended to group anxiety, 
depression and irritability together as 'emotional lability' (Morton, 
1950) or as 'negative affect' (Moos, 1969). Indeed, there is evidence 
from population surveys of women that premenstrual depression and 
anxiety are closely correlated (Moos, 1968; Golub, 1976). Despite 
this, an attempt has been made to sub-divide patients into those with 
'anxiety-tension', lasthenia-depression', 'irritability-explosiveness, 
and feelings of swelling, which were all defined and diagnosed by - 
established criteria by Blickstr6m & Mattsson (1975)- They found a high 
association between all the symptoMs, and a high correlation between 
oestrogen levels at day M-3 and anxiety, irritability and to a lesser 
extent depression. They found no correlation with progesterone lovols 
at day M-3, but this is not surprising as Backstr6m et al(1974) had 
already shown that a deficiency of progesterone in PMS had disappeared 
by day M-3. However this was a study on a very few women with slight 
to moderate symptoms with a small amount of data on each. One 
interesting point to emerge is that feelings of swelling do not 
correlate with either hormone levels or with anxiety, although there 
is an association with depression. 
Accordingly we had sub-divided our group into those 
suffering chiefly from'the water retention grouping of Moos (1968) 
and those complaining, of negative affect. The symptom groupings of 
Moos were used because they have been frequently used and tested by 
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subsequent authors (see Moos, 1977, for review). The 'negative 
affect' group in our study had lower progesterone levels, and in 
our earlier group of patients (Group I) low progesterone levels 
tended to be associated with raised oestradiol at day M-3 (Fig. 3-3)- 
Thus, although we were not able to repeat the work of Býckstr6m and 
Mattsson, it appears that a similar trend was emerging. 
The difference in progesterone levels that we observed 
is interesting in view of the well controlled study of Cullberg 
(19? 2) who was studying PMS from a completely different approach. 
By 'latent profile analysis' which is a method of classifying 
patients according to their tendency to cluster in response 
patterns to the questionnaires, he identified a group of women 
complaining of depression, irritability and tiredness before any 
medication, and these he regarded as a rather 'pure' PMS group. 
This class was also striking in that the women rqacted badly to 
oral contraceptives with increasing proportions of oestrogen, but 
improved on the highly progestogenic combinations. Another class 
of women, suffering chiefly from. weight gain and breast tendorness 
premenstrually, seemed'to react less consistently to the various 
hormonal combinations. 
These two classes would correspond with the 'negative 
affect' and 'water retention' types of PMS seen in our study, and 
which appear to differ in their progesterone status. This cuggests 
that the mood changes are strongly hormone dependent, while symptoms 
of water retention may depend on individual 3ýesponses at the tissue 
level. However it should be pointed out that there was considerable 
overlap of all the symptoms, and this was also found by Cullberg. 
Some further support for the concept of two aetiologies 
has come from the double blind study of the therapeutic effect of 
bronrocryptine and bumetanid, a diuretic (Andersch, et al. 1978 a). 
They found that the former treatment relieved tension and pain in the 
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breasts and irritability while the latter relieved bloating. From 
this rather slender evidence they suggest that mood changes, with 
mastalgia, occur separately from bloating. 
Psychiatric illness and-PMS 
We had anticipated that this group might include some 
women suffering from neurotic illness, and that the premenstrual 
symptoms might be closely linked with and even secondary to the 
psychological disturbance. 
Coppen & Kessel (1963) found a close association botween 
neuroticism and premenstrual tension, and Clare (1977) using the 
General Health Questionnaire, found that GHQ positive (i. eq 
stressed) women had an 87% incidence of some premenstrual complaints 
while only 33% of unstressed women (GHQ negativeýo complained of such 
symptoms. However this is not evidence of cauzality in either 
direction. 0 
It was expected that the GHQ positive women in our grou-D 
might be characterised by their symptoms or some other aspect of their 
history but this was not the case. Neither did the progesterone levels 
differentiate between the stressed and the unstressed. However, 
interestingly, although a case of hyperprolactinaemia occurred in 
the GHQ positive group the rest of this group had lower prolactin levels 
than the 'non-neurotic' group. Thistrend is perhaps in the opposite 
direction to that expected, although as prolactin values were not 
available in all the women it may be rather premature to base any 
conclusions on this. An additional factor is that the criterion of 
a positive GHQ is only an indication of recent psychiatric ill- 
health or stress, but does not give a more specific diagnosis 
(Goldberg, 1972). Therefore at present it seems that PMS cannot be 
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subdivided neatly into psychosomatic and endocrine disease, 
although further work may clarify this. 
Golub (1976) showed that anxiety and depression are 
raised premenstrually but that the extent of these temporary 
symptoms does not approach clinical depressive or anxiety 
states. This is borne out in our study, where being 'premenstrual' 
at the time of answering did not lead automatically to a positive 
score. 
These re3ults, taken overall, suggest that premenstrual 
tension is a true cyclical state and is not a function of personal 
adjustment to other stresses. The psychological illness seen in 
our sample and indeed seen in any sample of women (Clare, 1977) 
may yet be associated with some aspect of the menstrual cycles but 
further research is needed. 
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CHAPTER I 
Treatment of premenstrual syndrome with 
dydrogesterone in relation to the progesterono 
status of the patients. 
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1. PAT"IENTS) (GROUP III) 
Patient Protocol 
These women were largely self-referred following 
another discussion of PMS in the press, and after clinical 
assessment 103 women gave their informed consen'tto taking part 
in a single-blind controlled trial of dydrogesterone therapyo 
Initially the women were asked about eight symptoms; depressioh, 
irritability, lethargyq swollen breasts, swollen abdomens swollen 
fingers or anklesq headaches and premenstrual stomach ache, and 
they were asked to keep record of these throughout the six-month 
trial, by giving each symptom a daily score from 0 to 3 (0 is absent, 
1 mild, 2 moderate, 3 severe). Morning temperatures were taken daily. 
Four blood samples were taken during the cycle preceding 
treatment, on days 12,18,22 and 26 of a 28 day cyclet and 
extending or shortening these intervals to adjust for longer or 
shorter cycle lengths. The sampling was repeated four cycles later 
after one cycle of placebo and two of dydrogesterone 10 mg. m. b*d* 
and during the third cycle of active therapy. The course of 
medication was from day 12 until day 26, adjusted as above for 
longer or shorter cycles. 
Progesterone estimations were carried out on all the 
samples and a computer index of the progesterpne peak was calculated 
for 63 cycles before therapy and in 39 cycles during therapy. 
Characteristics of the patients 
36 women withdrew during the six-month trial; 15 of 
these stopped due to medical problems unconnected to the trial, 
19 defaulted before treatm-3nt, and two gave up due to adverse 
effects on active treatment. 
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The remaining 67 women were of mean age 30. t 5.2 (SD) 
years, range 24 - 44 years, and the menstrual cycle length was 
27.9 ± 2.4 (SD) days, range 21 - 35 lays. The other details about 
this group were very similar to Group II. The only slight differenne 
was that 79961 of Group III were parous, compared to 59% of Group III 
and this difference was reflected in a rather higher history of 
onset of PYIS at childbirth in Group 111; 43%, compared to 2%, of 
Group II. - 
2. PLASMA PROGESTERONT VALUES 
Me mean progesterone peak for this group, as judged 
by the computer model, was 41.3 1 13-3 (SD) nmol/l(n - 63)- Of the 
66 women who had at least one blood test , 21 
ON, ) were judged to 
have 'low' progesterone curves in comparison with our control group 
(see Fig. 4.1). The 'low' prog, -, sterone group included two patients 
who had shorý luteal phases of 7 and 8 days and one patient with a 
'defective' luteal phase (values of 15 nmol/l or less). 
The luteal phase was slightly shorter in the women with 
low progesterone peaks; a mean of 11.8 + 2.0 days (n = 17) compared 
to 13.6 + 1.0 days (n = 40) in the women with normal progesteronet 
I. and this difference was statistically significant (p <0.01). The 
'low progesteronel group-did not have symptoms for a longer time than 
the 'normal progesteronel group (a mean duration of 9 days in both 
groups) nor was there any indication that the symptoms were more 
severe, since 60% of both groups were rated as having 'severe' 
symptoms by the physician. 
Progesterone values and Response to Therapy 
The overall response of the patients, whether they were 
the same, betterl or worse, was determined from the physicians 
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assessment. 47 patients (72%) reported improvement during the 
months of active treatment, although initial improvement on placebo 
was 44%. However 15 (23%) reported improvement on dydrogesterone 
alone while only 4 (6%6) reported improvement only on placebo. Seven. 
(10%) reported that they felt worse on dydrogesterone, while only 
one reported that she was worse in the initial placebo month. 
The response of individual symptoms was obtained by 
counting qymptom scores cycle-by-cycle on the individual diaries. 
The results are shown in Table 5.1. Improvement was assessed by 
comparing mean scores for each treatment with the symptom score in 
the cycle preceding treatment. 
Table 5.1 Reponse of individual symptoms to treatment with 
dydrogesterone and placebo. 
IMPROVED (No. ) MADE WORSE (No. ) 
Symptom No. Initial Active Second Active P2. acebo 
complaining placebo placebo , 
Depression 56 18 44** 14 1 0 
Irritability 61 19 41** 12 0 0 
Tiredness 57 17 26 11 1 0 
Swollen breasts 56 11 14 15 9 3 
Swollen abdomen 51 12 26* 21 5 2 
kLcT. ive grearcer Tnan initiai placeoo< U*UJL' 
40.001" 
Active greater than 2nd placebo month only: M01 
+ 
The mean progesterone indices of the 'responders' and 
e 
'non-r. esponders' was compared. Responders were considered to be those 
who responded to dydrogesterone alone or dydrogesterone plus one 
course of placebo, and non-ramponders were-those who did not 
improve on the courses of active therapy or who responded well 
to all the courses, including all placebo treatments. 
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The mean progesterone index for the 'responders' was 
39.7 + 13.0 (SD) nmol/i (n = 38) and the mean for the Inon- 
responders' was 46.2 + 13.6 (SD) nmol/l (n = 25), but this 
difference was not statistically significant (StudentsYtest). 
The mean of the seven adverse responders already 
included in the 'non-resporiders' above was 46.3 + 9-9 (SD) nmol/l. 
The mean progesterone values for the individual days 
were grouped into two-day intervals for the responders and non- 
responders (Fig. 5-1). It appears that in the 'responders' the 
luteal peak of progesterone occurs earlier and then regresses 
more sharply, but none of the differences were statistically significanto 
There were no other differences apparent between those 
who did or did not respond, except that the responders had originally 
complained slightly more frequently of depression and irritability- 
ProEesterone values while on active treatment 
Four samples for progesterone were obtained in both cycle 
1 (pre-treatment) and cycle 5 (dydrogesterone) in 34 patients and 
during cycle 1 and cycle 6 (placebo) in five patients. The mean I 
values for the computer index are shown in Table 5.2. 
Table 2.2 Progasterone indices compared between 
pre-treatment cycle and either dydrogesterone- 
or nlacebo-treated cvclp. 
PRO! Index ninol/l (mean 
Treatment No. Cycle A Cycle B B/A % P 
cycles pre, treatment (mean ; LSE) 
treatment 
B 
dydroges erone 34 41. Z+12.6 35-2ý±15-0 84+4-3 ý0.01* 
B= 
placebo 5 46.2+6.6 44.8+18.9 97-+4-5 ns 
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This illustrates an overall reduction of progesterone 
secre'tion during the luteal phase while under active treatment. Three 
women were not included in Table 5.2 as during dydrogesterone 
treatment they had progesterone values in the second half of the 
cycle of less than 10 nmol/1 and were therefore considered to be 
anovulatory (Israel et al., 1972). Amongst the other women the re 
was a very wide range of progesterone values, from 150% to 29% 
of the initial pre-treatment cycle; so that not everybody experienced 
a reduction in progesterone levels. It was thought possible that 
patients who did not respond to dydrogesterone therapy might be 
those who suffered the greatest suppression of luteal function 
during active therapy. However there was no difference between 
th6 mean percentage fall in progesterone during dydrogesterone 
treatment of the 20 'responders' (85 + 26%) and of the 14 'non 
responders' (81 + 27%). 
DISCUSSION 
The age distribution and menstrual cycles of the third 
group of women were similar to Group II (Chapter 4). The mean 
progesterone index was also similar; 38.9 ± 9.1 nmol/1 (n = 77) 
in Group II compared to 41-3 :t 13.3 (n = 63 ) nmol/l in Group IM 
A veýyhigh placebo effect was noted (44%) which agrees 
with the findings of other 'blind' studies (Mattsson & von Schoultz, 
1974). It is interesting that a good response to dydrogesterone was 
only significant for the symptoms of depression, irritability and 
swollen abdomen and in some women breast tenderness and swollen 
abdomen were aggravated. The symptoms which improved such as 
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depression, are the most subjective ones where perhaps an 
'improvement' could be suggested unconsciously by the physician, 
who was not 'blind' to the sequence of tablets. This pitfall was 
avoided as the individual symptoms were assessed from the daily 
scores on the patients' diary. 
The two placebo effects, both before and after active 
treatment were very similar for most symptoms apart from swollen 
abdomen (Table 5.2) which probably rules out any 'carry over'-effect 
of dydrogesterone. 
The responders had slightly lower progesterone value3 
than the non-responders although the difference was. not sufficiently 
great as to suggest the role of dydroge'sterone as hormone replacement 
therapy. One explanation for the difference is that the responders 
are a slightly different group, with more symptoms of depression, 
irritability and swollen abdmen these being the symptoms most 
responsive to treatment. 
In fact the 'responders' in Group III did complain 
initially of slightly more depression and irritability than the 
'non-responders'. This would also correlate with evidence suggesting 
that the women suffering fromInegative effect' tend to have lower 
progesterone values (Chapter 4). There is no reason to believe that 
dydrogesterone and its main metabolite, DHD, interfere in the assay 
since the plasma levels of these substances in blood are thought 
to be in the low nanogram range (L. C. Post, personal communication), 
and th6 cross-reactivities of these substances was in the order of 
1% for our antiserum (see page 88). 
Indeed progesterone levels were low during the 
dydrogesterone-treated months. This could be due to some unknown 
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interference in the assay but it seems more likely that 
progesterone secretion is being reduced. Johansson (1971) 
administered progestogens to seven volunteers at three days 
after. ovulation for varying lengths of time. He found that 
norethisterone and norgestrel, even at doses of 5 mg per day 
over six days or 100 mg per day over two days, reduced the 
progesterone levels over the remainder of the luteal phase to 
between 7 and 75% of the control cycles, and 300 mg clormadinone 
acetate and 360 mg medroxyprogesterone had the same effect. 
In our study a total of 240 mg of dydrogesterone 
over 12 days gave a change in progesterone levels ranging from 
150% to 2Sr/6 of the control cycles, indicating that it is not as 
potent as other progestogens in this respect. The effect of 
dydrogesterone on lutqal function has been noted before by Bell 
& Loraine (1965) although in their study the drug was given from 
day 5 to day 25, for dysmenorrhoea. In three out of five of their 
patients pregnanediol excretion was atypically low, and there was 
some doubt, from the excretory pattern of other hormonesl whether 
two of these cycles were ovulatory. 
-The mechanism by which the progestogens reduce 
progesterone levels is not truly luteolytic, since a strongLurge 
of progesterone can be induced by an injection of HCG (Johanssons 
1971). There could be a negative feedback mechanism either on the 
hypothalamic-pituitary system or on the ovary itself. In support 
of the latter idea, there is some evidence that progestogens inhibit 
enzymes such as 3/3-ol-hydroxysteroid dehydrogenase of the ovarian 
steroid pathway (Aaakvaag, 1970) and the isomerases and aromatases 
(Schilrenkamper & Lisse, 1978) (see Figure 6.1. ) 
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Progestogens are not identical to progesterone in 
their metabolism, and their progestogenic properties may be combined 
with anabolic, oestrogenic and/or androgenic effects. The progesto- 
gens behave differently on the control of prolactin secretion 
(Gr a*"f, Neumann, Nishino, Mehring & Hasan, 1973) and on the renin- 
aldosterone axis (Oelkersl Sch8nesh8fer & BliUmel, 1974). Another 
complication is the suppression of endogenous progesterone levels, 
described above. 
All these factors make it difficult to draw any con- 
clusions about the role of progesterone in PMS from the success or 
otherwise of progestogen treatments. It is encouraging however that 
dydrogesterone is a significantly helpful treatment in PMS where 
other progestogens are not (Jordheim, 1972), and this may be partly 
due to its 'pure' progestogenic effects, that is without anabolic 
or oestrogenic qualities (Backer, 1962). However dydrogesterone 
had an apparently pharmacological and not a physiological 
, 
therapeutic effect, and in addition may aggravate some of the 
symptoms. 
In conclusion the results from Group III lend some 
support to the idea that progesterone activity may be involved in- 
the emotional symptoms of PMS, although an absolute deficiency of 
progesterone is unlikely to be an important factor. 
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CHAPTER 
General Discussion and Conclusions 
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General Considerations 
There were a-few general difficulties which are inherent 
in a study of this type; chiefly the classification and diagnosis of 
patients, the categorisation of symptoms and the collection of sufficient 
. blood samples. 
It was felt that a longitudinal self-report was a better 
diagnostic tool than a retrospective questionnaire such as that of 
Moos (1968). In as early as 1937, McCance, Luff & Widdowson found 
poor correspondence between these ýwo types of record, and they 
concluded from their study of 167 women that little reliance could be 
placed on the use of a history cr retrospective questionnaire. Also 
a longitudinal study yields more accurate information about the duration 
and timing of symptoms. 
Another problem encountered was the variability of symptoms 
from cycle to cycle in each woman. Although the cyclical variation in 
subjective feelings is well documented, there is no evidence for a 
cyclic pattern to non-verbal behaviour which can be measured objectively, 
such as task performance (Sommerg 1973). Consequently there was no 
objective means to gauge how far outside factors might have affected 
a particular cycle. For instance, several women noted that the study 
cycle was atypical as they felt better than usual. This may have been 
a 'placebo' effect of the course of venqpunctures, but we did not feel 
justified in excluding these cycles from the study. 
It would have been far better to have daily blood samples 
from at least some of the patients, and although this was almost 
achieved with the controls and a few patients who were staff members, 
the other patients often came long distances and could attend for 
four samples at most. Other workers have partially resolved this 
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problem by daily sampling of only the last six or ten days of tho 
cycle (Ba'ckstr6m & Carstensen 1974; Býckstr`o*m et al., 1976b) , although 
even this would have been difficult for most of our subjects. 
Despite these difficulties we found some significant 
differences in endocrine relationships in the PMS group, and tho 
individual findings have been discussed in Chapters 3-5. Howover 
it is possible to make some general conclusions from the project as 
a whole and to pos6-Ulate an aetiological model from our findings. 
For this purpose the results in Chapter 3 regarding progestorone and 
oestradiol and those in Chapter 4 will be discussed. 
The first finding of some interest is that progesterone 
levels are low in the early luteal and mid-luteal phase, but decline 
normally, while oestradiol levels are normal in the early and mid- 
luteal phases, but become increased four days premenstrually. The' 
evidence for an imbalance between these two steroids is now quite 
strong, both from this work and that of others, as diecusned in Chapter 
3- 
However, although a statistical difference was seen in 
Group 1, there were many women in Groups II and III with apparently 
normal or high progesterone levels. This implies that there are no 
sharply discrete 'pathological' disorders of steroid secretion in most 
women with PMS, but rather that the patterns of luteal function follow 
a continuous distribution. Indeed, examination of both columns in 
Figure 2.16 indicates that there ic indeed a fa--; -r ly continuous 
distribution of progesterone peaks, and the diViding line between 'low, 
and 'normal' progesterone is rather arbitrary. This is analogous 
to the continuous distribution of blood pressure valueel with the 
consequent problems of deciding a dividing line for essential 
208 
hypertension (Taylor, 1977b). 
Women with progesterone values at the extreme low and 
of the distribution curve'might have the most severo symptoms 
(although we saw no evidence of this) or it could be that individual 
sensitivity is important. Another explanation could be that women with 
high or normal peaks of progesterone have their symptoms after the 
progesterone peak is reached, while the levels are falling rapidly, 
since at this time oestradiol levels are falling less sharply. If 
this were the case, one might expect women with high progester9no 
levels to have symptoms for a shorter time, but this did not amergo 
from the histories (see p. 197), 
The alteration in the temporal pattern of steroid 
secretion during the luteal phase may be itself a causal factor in 
PMS, or it may be that a hypothalamic factor is the primary aGents 
inducing indirect changes in ovarian steroids. It may be pertinent 
in this context to discuss factors that aro likely to control 
ýteroidogenesis in the corpus luteum, and which may thoroforo bo 
responsible for the altered progesterone/oestradiol ratio. 
Possible mechanisms for the altered steroid ratio 
There are two possible ways in which an altorod 
progesterone/oestradiol ratio could be brought about. The first 
mechanism could occur via alteration of the steroid pathways within 
the corpus luteum itself. The overall scheme for steroid biosynthosic 
in the ovary is shown in Figure 6.1. 
Both granulosa. and thecal cells from the Graafian follicle 
undergo luteinisation in the human, and both types of luteinioed coll 
are found in the corpus luteum as a direct result of the presence of 




























Figure 6.1. Steroid biosynthetic pathways in the human 
corpus luteum. The most important products are underlined* 
M-OH SH is 313-hydrox-j Steroid Dohydrogenases and 







after ovulation, such as the cow, only luteinised granulosa cells 
are present in the corpus luteum (see Eckstein, 1977, for review). 
It now seems established, from studies in vitro of carefully separated 
non-luteinised human cells (Moon, Tsang, Simpson & Armatrong, 1978j 
Fowler, Fox, Edwards, Walters & Steptoe 1978) that thecal cells 
produce the androgens, and these are aromatized by the granulosa 
cells. 
Therefore relative numbers of thecal cells nnd granuloan 
cells could be a factor in the alteration of the progesterone/ 
oestradiol ratiol but control of these morphological changes is little 
understood, despite many histological atudion. 
It is possible that the gonadotrophina are able to alter 
the steroid balance within the corpus luteum, although the evidence so 
far does not supportthis. LH stimulates steroid synthesis by wholo 
corpora lutea in vitro, but it stimulates all ovarian steroideuniformly 
(Rice 
, Hammerstein & Savard, 1964), probably by control at the stop 
from cholesterol to pregnenolone. It is possible however that FSH MiGht 
have more subtle effects on the pathway. In rats FGH appears to 
stimulate aromatase activity of granulosa cells and al3o stimulates III 
receptor sites (Dorrington, Moon & Armstrong, 1975). Although in 
humans the function of FSH after ovulation is uncertain, a role for 
FSH in subtle endocrine change seems poqsible, especially as Nickatr6m 
et al (1976b) found increased FSH levels in their PMS group in the 
early luteal phase (see below). 
Another pituitary hormone, prolactin, may act directly 
on ovarian steroidogenesie. In rats prolactin in luteotrophic and 
the mechanism is possibly via its inhibitory effect on the activity of 
20-hydroxy-steroid dehydrogenase, thus preventing the breakdown of 
progesterone to 20-, 4y c*progesterone (Armstrong, Knudsen & Miller, 1. , 
Ii 
1970)- However the situation in the human corpus luteum is vory 
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different, as prolactin has a biphasic atimulatory and then 
I 
inhibitory effect on progesterone aynthesis (McNatty et al., 1974), 
although it is not clear as yet whether prolactin affects oestradiol 
synthesis directly. 
It appears from the above that there is no information at 
present about a single controlling factor which could cause the 
progesterone/oestradiol imbalance seen in our patients. 
The second mechanism to account for the altered 
progesterone/oestradiol ratio has been suggested by BNckstrlom ot al 
(197ýb) and involves steroid synthesis by ovarian components other 
than the corpus luteum. These workers studied serum FSII and U1 in the 
last ten days of the cycle in'women with PMS, and they found that FGH 
was rained in these women compared to controls from 6 to 9 days 
premenstrually, although LH was unchanged. They also found that 
oestrogen was raised from day 5 premenstrually onwardal and U110Y 
postulate that this reflects the stimulation of a second sot of 
follicles, as a response to the increased FSH levels. They explain 
the subsequent decline in FSH levels in these women by negative 
feedback from the increasing oestrogen levelsq so that the second 
set of follicles will regress at about the time of lutoolycia. 
Presumably there is no positive feedback leading to further oestradiol 
6ecretion, an LH surge and ovulation in this second set duo to the 
luteal -levels of progesterone present, since Dierschke ot al. (1973) 
found that high progesterone levels inhibit the ability of oestradiol 
to provoke positive discharge of TII* 
Bdckstroms group explain the increase in FSII levola early 
in the luteal phase as a response to the low levels of both progestorone 
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and oestradiol at this time, since the presence of low levels of both 
steroids lowers the threshold for FSH secrotion (Boau, Johanason 
Gemzell, 1973; Hagino & Goldzieherl 1970). 
What Bgckstro**ms group do not account forl howaver, ia tho 
low steroid secretion seen by them in the early luteal phase, for both 
progesterone and oestradiol, which suggests some form of inadequate 
luteal development. We saw a slightly different pattern in that 
progesterone was low from 4 days after ovulationg but oentradiol 
was not markedly lower at this time (see Figure 3-4ý- 
Two forms of inadequate luteal phase have been described 
in infertile, but regularly menstruating women; the short luteal phaseq 
lasting less than ten days, with lowered secretion of both ateroida; 
(Strott et al., 1970; Sherman & Korenman, 1974) and the defoctive 
luteal phase of normal length, but with lowered steroid secrotion 
(Pearce, Fahmyj Morgan, Evans, Groom, Boyns & Cooýej 1971; Dodson 
MacNaughton & Coutts, 1975). The function of the corpus luteum in 
the women in our study resembled the latter, in that progeoterono 
secretion was initially low in the luteal phase but the luteal phase 
was not markedly shortened. If this is the originalcbfoct in our 
patients, one might expect a proportion of them to be infertileg but 
although this information was not specifically sought, few women gave 
a history of infertility. However the age distribution wao ouch that 
most women had completed their families and presumably secondary 
infertility would not be noticed. Furthermore anovulatory cycles, 
and therefore perhaps other cycle defects, are more common in older 
women (Sherman & Korenman, 1975). 
Even if the defects seen in our study could be fitted into 
the existing categories of luteal phase defects, there is little known 
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about the aetiology of these defects which would holp in tho study 
of PMS. For instance, Pearce et al (1971) and Dodson et al (1975) 
found low pre-ovulatory levels of oestrogens and low levels of 
follicular phase FSH in thecbfective luteal phase but the UI peak 
was not altered. Unfortunately follicular phase levels of FSII waro 
not measured by us or by Blickstr6m et al (1976b) but in our study 
the pre-ovulatory levels of oe8tradiol did not appoar to bo lowerod 
(see Fig. 3-, 4-)- 
Another type of defective luteal phano haa beon doccribed 
by Lentons Adams & Cooke (1978) in which only progesterone secretion 
seemed to be altered. A variety of treatments were applied, such aa 
progesterone suppositories, anti-oeatrogens and exogenoua gonado- 
trophins, and although all these supplemented progesterone lavelos 
infertility was not improved. These authors concluded that the under- 
lying defect was not corrected. In an earlier paper Lenton, Sobowalo 
& Cooke (1977) had noted slightly raised prolactin levels in the early 
follicular phase of women whom they suspected, but had not proved to 
have defective luteal phases. Prolactin has been implicated in infertility 
and PMS, as described previouslyand high levels have been demonstrated 
in PMS patients compared to controls (11albreich et al, 1976). There- 
fore it seems possible that prolact . in hypersecretion may be one of the 
initial abnormalities in PMS, especially as an inverse relationship 
between prolactin and progesterone secretion in 1143 has already been 
noted in Chapter 4 
However interactions of prolactin with hormones of the 
menstrual cycle are little understood and rather controversial. 
Prolactin is known to inhibit the positive feedback of oostradiol on the 
LH peak at midcycle ( see page 189 ) yet the mid-cycle IS peak 
ii14 
is unchanged in defective luteal phases (see above) and III in 
unchanged in the luteal phase in PMS (Mckstr6w. at al., 1976b). 
Other possible modes of action of prolactin are by increasing the 
refractorine8S of the ovary to gonadotrophins (Rolland, Laquin, 
Schellekens & de Jongs 1976) or by depletion of LRF (Bohnet at all 
1975). Apparently the negative feedback of oostradiol is unimpaired 
in hyperprolactinaemial from the evidence of McGarriglo at al (1978) 
discussed on page 189. 
Another problem ie that many ctudies of hyperprolactinaamia 
and the menstrual cycle have based their conclusion on studies of 
bromocryptine therapy, yet bromocryptino is cffectivo in infertility 
even when prolactin levels are low (van der Steee & Coolingh Benninkj 
1977). This is attributed to the wider dopaminereic activity of 
bromocryptine acting directly on LRF or gonadotrophina. It could 
be therefore that raised prolactin js acting as a marker of reduced 
dopaminergic activity rather than affecting the cycle directly and 
this is discussed more fully on page 223- 
Therefore, if prolactin in a factor in the endocrine 
changes seen in the premenstrual syndrome, its exact role in not 
known, although one can speculate that high levels of prolactin at 
some point in the follicularg early'luteal, or oven in the preceding 
luteal phase, are reflected in reduced steroid secretion in the 
early luteal phase, brought about either directly or via releasing 
factors or gonadotrophins. 
The overall hypothesis is that transient high prolactin 
levels, due to stress, or a hypothalamic factor, lead to impaired 
follicular secretion of oestrogens or gonadotrophina and a Idefectivo 
luteal phase, followed by asynchronous follicular development as 
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described above. A summary of the postulated scheme is described 
in Figure 6.2. This hypothesis is attractive in thut it explains 
. he separation in time between the changes in progesterone and those 
in oestradiol. Also in this scheme of events cne could envisage 
a 'vicious circle' being set up, whereby PMS-induced stress could 
trigger off events in the next cycle, and so on. This miCht explain 
the very high placebo effect in PMS. 
7here is also support for the scheme in that many 
different follicles are present in the human ovary at different 
stages of developmentq and that most of these follicles aru dootined 
for atresia despite early hormonal activity (Fowler, Chan, Waltoral 
Edwards & Steptoe, 1977). Another possibility is that ovarian otromal 
tissue might make a steroidal contribution, stimulnted by FSII in the 
luteal phase, although the principal products of stromal tiesuo in 
vitro are the androgens (Rice & Savard, 1966). 
Although we can speculate 
. that the scheme in Figure 6.2 
is an explanation of the hormonal changes seen in our patients in 
Group I and Group II, it does not tell us which, if any, of those 
stages are responsible for the actual symptoms of MS. Possible 
mechanisms will be described in the light of our results. As we 
obtained slightly different progesterone patterns for patients with 
chiefly psychological and somatic disorders, these components will 
be discussed separately. 
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HORMONAL CHANGES STAGE OF CYCLE 
(M=lst day monsea) 
Increased prolactin follicular and early 
(or dopaminergic mechanism) 111toal 
refractory 
ovary decreased + ve 
I feedback oestradiol 
low 
opstradiol 
secretion - lowered LRF 
lower FSH 
and/or U1 levels 
poor corpi4s luteum M-10 to -7 
(low progesterono 
low oestradiol) 
A FSH M-9 to -6 
stimulation of oestrogen m-4 to mo 
in other follicles or stroma 
anxiety, stress 
decreased dopamine late luteal 
raised prolactin late luteal, 
follicular 
Figure 6.2 Possible mechanisms to account for changes in 
progesterone and oestradiol seen in our PMS study. Evidence 
for some of the stages (marked*) is described in the text. 
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The relationship between ovarian cteroids and mood disorder 
As mentioned in Chapter 1, there is evidence from work 
in animals that ovarian steroids accumulate in the brain and that 
the ovarian steroids influence behaviour. Although the conclusions 
from these animal studies cannot be extrapolated directly to humans, 
it now appears that there is a cycle to female-initiatod sexual 
activity (Adams et al., 1978), and the effects of pharmacological 
doses of progesterone and oestradiol on human behaviour have already 
been mentioned (see Chapter 1,3-1). Those latter studios give the 
general impression that progesterone is tranquilliaing and hypnotic, 
while oestrogens tend to increase nervous activity. Seen in theaO 
general terms, it would appear that the tension and irritability seen 
in PMS patients in the last days of the cycle could be explained by 
the coincident lowering of the pr9gesterone/oestradiol ratio. 
However there are several observations which at first sight contradict 
this view. The first is that, as pointed out by Smith (1975)9 the 
progesterone/oestradiol ratio is far lower at the time ofibilicular 
ripening than at any time in the iuteal phase and one would therefore 
expect 'pre-ovulatoryl as well as 'premenstrual' tension. Such cason 
have been noted; Geiringer (1951) describes a woman with clear bouts 
of pre-ovulatory and premenstrual depression, lasting 2 and 4 days 
respectively, and Greene & Dalton (1953) also montion some cases with 
bimensual attacks, although no details are given. However in a 
prospective study daily scores of anxiety and aggression were lowest 
at midcycle, and the only peaks occurring at this time were a small 
increase in pain (presumably mittelochmortZ), and peaks for 'self- 
rated pleasantnesal and sexual arousal (Moos et al, 1969). Although 
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this was a study of only 15 women, some of them with PMS, an earlier 
study had noted the same effect (Altmann et al., 1941). 
Examination of the daily charts of our patients was carried 
out in the hope of solving this problem. In Group I thore was no 
indication of a bimensual pattern in the group as a whole (Fig. 3-1), 
although three individuals had bouts of irritability from 10 to 12 days 
premenstrually and again from 5 days before mensess and two womon had 
a bout of depression between 18 and 14 days premenstrually, which could 
be interpreted as pre-ovulatory. Thore was no such pattorn in brenst 
tenderness or lethargy, and most of the women had no symptoms beforo 
the last week of the cycle. The same pattern was confirmod in Group 
III, where 10% of the women had a few days of irritability at around 
midcycle. Therefore it appears that pre-ovulatory tension is not a 
common feature of the syndromo. 
One explanation of this'could be that progooterono(or . 
come 
other product of the corpus luteum) is synergistic with oeatradiol at 
critical ratios, and such effects on behaviour are now established (Fodor 
& Marrone, 1977). In ovariectomised rhesus monkeys administration of 
oestrogen leads to increased sexual activity towards the mate and 
aggression towards surrounding objects. If progeoterone is added 
aggression towards the mate increases, (akin to the 'post-ovulation 
refractoriness'seen in rodents)but hostility decreanee towards a 
third individual or inanimate objects Mumpe & Michael, 1970). This 
has an interesting parallel in the subjective feelings of some of the 
patients in our study, who remarked that they were hostile towards 
their husbands and sometimes children, but not towards strangers or 
acquaintances, although family relationships were harmonic at other 
times of the month. A similar anecdote is mentioned by Dalton (1969). 
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A fascinating, but admittedly unlikely corollary to thia 
is that married women have much higher depression rates than single 
women, although the opposite trend occurs for men (Weissman & Klerman, 
1977), and it could be that 'hormone-induced hostility' to the mate, 
on a par with the work in monkeys of Zumpe & Michael (1970) may be a 
factor in marriage-induced depression. However it is more likely to 
have a psychosocial interpretation, in that married women tend to have 
low socioeconomic statual or it could even have a physiological 
interpretation, if childbitth is a precipitating factor in some forms 
of depression. 
The second possible paradox for the limbalahcol theorY 
is that the menopause is often associated with depression, amongat 
other problems, yet oestr*ogens are very low at the menopauso. However 
it now seems likely that there is no direct relationship between 
depression and the menopause (McKinlay & Jefferys, 1974) and preliminary 
double-blind trials on oestrogens in the menopause have proved 
ineffective for depression per se (Thomson, 1976), although othor 
conditions such as bone-loss and hot flushes are certainly reaponsiva. 
One anomalous finding is in a double-blind trial of 
oestrogen by Klaiber et al (1974) for the treatment of depression 
of both menopausal and pro-menopausal women, whero thoy found that 
oestrogens caused an improvement in mood, and this coincided with 
a decrease in plasma MAO activity. 
Another slightly controversial point in the relationship 
between PMS and anovulatory cycles especially as both phenomena 
almost definitely coincide (Adamopoulos et al, 1972 ; Andersen ot al, 
1977). In Group III, three patients were anovulatory during 
dydrogesterone treatment and two of these recorded complete roliof 
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during these cyclea. However the confounding effect of dydrogesterone 
therapy makes these cycles rather hard to interpret, and as a few caaes 
of anovulatory patients complaining of PMS have been noted in the clinic 
but were excluded from the studies, it seems likely that PMS does occur 
in anovulatory cycles. This may still be compatible with the 'imbalance, 
theory, since the progesterone/oestradiol is very low in the second 
half of anovulatory cycles (Sundsfjord & Aakvaag, 1972), 
Assuming meanwhile that an ovarian steroid imbalance is 
at least partly responsible for the mood changes in PHS, it is still 
difficult to envisago the mechaniems at brain lovel. From work in 
animals and from studies of monoamine oxidase in the manotrual cycle 
reviewed in Chapter 1 it seems likely that the biagonic amines are 
mediating factdrs. The two main groups of biogenic aminos are the 
indoleamines such as 5-hydroxytryptamine (serotonin) which in 
involved in serotonergic transmitter systems, and the catecholaMinou 
such. as dopamine and noradrenaline which are involved in cholinergic 
and noradrenergic systems respectively. The metabolic pathwaya aro 
shown in Figure 6.3- 
Unfortunately we were not able to throw any light on tho 
possible involvement of these systems from the results obtained 
during this project. But come information is available on the 
psychoendocrinology of some psychiatric disorderal, and this may have 
links with the endocrinological results we have obtained. The only 
problem is that PMS has not been classified within the diagnostic 
framework of psychiatry. Most of the studies of psychoendocrinology 
have been on endogenous depressiong and the relationship between this 
entity and PMS is uncertain at most, as PMS can be compared in 
magnitude to a moderate anxiety state (Golub, 1976) rather than to 
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Figure 6-3- Metabolic pathways of the major biogenic 
amines in brain. Possible rate limiting steps (*) and also 
interactions with pituitary hormones are indicated. 
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of psychiatric ill-health did not appear to correlate with any 
particular aspect of PMS. 
In the last decade a lin! has been established between 
neurotransmitter research and endocrinology when it was found that 
monoamine pathways are involved in the regulation of hypothalamic 
releasing factors. This is particularly encouraging as releasing 
factors can now be measured in blood (see page 14)and are therefore 
potential peripheral 'markers' of brain neurochemistry. 
Most work has been carried out on the noradrenorgic 
system. It was first noted, by Sachar, Hellman, Roffwarg, Halpern, 
Fukushima, Gallagher & Bronx (1973) that the 24-hour profiles of 
cortisol showed abnormally high peaks in patients with a particular 
type of endogenous depression. This condition did not seem to be 
a stress-related artefact, since the pattern was remarkably constant 
within and between' individuals, and it returned to normal when the 
patient recovered. It was concluded that in certain types of 
depression there is a failure of tho normal inhibitory influence 
of the brain on the release of ACTH and corticolo 
The neuronal control of CRF (corticosteroid reloasing 
factor) and ACTH is complicated and encompasses serotonergict 
noradrenergic and cholinergic systemaq but there is some evidence, 
reviewed by van Praag (1978) that noradrenergic systems have an 
inhibitory effect on CRF, and it is this mechanism which is 
disturbed in patients with endogenous depression. For instance 
the response of Growth Hormone (GH) to insulin in disturbed in such 
depressed patients, and this mechanism is known to involve nor- 
adrenergic pathways. Thus cortisol appears to be acting as a 
peripheral marker of lowered noradrenaline function in depression. 
The gonadotrophins may also emerge as marks of central monoaminergic 
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activity. In a controlled study of depressed women in the 
menopause LH levels were lower in the depressed than in the 
non-depressed (Altman, -Sachar, Gruen, Halpern & Eto, 1976). 
There is some evidence that Ili secretion is mediated by nor- 
adrenaline (Ojeda & McCann% 1974)9 and assuming that oestradiol 
levels were the same in non-depreseed and depressed groups 
(which was not tested), a deficiency of LH implies a defect 
in noradrenergic pathways* 
The effect of dopaminergic aystems in paychiatric 
illness is not yet certain although prolactin may omergo an a 
useful marker for central dopaminergic activity Olorrobin at all 
1976). Prolactin was raised in the last few daya of tho cyclo 
in our patients, and this suggests a relative deficiency of 
dopamine at that time, although further work is needed. 
Serotonergic effects in neuroandocrinology are alGO 
little understood, although serotonin (5-hydroxytryptamino) hac 
been studied indirectly in depression by measuring levels of the 
precursor tryptophan in plasma, and metabolites in urine and 
cerebrospin4l fluid. Levels of plasma free tryptophan have boon 
inversely correlated with depression (Coppen & Wood, 1978), but 
the effectiveness of tryptophan treatment in depression io atill 
disputed (Carroll, Mowbray, & Davis, 1970)- 
Much remains to be learnt about the effects of central 
amines on hormonal secretion and mood disorders and espocially tho 
precise mechanisms involved. But the idea. of a central noradrenorgic 
defect in certain types of depression is supported by several 
neuroendocrine findings and this field is likely to expand in the 
future. 
A second approach to neuroendocrinology is to otudy tho 
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inverse relationships, that is the effects of hormones on neuro- 
chemistry and therefore ultimately on behaviour. Most of the work 
has of necessity been carried out in animals and somo aspects aro 
described in Chapter 1 (page 44). 
There are many possible sitea of controls of monoamine 
function, such as via the enzymes which synthesise and degrade the 
amines, or through the control of amine storage by the pre-eynaptic 
nerve ending, or by affecting sensitivity of the post-synaptic 
receptors. 
It appears that oestradiol decreases tho activity of 
monoamine oxidase and decreases choline acetylace in rat hypothalami 
(Kobayashi, Kobayashi, Kato & Minkaguchi, 1966) . In women Klaiber 
et al (1974) found that oestrogens decrease plasma monoamino 
oxidase activity, while progesterone partially counteracto thia 
effect,, - 
Oestrogen metabolites also appear to control enzymic 
functions. Major metabolites of oestradiol in hypothalamic tiSCUO4 
are the extremely labile (2-hydroxylated) catechol-oestrogans (Fioh- 
man & Norton, 1975), and these are excellent competitive inhibitora 
of liver catechol-0-methyl transferaoc (COMT) the enzyme which 
degrades catecholamines (Ball, Knuppen, Haupt & Breuer, 1972). But 
this enzyme is unlikely to be rate-limiting (Ball et al. 9 1972)9 
at least in peripheral conversions, and the functional significance 
of the other enzymic effects described above is still unknown. 
La Torre (1974), from a preliminary study of the effect 
of oestradiol on eating behaviour, which is known to be affected by 
adrenaline, has argued that oestrogens prevent the conversion of 
dopamine to adrenaline. The relative concentrations of these 
monoamines may be important in behaviour as well as in gonadotrophin 
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control, especially in view of the evidence for the involvoment 
of noradrenaline in depression (page 222), 
Oestrogens may also increaso brain serotonin lovola 
indirectly by making available more of the free (presumably active) 
precursor$ tryptophant by competitive displacemont from plasma 
binding proteins ( Thomson, Maddock, Aylward & Oswald, 1977) 
There is also evidence from in vitro studies in rat brain 
that oestradiol inhibits uptake of dopamine from thalamun, and 
progesterone and oestradiol inhibit uptake by cortex, pro-optic 
and septal regions, which is presumably an effect on receptor 
sensitivity (Wirz-Justice, Hackmann & Lichtsteiner, 1974). 
It can be concluded that the oestrogons havo wido- 
ranging effects on neurochemistry, but that the consequencoo of 
all the effects are probably not unidirectional. Although the very 
early lamine hypothesis' implied that monoaminas wore deficient in 
depression (Schildkraut, 1965) this view has been modified in recent 
years and the role of the many components of amine function io atill 
under debate (see page39); therefore with present knowledge the exact, 
role, if any, of oestrogens in mood disorder is atill unknown. 
i 
The role of progesterono in neurotranamitter chemiatry 
is even more obscure. The effectýof progesterono on E. E, G, pattorna 
are well known (Sawyer & Kawakami, 1961), and progestorone can aloo 
affect the uptake of serotonin, in vitro (Wirz-Justice et all 1974)1 
both of these effects could be due to an alteration in the sonsitivity 
of post-synaptic receptorso 
Some other interesting compounds are the saturated 
-3,20-oxygenated steroids which are very potent anacathetica in 
mice (Holzbauer, 1976) and which are the chief metabolites of 
progesterone in rat hypothalami (Karavolas & Nuti, 1976). These 
I 
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compounds have no conventional progestational activity, but as 
they are located in neural tissue this strongly suggests that they 
are involved in neuroendocrine feedback mechanisms- 5c(-pregnano- 
3,20-dione has a cyclical pattern in the peripheral blood of women, 
with a constant ratio of progesterone to pregnanediono of about coven 
(Milewich, Gomez-Sanchez, Crowley, Porterl Madden & MacDonald, 1977). 
It would be interesting to find the value of this ratio in women with 
PMS. 
It seems therefore that very few conclusiona can bo drawn 
about the mechanisms at the basis of mood disordart although come 
fairly new research would indicate that steroid patterns such as the 
24 hour profile of cortisol are disturbed, in some forms of doproacions 
but that they are acting as 'markers' of disturbances in releasing 
factor and hence neuro transmitter activity. Therefore the poonibility 
exists that the progesterone/oeErtradiol ratio has no direct role in 
mood disorder, but is itself acting as a marker of disturbancoo at 
the hypothalamus or other higher centres. However the timing of the 
'imbalance' (almost coincident with mood changes) and the evidence 
quoted above for the effects of progesterone nnd ocatradiol on amino 
function and behaviour would suggest that the ovarian steroids have a 
more direct role in the production of mood change. The oearch for 
interactions between hormones and nerves at the biochemical level 
is only just beginning and should yield more answers in the future. 
Possible mechanisms for the somatic eymptoms 
In Chapter 4 symptoms were grouped according to tho 
clusters of Moos et al (1969) which groups breast tenderness and 
cwelling together with symptoms of water retention. There was somo 
indication, however that these two symptoms may behave differently. 
Although in Group 111 41 women had both breast and abdominal swelling, 
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ten and twelve respectively had one symptom only. Dydrogenterono 
improved symptoms of swollen abdomen but in some women it mado 
breastaqelling worse (Table 5-1)- Although this may reflect 
paradoxical effects of the progestogen on different target tissuee, 
it also suggest different aetiologies. 
Preece, Richards, Owen & Hughes (1975) measurod total 
body water and weight in 17 controls and 39 women with mastalgia 
(defined as premenstrual breact pain with or without nodulea) and 
they could find no association between water retention and breact 
symptoms. However this is not surprising as even where bloatednooo 
is a main complaint in PMS, weight gain is not a feature (Bruce 
& Russell, 1962). 
The other evidence for treating breast swolling and 
bloatedness as separate complaints is that Andorsch at al (1978a) 
found that mastalgia responded tP bromocryptine whilO blontednOOD 
was relieved . by a diuretic. Therefore the aotiology of theco two 
symptoms will be considered separately. 
The study of breast pathology has centrod on neoplantic 
conditions and there is curiously little information about bonign 
disease. However in vitro studies have established that human 
mammary development is under complex control with tho involvemont 
of prolactin, growth hormone, insulin, adrenal and ovarian ateroidn 
(Ceriani , Contesso. & Nataf . 1972). 
Sitruk-Ware et al (1977) have found low progosterone 
levels but unchanged oestradiol levels in women with cyclical and 
non-cyclical breast disease, which was a mixed group defined as 
mastodynia with or without cystic mastitis. It was shown in 
Chapter 4 that low progesterone is associated with clightly raised 
prolactin and the association of high prolactin levels with breast 
disease is well known. Indeed bromocryptine is effective in 
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reducing premenstrual breast discomfort (Andersen et al., 19771 
Andersch et al., 1978b). All these facts point to a high prolactin 
(and consequent low progesterone) as responsible for breast symptom3a 
Yet this idea is at variance with our finding of high 
or normal progesterone in women complaining chiefly of the admittedly 
heterogeneous water retention cluster, which includes breast tendorneass 
and also with the adverse effects of dydrogesterono on this symptom 
(Chapter 5)- There may be other explanations, for instance it could 
be that the prolactin/oestrogen ratio is the critical factor. 
It has been suggested that in the puerperium milk 
production is a response to rapid falls in oestradiol after birth 
combined with unchanged levels of prolactin (McNeillys 1975)- Thia 
suggests a prolactin/oestrogen antagonism on the breasts and indeed 
breast tissue is most sensitive to stimuli after ovulation and at 
menstruation, when oestradiol levels are fallir; e (Robinson & Short, 
1977). This biphasic pattern is not seen however in the breast 
N symptoms of the patients, although in some women pain and swelling 
starts 14 days premenstrually (Fig- 3-1). Another factor must be 
local since Preece, Hughes, Mansell Baum, Bolton & Gravelles 
(1976) in one of the few surveys of benign breast disease, found 
that even premenstrual breast pain might be confined to one breast 
or part of the breast. This-could be due to hormonal effects on 
fibrocystic ocars. I 
In this respect it is interesting that half our 
control group (Table 3-1) also had breast symptoms and in their 
survey of G. P. practices Kessel & Coppen (1963) found breast 
swelling in over half the women sampled. Before the aotiology 
can be defined a clear classification between physiological and 
non-physiological breast change is needed. 
As already described'in Chapter 11 consistent weight 
gain is not a feature of PMSj although Good (1978) has shown that 
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serum osmolality varies inversely with oestradiol in the normal 
menstrual cycle, and he has suggested that uptake of water by 
tissues may be a critical factor in events of the menstrual cycle, 
for instance water uptake by the follicular fluid may be the 
mechanism for ovulation. In target tissues such as endometrium 
hydration may occur in response to protein synthesis, but this 
seems an unlikely explanation for abdominal bloatedness. This 
symptom remains therefore soi,, iewhat of a puzzles although local. 
actions of oestrogen together with other hormones, remains the 
most likely explanation. 
Rirther research into PMS 
Although attracting some attentýon from psychologists 
and gynaecologists, PMS has been the subject offew properly 
%controlled endocrinological studies. This is partly a result of 
technical difficulties of hormone assay in the past which are now 
largely overcome. Another difficulty has been the problem of defining 
the syndrome, especially in view of the 'overlap' between gynaecology 
and psychology. 
However PMS merits further endocrine research for 
several reasons. The first is that, although not a life-threatening 
disorder, there is a very high degree of personal and family distress 
In severe cases. Secondly, mental illness in various forms takes up 
a very high proportion of hospital beds and also outpatient care in 
tbe. National Health Service , and depressive illness has twice the 
incidence in women compared to men (Weissman & Klerman, 1977)- 
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Although it has been repeatedly emphasised in this thesis that 
P14S does not bear any obvious relationship to classified mental 
illness, the fact that the sex disparity in depression rates is 
fairly constant in different cultures argues that it has some 
physiological basis. Therefore on economic grounds alone any 
research which casts light on at least some aspects of mental 
illness is to be welcomed, and PMS is a fascinating model in that 
each patients acts as her own control in having phases of 'illness' 
and 'recovery' in the same cycle. 
Much remains still to be learnt about the hormonal 
changes in PMS. It may yet emerge that one variable, such as. a. 
steroid, hypothalamic or pituitary hormone, or neurotransmitter, 
may be grossly altered in the syndrome, but it seems more likely 
that more subtle endocrine changes will be found. 
The most pressing need to emerge from this thesis 
is for a daily comparison of LH, FSH, progesterone, oestradiol 
and prolactin throughout more than one cycle in at least twenty 
RIS patients and twenty controls. This would help to clarify some 
of the controversy in the literature regarding the levels of. 
oestrogen and progesterone in PMS, which may have been caused 
partly by small numbers of patients in previous studies. It would 
also help to confirm and extend the interesting observations of 
Bgckstro'm et al (1976b) regarding gonadotrophin levels. Further- 
more, although sev6ral papers have now looked . at prolactin through- 
out the cycle, there is no agreement regarding a cyclical pattern. 
A daily study of both women with PMS and controls may help to 
clarify why these discrepancies exist. 
However such a study would be of limited value 
without a proper definition of PMS and a universally agreed method 
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of assessing the syndrome. From our own work it appears that the 
mental and somatic symptoms can be distinguished in terms 6f response 
to therapy-vithin the same individual and in terms of hormone 
patterns between groups of women. It seems therefore that further 
research will be more fruitful if these various components can be 
dissected out, but with due regard for the relationships between 
the, unlike some psychologists who seem to ignore the somatic 
symptoms completely (Parlee, 1973)- 
The symptom diaries in our study were useful, but 
valuable data about the type of mood change was often missed. The 
Moos Menstrual Distress Questionnaire also suffers drawbacks'in'that 
itmay induce over-reporting of symptoms (Ladisich, 1577) and the 
symptoms 'clusters' found by Moos (1968) are rather too general. 
Cullberg (1972) and Golub (1976) have tried other psychological 
approaches with some success, although they had to use a whole 
battery of different questionnaires. 
A useful approach. would be to measure 'trait' 
anxiety and depression in patients at the first clinic visit, 
along the lines of the study of Golub (1976). This would give a 
quantitative measure of the patients background mental states and. 
it could be combined with a short retrospective menstrual 
questionnaire. This could then be confirmed during the study 
by a daily record of symptoms, preferably on a tear-off pad so 
that the patient would immediately remove the record for each days 
and so could not be influenced by the previous days reports. 
At the same time, in this postulated study, it 
would be useful to have an objective gauge of bodily changes, such 
as oedema, which could be measured by change in ring size or 
abdominal girth. Feelings of breast swelling could be measured 
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by the water displacement technique used by Milligang Drife & 
Short (1975). 
Although we were not able to show an definite 
changes in aldosterone in our PMS group, the conditions were not 
as controlled as we would. have liked, and relatively few patients 
were studied. Therefore a study of aldosterone, renin activity, 
and angiotensin III all of which are known to have a cyclical 
pattern, would be most useful contribution. It would also be 
interesting to study the response to upright posture in women 
with PMS throughout the cycle, as it has been shown by Edwards & 
Bayliss (1973) that the retention of sodium on upright posture is 
increased in the luteal phase. It may be that this effect is 
exaggerated in women with premenstrual bloatedness. 
Another hormone which may be of interest is 
testosterone. A female preponderance of depression, as described 
above, could have another interpretation in that come factor in 
men actually protects them from depression. Testosterone could be 
such a hormone, especially as there is a mid-cycle peak in 
testuosterone levels (Judd & Yen, 1973) which coincides with the 
time of self-rated 'pleasantness' in women (Moos et all 1969). It- 
is possible that it is the interactions between testosterone and other 
hormones such as oestradiol which are important. 
Several of our patients mentioned a craving fo. - 
sweet things premenstrually, and a paper by Smith & Sauder (1969) 
suggests that this has a psychological elentent, but a physiological 
basis exists in some women. This craving, and a tendency to bruise 
easily, which was also mentioned by a few of our patients, is thought 
to be due to hypoglycaemia (Billig & Spaulding, 1947). Therefore it 
would be of interest to carry out glucose tolerance tests in some 
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women with PMS, and perhaps linking them with progesterone 
estimations, since as already described, progesterono is 
catabolic in man (unlike the situation in animals) and lowered 
amino-acid levels due to progesterone could stimulate appetite 
and sugar craving. It would also be interesting to study 
cortisol levelsq since cortisol is required for gluconeogenesiss 
and especially as cortisol is one of the few steroids which seems 
to have a characteristic and genuine alteration in secretion with 
depression (see page222). The ideal study would be 24-hour 
profiles of cortisol in women with PMS, during follicular and luteal 
phases. 
The study of neurotransmitter biochemistry and the 
biogenic amines in particular, would be fascinating, but studies 
of substances such as monoamine oxidase in blood are the only 
practical measures at the moment. The measurement of the monoamines 
themselves is technically difficult and peripheral levels are 
probably'misleading. One useful development however is the link 
between central amines and releasing factors such as luteinising 
hormone rble&siilg hormone aiid prolactin inhibitory factor(dopamine). 
There is some evidence that some of the releasing 
factors have behavioural effects (Griffiths, Hooper & Jeffcoate, 
1975), and it may emerge that they are very closely linked indeed 
to neurotransmitter biochemistry. As some releasing factors are 
now measurable in peripheral blood (Arimura e't al., 1974) they 
may yet prove to be useful peripheral markers of noradrenergic 
and serotonergic systems in the CNS. Prolactin may already bo 
regarded as a 'marker' of cholinergic systems and a 24-hour profile 
of prolactin in RIS may show up important follicular and luteal 
differences. 
- The possibility of an animal Model for PMS seems 
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rather more unlikely at the present time, but it would be 
extremely useful in the study of central mechanisms. It might 
be possible to study monkeys or primates with true menstrual 
cycles, but a measure of 'premenstrual tension' would have to be 
cievised in these animals, and unfortunately there are no 
objective nbn-verbal measures of PMS as yet which could be 
applied to these animals. 
Other hormones to measure could be the highly 
anaesthetic metabolites of progesterone, such as pregnanediongg 
which is present in large amounts in neuroendocrine tissue. It 
could be that this hormone is the important one in central affect, 
rather than progesterone itself, of which the main target organ is 
the uterus. 
Another inte-esting compound is pyridoxinel which 
is a co-factor in key steps of the metabolic pathway of serotonin 
and also of dopamine. It could be that a deficiency of this vitamin 
occurs in some women or that some women have a greater requirement 
than'others, perhaps influenced by oestrogen levels (Brush, 1977)- 
Therefore a study of pyridoxal phosphate in plasma may help to 
discriminate still further between different forms of PMSo 
There are also many studies which could be made 
outside the fields of endocrinology, but which may help in the 
understanding of this syndrome. So far the study of treatments 
has not been very helpful, as the studies have been uncontrolled 
or on few women, or because pharmacological agents have been used. 
For instance in our study of dydrogesterone, a fairly 'clean' 
progestogen, there were adverse effects on luteal function, and 
improvement seemed to be due to a pharmacological rather than a 
physiological action. 
One useful study would however be a double-blind 
1ý 
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trial of progesterone itself. Although this has problems as 
progesterone has to be given as either suppositories or by 
injection, progesterone is one of the few treatments where 
almost total success has been claimed (Dalton, 1977). 
Another observation, by Beriedek-Jaszmann 
& Hearn-Sturtevant (1976) was that PMS occurred in association 
with in'Lertility* There were flaws in this study, but the 
findings have important implications for the understanding of 
both conditions. For this reason it would be interesting to 
study the incidence of PMS in women with unexplained infertility 
(that is, no obvi. pus anatomical or endocrinological reasons) and 
to compare this with the incidence in a matched control group, 
for instance a group of parous women attending a family planning 
clinic. 
It has also been suggested that individual 
predisposition plays a part in PMS, and some studies of the 
incidence in families, beyond anecdotal reports, may determine 
whether the disorder has any genetic component. 
SUMMARY OF ORIGINAL FINDINGS 
1. In a comparison of 20 women with premenstrual syndrome and 
10 control cycles there were significantly lower progesterone 
values from 5 to 8 days premenstrually, and significantly higher 
oestradiol levels in the last four days of the cycle, in the women 
with PMS. This confirms and extends obse: rvations by Mckstr8m 
& CarstensenC1974) and Ba'ckstr8m et al (1976b). 
.1 
2. There were no significant differences in plasma aldosterore 
in PMS patients and controls under non-fasting, ambulitnt 
conditions. In both groups there was a gradual pre-ovulatory 
rise in plasma aldosterone levels and a second rise in mean 
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aldosterone values in, the luteal phase, although levels were 
highly variables 
I 
These findings confirm a cyclical pattern of secretion of 
aldosterone in the normal menstrual cycle, as found by several 
authors, but there was no evidence from this study that the 
renin-angiotensin-aldosterone system is altered in the premenstrual 
syndrome. 
3. In a larger group of patients (105) the symptoms were 
classified and those complaining chiefly of depression and irAtability 
had significantly lower progesterone plasma levels during the luteal 
phase than those patients complaining chiefly of breast tenderness 
and bloating as their main symptoms. Progesterone values of womon 
not complaining of premenstrual symptoms were intermediate between 
the mean values for the two symptom groupings. 
4. The incidence of psychiatriQ ill-health in the women was quite 
high (45%) but this ill-health could not be correlated with a 
particular pattern of progesterone values or any other characteristic 
of the patients studied* 
5- Prolactin was also measured in the serum of some PMS patients 
and although not compared with a control group for PMS, the values 
were within the range for women without obvious pituitary diseasa. 
Prolactin levels in the early luteal phase were higher in 
women with low progesterone peaks, which-may suggest a. relation- 
ship between prolactin and the ovary * 
6. In a study of the therapeutic effect of dydrogesterone during the 
luteal 'phase , in a 
'single-blind trial 47'women (72%) responded to 
active treatment but no significant differences could be seen in 
the progesterone levels of those women who responded compared to 
those who did not. Dydrogesterone lowered plasma progesterone 
levels to a mean of 84 % of pre-treatment levels, although 
anovulation occurred in only three cases. 
237 
lDr, rm,, Dr&Trrc 
AAKVAAGjA. (1970) Steroid formation in porcine ovarian tissues in vitro. 
Acta Endocrinol. 65,261-272 
ABRAHAM, G. E. (1969) Solid-phase radioimmunoassay of estradiol-176. 
J. Clin. Endocrinol. Metab. 29,86-8ýo 
ABRAHAM, G. E. (1974) Radioimmunoassay of steroids in biological 
materials. Acta*Endocrinol. (Kbh) 75. (Suppl) L82 7-42 .-I 
ABRAHAM, G. E. (1975) Discussion. In Steroid Immunoassay (Cameron, E. H. Do 
Hillier, S. G., & Griffiths, K. eds) p 129 Alpha Omega Publishing Ltd, 
Cardiff. 
ABRAHAM. G. E., SWERDLOFF, R. 9 TULCHINSKYID... & ODELLlW. D. 
(1971) 
Radioimmunoassay of plasma progesterone. J. Clin. Endocrinol* 
Metab. ý2,619-624 
ABRA. HAM, G. E. SWERDLOFF9 R. S. 9 TULCHINSKY9 D., HOPPERIK. & ODELL 
W. D. 
(1971a) Radioimmunoassay of plasma 17-hydroxyprogestorone. 
J. Clin. Endocrinol. Metýb. 2ý, 42-46 
ABRAHAM, G. E., BUSTER, J. E., KYLEIF. W. CORRALE, P. C. & TELLERIR. C. 
(1973) Radioimmunoassay of plasma pregnenolone, 17-hydroxy- 
pregneholone and dehydroepiandi-osterone under, various 
physiological conditions. J. Clin. Endocrinol. Metab. ZZ,, 140-144 
ABRAHAMt G. E. MARCULIS, G. B. & MARSHALL, J. R. (1974) Effect of 
ovulation and corpus luteum function using measurement of 
plasma progesterone. Obstete. Gynecol. 44 1522-525 
ABRAMSON, M. & TORGHELE, J. R. (1961) Weight, temperature changes 
and psychosomatic symptomatology in relation to the menstrual 
cycle. Am. J. Obstet. Gynecol. 81 f 
223-232 
ADAMOP0ULQS, D. A. LORAINEIJ. A. LUNNIS. F., COPPEN$ A. J. & DALY, R. J. 
(1972) Endocrine profiles in premenstrual tension. Clin. 
Endocrinol. 1 
1283-292 
ADAMS, D. B. GOLDjA. R. & BURTIA, ý. (1978) Rise in female -initiated 
sexual activity at ovulation and its suppýession by oral 
contraceptives. New England J. Med. 299: -91145-1150 
ADAM49 P. W. 9 ROSE, D. P., FOLKARDIJ. WYNN, V., SEED, M. & STRONG 
R. (1973). Effect of pyridoxine hydrochloride (vitamin 
B6) upon depression associated with oral contraception. 
Lancet 1 9897-904 
238 
ALLEN, E. & DOISY, E. A. (1923) An ovarian hormone; preliminary 
report on its localization, extraction and partial purification 
and action in test animals. J. Am. Med. Assocn. 81,819-821. 
ALTMANjN. SACHAR, E. J. GRUEN, P. 11. HALPERN, F. S. &ETOIS (1976) 
Reduced plasma LH concentration in postmenopausal depressed 
women. Psychosom. Med. a, 274-276 
ALTIAANN, M. KNOWLES, E. & BULL, H. D. (1941) A psychosomatic study of 
the sex cycle in women. Psychosom. Med. J3.199-225 - 
ANDERSCHIB. HAHNIL., ANDERSSO'NIM. F. ISAKSSON, B. (1978a) Body water 
and Veight in patients with premenstrual tension. Br. J. Oýatet. 
Gyaecol. 85 9546-550- 3 
It ANDERSCHIB. HAIDTV L. WENDESTAIM, C., OHMAN, R., & ABRXHA14SSON, L. 
tensio (1978b) Treatment of premenstruai/synTrome with bromocriptinee 
Acta Endocrinol. 88 (Suppl) 216 165-174 
ANDERSEN, A. N., LARSEN, J. F., STEENSTRUP, O. R. 9 SVFTqDSTRIJPlB. 9 & 
TIIELSEN, J. (1977) Effect of bromocriptine on the premenstrual 
syndrome. A double-blind clinical trial. Br. J. Obstet. Gynecole 
84,370-374 
1 
AONO, T. MIYAKE, A.,, pSHIOJI, T., KINUGASA, T. ONISHI, T. & KURACHI, K. 
(1976) Impaired LH release following exogenous estrogen 
administration in patients with amenorrhoea-galactorrhooa 
syndrome. J. Clin. Endocrinol. Metab. 42,696-702 
ARIIIURA, A. KASTIN, A. J. SCHALLY, A. V., SAITO, M., KUMASAKA, T. 
YAOI, Y., NISHIqN. & OKHURA, K. (1974) Immunoreactive LH-rcleasing hormone 
in plasma; midcycle elevation in women* J. Clin. Endocrinol. 
Metab- 389 510-513 
P. RMSTRONG, D. T., KNUDSEN, K. A. & MILLER, L. S. (1970) Effect of prolactin 
upon cholesterol metabolism and progesterone biosynthesis 
in corpora lutea of rats hypophysectomized during pseudopregnancy, 
Endocrinology 86,634-641 
ASHCROFT, G. W. CRAWFORD, T. B. B., ECCLESTON, D. SHARMAI; D. F., MacDOUGALL, 
E. J., STANTON, J. B. & BINNS, J. F. (1966) 5-hydroxyindole 
compounds in the cerebrospinal fluid of patients with psychiatric 
or neurological diseases. Lancet ii 1049-1052 
239 
ASO, T. GUERREROIR., CEKAN, Z. & DICZFALUSY, E. (1975) A rapid 
5 hour radioimmunoassay of progesterone and oestradiol in human 
plasma. Clin. Endocrinol. 4,173-18? - 
BACKER, T. (1962)Isopregnenom(Duphaston) a new progestational 
agent. Obstet. Gynecol. 1.9.. 724-729 
BACKSTROM, T. (1978) Estrogen and progesterone in relation to 
different activities in the central nervous system. Acta 
Obstet. Gynaecol. Scand, (Suppl) 66,1-17 
BACKSTROMIT. & CARSTENSEN, H. (1974) Estrogen and progesterone 
in plasma in relation to premenstrual tension. J. Steroid 
Biochem. 2,257-260 > 
BACKSTROM, T. & MATTSSON9B. (1975) Correlation of symptoms in 
pre-menstrual tension to oestrogen and progesterone concentrations 
in blood plasma. Neuropsychobiology. 1.80-86 
BACKSTROM, T. CARSTENSEN, H. & SODERGIRD, R. (1976a) Concentration 
of estradiol, testosterone and progestarone in cerebrospinal 
fluid compared to plasma unbound and total concentrations. 
J. Steroid Biochem. Z, 469-472 
40 .000a 
BACKSTROM, T., WIDE, L., SODERGARD, R. & CARSTINISEN, H. (1976b). FSH, 
LH, Te-BG-capacity, estrogen and progesterone in woman with 
premenstrual tension during the luteal phase. J. Steroid Biochem 
. 
Z, 473-476 
BAGSHAITE, K. D., WILDE, C. E. & ORR, A. H. (1966) Radioimmunoassay for 
human chorionic gonadotrophin and luteinising hormone. Lancot 
il 1118-1121 
BAIRD9-D. T. (1968) A method for the measurement of estrone and 
estradiol-17/3 in peripheral human blood and other biological fluids 
using 
35S 
pipsyl chloride. J. Clin. Endocrinol. Metab. 28,244-258 
BAIRD, D. T. & GUEVARA, A. (1969) Concentration of unconjugated estrone 
and estradiol in peripheral plasma in non-pregnant women throughout 
the menstrual cycle, castrate and postmenopausal women and in 
men. J. Clin. Endocrinol. Metab. 29,149-156 
BALL, P., KNUPPEN, R., HAUPT9M. & BREUERIH. (1972) Interactions between 
estrogens and catecholamines. III. J. Clin. Endocrinol, 
Metab- 34,736-746 
240 
'BAP, RACLOUGHqC. A. & CROSSIB. A. (1963) Unit activity in the hypothalaruG 
of the cyclic female rat: effect of genital stimuli and 
progesterone. J. Enýdocrinol. 26,339-359 
BARTON, M. & WIESNER, gB. P. (1945) Thermogenic effect of progesterone. 
Lancet 2 671-672 
BAYARD, F., BEITINS, I. Z. 9 KOWARSKI, A. & MIGEIO, C-J-(1970) Measurement 
of plasma aldosterone by radioimmunoassay. J. Clin. Faidocrinol. 
Metab. 3191-6 
BECKtR. P. 9 MORCOSIF., FAWCETTjD. &WATANABE,,: M. 
(1972). Adrenocortical 
function studies during the normal menstrual cycle and in women 
receiving norethindrone with and without mestranol. Am J. 
Obstet. Gynecol. 112,364-368 
BELL, E. T., & LORAINE, J. A. (1965) Effect of dydrogesterone on hormone 
excretion in patients with dysmenorrhoea. Lancet 1,403-406 
BELMAKER, R. H., YURPHY, D. L., WYATTIR. J. & LORIAUX, L. (1974) Human 
platelet monoamine oxidase changes during the menstrual cycles 
Arch. Gen. Psychiatry -ý-1,553-556 
BENEDEK, T. & RUBENSTEIN, B. (1939) 'cited by-SMITft-. (1975) 
BENEDEK-JASZMANN, L. J. & HEAPJI-STURTEVANT, M. D. (1976) Premenstrual 
tension and functional infertility. Lnacet 1,1095-1098 
BEERRY, C. & McGUIRE, F. L. (1972)* Me4strual distress and accepitance. of 
sexual role. Am. J. Obstet. Gynecol. 114,83-87- 
BERSON, S. A. & YALOWlR. S. (1959) Quantitative aspects of the reaction 
between insulin and insulin-binding antibody. J. Clin. Invest. 
38,1996-2016 
BESSER, G. M. PARKE, L. EDWARDSIC. R. W., FORSYTH, I. A. & McNEILLY, A. S(1972). 
Galactorrhoea: successful treatment with reduction of plasma 
prolactin levels by brom-ergocryptine. Br. Med. J. 21 669-672 
BEUMONT, P. J. V., RICIIARDS, D. H. & GELDER, M. G. (1975) A study of minor 
psychiatric and physical symptoms during the menstrual cycle, 
Br. J. Psychiatry 126,431-434 
BICKERSIW. & WOODS, M. (1951) Premenstrual tension: rational treatment. 
Texas Reports Biol. Med. 9,406-419 
BILLIGIH. E. & SPAULDING, C. A. (1947) Hyperinsulinism Of mensese 
Industrial Med. 16,336-337 
241 
BINOUX, M. A. & ODMLI W. D. (1973) Use of dextran-coated charcoal to 
separate antibody-bound from free hormone: a critique. J. Clin. 
Endocrinol. Metab. 36,303-310 
BOHNET, H. G., DAHLEN9 H. G. & SCHNEIDER, H. P. G. (1974) Hyper- 
prolactinaemia and pulsatile LH fluctuation. Acta Endocrinol. 
(Kbh) Suppl) 184,109 
BOHNET, H. G., DAHLEN, H. G., WUTTKE, W. & SCHNEIDER, H. P. G. (1975) 
Hyperprolactinaemic anovulatory syndrome. J. Clin. 
Endocrinol. Metab. 42,132-143 
BOSUj W. T. 9 JOHANSSON, E. D. B. & GEMZELLI C. 
(1973) Peripheral 
plasma levels of oestrone, oestradiol-17A , and progesterone 
during ovulatory menstrual cycles in the rhesus monkey with 
special referenge to the onset of menstruation. Actw 
Endocrinol. 74,732-742 1- 
BRAV09 E. L. & TRAVIS, R. H. (1967) A quantitative gas-liquid 
chromatographic method for aldosterone in human urine. 
&ý Lab. Clin. Med.. 70,831-84o 
BRENNER9 P. F. 9 GUERRER09 R. 9 CEKANI Z. & DICZFAI; USYs E- 
(1973) 
Radioimmunoassay method for six steroids in human plasma. 
Steroids 22,775-794 
BROWN, J. B. (1955a) Urinary excretion of oestrogen during the. 
menstrual cycle, Lancet 1,320-323 
BROWN, J. B. (19.5.5b) A chemical method for the determination of 
oestriol, oestrone and oestradiol in human urine. Biochem. 
6o, 185-193 
BROWN, J. B. 9 KLOPPER9 A. & LORAINE9 J. A. 
(1958) The urinary 
excretion of oestrogensl pregnanediol and gonadotrophins 
during the menstrual cycle. J. Endocrinol. 17,4ol-41o 
BROWN, P. S. (1955c) The assay of gonadotrophin from urine of non- 
pregnant subjects. J. Endocrinol. 12,59-64 
BRUCE, J. & RUSSELL, G. F. M. (1962) Premenstrual tension. A study of 




BRUSH9 M. G. (1977) The possible mechanisms causing the premenstrual 
syndrome. Curr. Med. Res. Opin. 4 Suppl. 4.9-15 
242 
tUSH, I. E. (1961) The chromatography of steroids. Pergamon Press. 
Oxford & London 
CAMERON9 E. H. D. & SCARISBRICK9 J. J. (1973) Radioimmunoacsay of 
plasma progesterone. Clin. Chem. 19,1403-1407 
CARROLL9 B. J., MOWBRAY, R. M. & DAVIS, B. (1970) Sequential 
comparison of L-tryptophan with ECT in severe depression. 
Lancet i, 967-969 
CASTRO, A., KUTAS, M., JELEN, B. & BARTOS, D. (1974) A 
simultaneous measurement of plasma aldosterone and 
deoxycorticosterone by radioimmunoassay. J. Steroid Biochem. 
2121-26. 
CATTI K. J. (1971) An ABC of endocrinology. The Lancet Ltd, 
London. 
CERIANI, R. L., CONTESSO, G. P. & NATAF, B. M. (1972) Hormone 
requirement for Growth and Differentiation of the Human 
Mammary Gland in Organ Culture. Cancer Res. 22,2190-2196 
CHIAZZE, L., BRAYER, F. T., MACISCO, J. J., PARKER, M. P. & DUFFYj B. J. 
(1968) The length ahd variability of the huýan menstrual cycle. 
J. Am. Med. Assocn. 203.377-392 
CLARE, A. W. (1977) Psychological profiles of women complaining of 
premenstrual symptoms. Cýurr. Med. Res. Opin. 4 Suppl 4,23-28 
CLARK, H. & GURPIDEj E. (1972) Measurement of the solubility of 
progesterone under competitive protein binding conditions. J. 
Clin. Endocrinol. Metab. 34, lo85-1086 
CLEMETSON, C. A. B., KIM, J. K. Ide JESUS, T. P. S., MAIIIKARJUNESWARAJ 
V. R. 
WILDS9 J. H. (1973) Human uterine fluid potassium and the menstrual 
cycle. J. Obstet. Gynaec. Br. Commwlth 80,553-561 
COGHLAN, J. P. & BLAIR-IfFST, 4. R. (1967) Aldoaterone. in Hormones in 
Blood Vol II. (dray, C. H., & Bacharach, A. L. Eds)PP 391-488. 
Academic Press. New York. 
COGHLAN J. P. & SCOGGINS, B. A. (1967) Measurement of aldosterone in 
peripheral blood of man and sheep J. Clin. Endocrinol. 
Metab. 27, JLý70-1486 
243 
COLLINS, W. P. & SOMMERVILLE, I. F. (1964) Quantitative determination 
of progesterone in hwman plasma by thin-layer and gas-liquid 
radiochromatography. Nature 203,836-839 
COPPEN, A. J. (1970) The chemical pathology of the affective 
disorders. In The Scientific Basis of Medicine Annual Reviews. 
p. 189 Athlone Press, Univ. London. 
COPPEN, A., & KESSEL, N. (1963) Menstruation and personality. Br. 
J. Psychiatry 109,711-721 
COPPEN A. J. & SHAW, D. M. (1963) Mineral metabolism in melancholia. 
Br. Med. J. ii, 1439-1444 
COPPEN A. & WOOD, K. (1978) Tryptophan in depression. Scot. Mod. 
J. 23,75-76 
CORENBLUM, B. PAIRAUDEAUj N. & SCIIEWCHUK9 A. B. (1976) Prolactin 
hypersecretion and short luteal phase defects. Obstet. 
Gynecol. 47,486-488 
CRANE, M. G. & HARRIS J. J. (1969) Plasma renin activity and aidosterone 
excretion rate in normal. subjects. 1. Effects of ethinyl 
oestrýdiol and medroxyprogesterone acetate6 J. Clin. Endocrinol. 
Metab. 29,550-557- 
CRIGHTONI'D. B. 9 SCHNEIDER, H. P. G. & McCANN, S. M. 
(1970) Localization 
of LH-releasing factor in the hypothalamus and neurohypophysis 
as determined by an in vitro method. Endocr-Alnology 87ý323-329 
CULLBERG, J. (1972) Mood changes and menstrual symptoms with different 
gestagen/oestrogen combinations. Acta Psychiatr. Scand. Supplo 
236 J-84. 
DALTON, K. (1960) Effect of menstruation on schoolgirls weekly work 
- Br. Med. J. i, 326-328. 
DALTON9 K. (1964) The premenstrual syndrome. W. -Heinemann Medical 
Books Ltd. London. 
DALTON, K. (1969) The menstrual cycle. Penguin Books, Middlesex, 
England 
DALTON, K. (1977) The premenstrual syndrome and progesterone therapy. 
W. Heinemann. Ltd. London 
241f 
DANIEL, J. Y. 9 MION, H. 
'& SOULAS, D. (1974) Radioimmunoassay of 
plasma aldosterone by chromatography on Sephadex L1120. 
Clin. Chim. Acta 55,235-243 
DAVIDSON, E. T., de VENUTO, F. & WESTPHAL, U,. (1962) Steroid- 
protein interactions IX. Interactions of aldosterono with 
Human Serum Proteins in competition with spiruholactone 'and 
other steroids. Endocrinology Z11893-900 
DEAN, P. D. G. EXLEY, D. & JOHNSON, M. W. (1971) Preparation of 17/s- 
oestradiol-6-(o-carboxymethyl) oxime-bovino serum albumin 
conjugate. Steroids 18,593-603 
DIERSCHKE, D. J., YAMAJI, T. 9 KARSCH, F. J., WEICK, R. F. 9 WEISSt G. 
& KNOBILl E. (1973) Blockade by progesterone of estrogen-induced 
LH and FSHrelease in the rhesus monkey. Endocrinology. 22, 
1496-1501 
DODSON9 K. S., MacNAUGHTON, 'M. C. & COUTTS, J. R. T. (1975) Infertility 
in women wiýh apparently ovulatory cycles. 1. Comparison of 
their plasma sex. steroid and gonadotrophin profiles with those 
in the normal cycle. Br. J. Obstet. Gynaecol. 82 615-624. 
DORRINGTON, J. H., MOON, Y. S. & ARMSTRONG, D. T. (1975) Estradiol-17A 
biosynthesis in cultured'granulosa cells from, hypophysectomised 
immature rats; stimulation by follicle-stimulating hormone. 
Endocrinology 9791328-1331 
DIRLUES, P. A. & Kowalski, A, J. (1974) Some marker dyes for locating 
steroids eluted from Sephadex LH-20 colunns. Clin. Chem. 20 
1451-1453 
DYRENFURTH, I., JEWELEWICZ, R., WARREN, M. FERINg M. & vande WIELE, 
R. L. (1974) Temporal relationships of hormonal variables in the 
menstrual cycle. In Biorhythms and Human Reproduction. (Ferin, 
M., Halbert, F., Richart, R. H., & vande Wiele, R. L. Eds) Chap. 
12. J. Wiley & Sons, New York 
ECKSTEIN, P. (1977) Endocrine activities of the Ovary. In the Ovary 
Vol II(Zuckermang P. L., & Weir, B. J. Eds. ) po 275-313. Academic 
Press New York, London 
EDITORIAL (1977) Prolactin updated. Br. Med. J. 4,846-848 
245 
EDMAN, C. D. & MacDONALD, P. C. (1976) The role of extraglandular 
estrogen in women in health and disease. In the Endocrine 
Function of the Human Ovary. (James, V. H. T., Scrio, M., 
& Giusti, P. edsý pp 135-140 Academic Press, London 
EDWARDS, O. M. & BAYLISS, R. I. S. (1973) Urinary excretion of water 
and electrolytes in normal females during the follicular 
and luteal phases of the cycle: the effect of posture. 
Clin. Sci. Moleo. Med. ý5 495-5o4 - 
MINS, R. P. (1971) Discussion. In. Radioiwunoassay nethods. 
( Kirkham, K. E. & Hunter, W. M. eds. )p. 615. Churchill Livingstone, 
Edinburgh & London 
EKINS, R. P. (1975) Discussion. In Steroid Immunoassay (Cameron, E. -H. D., 
Hillier, S. G., & Griffiths, K. eds) p. 311 Alpha omega Publishing 
Ltd. Cardiff 
EKINS, R. P., NEIMAN, G. B., PIYASENAq R., BANKS9 P. & SLATER, J. D. H, 
(1972) The radioimmunoassay of aldosterone in serum and urine: 
theoretical and practical aspects. J. Steroid Biochem. 21289- 
304 
EMMENT, Y-9 COLLINS, W. P. & SOMMERVILLE, I. F. (1972) Radioimmunoassay 
of oestrone and oestradiol in human plasma. Aota Endoc-rinol 
ý21567-582 
ENGLAND, B. G., NISWENDER, G. D., & MIDGLEY, A. R. (1974) Radioimmunoassay 
of Estradiol-17t5 without chromatography. J. Clin. Endocrinol. 
Metab 38,42-50. 
ENGVALL, E. & PERLMANN, P. (1971) Enzyme-linked immunosorbent assay 
(ELISA) Quantitative assay of immunoglobulin G. Immunochemistry 
8,871-874 
EPSTEINj M. T., HOCKADAY, J. M. & HOCKADAY, T. D. R. (1975) Migraine and 
reproductive hormones throughout the menstrual cycle. Lancet 
i, 543-548 
ERLANGER, B. F., BOREK, F., BEISER9 S. M. & LIEBERMAN9 S. (1957) 
Steroid-protein conjugates. I. Preparation and characterisation 
of conjugates of bovine serum albumin with testosterone and 
with cortisone. J. Biol. Chem. 228,713-727 - 
2 46' 
EXLEY, D., JOHNSON, M. W. & DEAN, P. D. G. (1971) Antisera highly 
specific for 17/3 _oestradiol. Steroids 18,605-620 
FAIMAN, C. & RYAN, K. J. (1967) Radioimmunoassay for human 
lu. teinizing hormone. Proce Soo. Exp. Biol. Med. 125, 
1130-1133 
FAPMER, R. W. BROWN, D. H., HOWARD, P. Y. & FABRE9 L. F. (1973) 
A radioimmunoassay for plasma aldosterone without chromatography. 
J. Clin. Endocrinol. Metab. 36,461-465 
FEDER, H. H. & MARkNE, B. L. (1977) Progesterone: its role in the 
central nervous system as a facilitator and inhibitor of 
sexual release. Ann N. Y. Acad. Sci. 286,331-354 
FEM, R., BELMAKER, R. H. 9 RIMON, R. & EBSTEIN, R. P. (1977) Platelet 
-rual syndrome. monoamine oxidase in women with premens'. 
Neuropsychobiology 2,105-110 
FELDMAN, H. & RODBARD, D. (1971) In Principles of Competitive 
Protein-Binding Assays. <Odell, W. D. & Daughaday, W. H. 
eds. ) P 158. J, B. Lipincott Co. Pa. 
FISHMAN, J. & NORTON, B. (1975)-Catecholestropn formation in the 
central nervous system of the rat. Endocrinology 96,1054-1059 
FLORENSA, E., SOMMERVILLE9 I. F. 9 HARRISON9 R. F., JOHNSON9 M-W- 
& 
YOUSSEFNAJADIAN, E. (1976) Plasma 20 or-dihydroprogooterones 
progesterone and 17-hydroxyprogesterone: daily and four- 
hourly variations during the menstrual cycle. J. Steroid. 
Biochem. Z, 769-777 
FOWLER, R. E., CHAN, S. T. H., WALTERS, D. E., EDWARDS, R. G. & STEPTOE, 
P. C. (1977) Steroidogenesis in human follicles approaching 
ovulation as judged from assay of follicular fluid. 
J. Endocrinol. 72,259-271 
FOWLER, R. E., FOX9 N. L. EDWARDS, R. G., WALTERS, D. E. & STEPTOE, P. C. 
(1978) Steroidogenesis by cultured granulosa cells aspirated 
from human follicles using pregnenolone and androgens as 
precursors. J. Endocrinol. ZZ, 171-183 
FRANCHIMONT, P., DOURCY, C., IXGROSI J. J. REUTER9 A., VRINDTS- 
GEVAERT, Y., von CAUWENBERGER, J. R. & GASPARD, V. (1976) 
Prolactin levels during the menstrual cycle. Clin. Endocrinol. 
5,643-650- 
FRANK, R. T. (1931) The hormonal causes of premenstrual tension. 
Arch., Neurol. Psychiatry (Chicago) 26,1053-1057 
247 
FRASER, R., GUEST, S. 1, HOLMES, E., MASON, P. A., WILSON9 A. & 
YOUNG, J. (1975). Comparison of radioimmunoassay and 
physico-chemical methods as means of estimating plasma 
aldosterone and plasma 11-deoxycorticosterone concentrations. 
. In Steroid Immunoassay 
(Cameron, E. H. D., Hillier, S. G., 
& Griffiths, K, eds) pp 283-292. Alpha Omega Publishing 
Ltd. Cardiff. 
FREDRICSSON, B., WORK, G. & CARLSTR6M, K. (1977) Short luteal 
phase and prolactin. Lancet. 1,1210 
FREF, DMAN, S. H., RAMCHARAN, S., HOAG9 E. & GOLDFIEN, A. (1974) 
Some phýaiological and biochemical measurements over the 
menstrual cycle. In Biorhythms and Human Reproduction 
(Ferin, M., Halberg, F., Richart, R. M., & van de Wielej 
B. L., eds) Chap. 16. J. Wiley & Sons New York. 
so FROLICH, M., BRAND, E. C. & van HALL9 E-V- (197. ) Serum levels Of 
unconjugated aetiocholanolone, androstenedione, testosterone, 
dehydroepiandrosterone, aldosterone, progesterone and oestrogens 
during the normal menstrual cycle. Acta Endocrinol. L1, 
548-562 
FUKUSHIMA, M., STEVENS, V. C., GANTTI C. & VORYS9 11. (1964) 
Urinary FSH and LH excretion during the normal menstrual 
cycle. J. Clin. Endocrinol. Metab. 24,205-213 
FURRI B. J. A. (1973) Radioimmunoassay of progesterone in peripheral 
plasma of the domestic fowl in various physiological states 
and in follicular venous plasma. Acta Endocrinol. 72989-100 
FURUYAMA, S. & HUGENT, C. A. (1971) A radioimmunoassay for plasma 
progesterone. Steroids 17.663-674 
GEIRINGER, E. (1951) Mittelwahn. A reconsideration of premenstrual 
phenomena. J. Obstet. Gynaecol. Br. Empire ý8, lolo-lo18 
GENAZZANII A. R., LEMARCHAND-BERAUD, Th., AUBERT, M. L. & FELBER, J. P. 
(1975) Pattern of plasma ACTH, hGh,. and corticol during 
menstrual cycle. J. Clin. Endocrinol. Metab. 41,431-437 
GHOSE, K. & COPPEN, A. (1977) Bromocryptine and premenstrual syndrome: 
controlled study. Br. Med. J. 19147 
248 
GILMORE, N. J., ROBINSON, D. S., NIES, A., SYLVESTER, D. & RAVARIS9 
C L. (1971) Blood monoamine oxidase levels in pregnancy and 
during the menstrual cycle. J. Psychosom. Res. 15,215-220. 
GLASS, M. R., SHAW, R. W., BUTT, R. W., LOGAN EDWARDS, R. & LONDON, 
D. R. (1975) An abnormality of oestrogen feedback in 
amenorrhoea-galactorrhoea. Br. Med. J. 19274-275 
GOLDBERG9 D. P. (1972) The Detection of Psychiatric Illne. ss by 
Questionnaire. Inst. Psychiatry Maudsley Monograph. No. 21 
O. U. P. London. 
GOLUB, L. J., MENDUKE, H. & CONLY9 S. S. (1965) Weight changes in 
college women during the menstrual cycle. Am. J. Obstet. 
Gynecol. 91,89-94 
GOLUB, S. (1976) The magnitude of premenstrual anxiety and 
depression. Psychosomatic Med. 38,4-12 
GOMEZ-SANCHEZ, C., KEMI D. C. & KAPLAN, N. M. (1973) A radioimmunoassay 
for plasma aldosterone by immunologic purification. J. Clin. 
Endocrinol. Metab., ý6,795-798 
GOOD9 W- (1978) Water relations of the ovarian-cycle. Br. Jo 
Obstet. Gynaecol. ý2,63-69 
GOY, R. W. & RESKO, J. A. (1972) Gonadal hormones and behaviour of 
normal and pseudohermaphroditic nonhuman female primates. 
Recent Prog. Horm. Res. 28., 707-733 
GRAF, K. J., NEUMANN, F., NISHINO, Y., MEHRINGs M. & HASAN, S. H. 
(1973) The effect of different progestogens on prolactin 
secretion in rats. In Human Prolactin (Pasteels, J. Le & 
Robyn. C., eds) PP 160-162. Excerpta Medica International 
Congress Series no- 308 
GRANT, E. C. G. & PRYSE-DAVIES, J. (1968) Effect of oral contraceptives 
on depressive mood changes and on endometrial monoamine 
oxidase and phosphatases. Br. Med. T- 29777-780 
GRAY, C. H., GREENAWAY, J. M. & HOLNESS, N. J* (1961) The Corticosteroids 
In Hormones in Blood. (Gray, C. H. & Bacharach, A. L. eds. ) 
pp 440-514 Academic Press. London & New York 
249 
GRAY, M.. J. STRAUSFELD9 K. S., WATANABE, M., SIMS, S. A. H. & 
soLomoN, s (1968) Aldosterone secretory rates in the 
normal menstrual. cycle. J. Clin. Endocrinol. Metab. 
28,1269-1275 
GREEN, A. R. (1978) The neuropharmacology of depression. Scot. 
Med. J. 23,66-67 
GREENE, R. & DALTON, K. (1953) The premenstrual syndrome.. Br. 
Med. J. 1,1007-lol4 
GREENHILL, J. P. & FREED, S. C. (1940) The mechanism and treatment 
of premenstrual distress with ammonium chloride. Endocrinology 
269529-531 
GREENHILL, J. P. & FREED, S. C. (1941) The electrolyte therapy of 
premenstrual distress. J. Am. Med. Assocn. 117,504-506 
GRIFFITHS, E. C., HOOPER, K. C. & JEFFCOATEj S. L. (1975) Role of 
hypothalamic releasing hormones in the central nervous system 
Lancet ii 
GUERRERO, R., ASO, T., BRENNER, P. F., CEKAN, Z., LANDREN B-M-i 
HAGENFELDT, K. & DICZFALUSY, E. (1976) Studies on the pattern 
of circulating steroids in the normal menstrual cycle. 
Acta Endocrinol. 81,133-149 
HAGINO, N. & GOIDZIEHER, J. W. (1970) Effect of timing and quantity 
of estrogen on gonadotroph-in-induced ovulation in J=ature 
rats. Endocrinology 86,29-33 
HALBREICH, U., BEN-DAVID, M., ASSAM, M., & BORNSTEIN, R. (1976) 
Serum prolactin in women with premenstrual syndrome. Lancet 
ii, 654-656 * 
HAMBURG9 D. A. (1966) Effects of progesterone on behaviour. In 
Endocrines and the Nervous System. Research Publicationst 
Association for Research in Nervous and Mental Disease 
43,251-263. Williams & Wilkins Co. Baltimore. 
HANING, R., McCRACKEN, J., St. CYR9 M., UNbERWOOD, R., WILLIAMSt G. 
& ABRAHAM, G. (1972) -1he evolution of titer and specificity of 
aldosterone binding antibodies in hyperimmunised sheep. 
Steroids. 20.73-88 
250 
HARMS, P. G., OJEDA, S. R. & McCANN, S. M. (1973) Prostaglandin 
involvement in hypothalamic control of gonadotrophin and 
prolactin release. Science 181,760-761 
HECKEL, G. P., LEAHY, M. F. & PLEGER, B. (1958) Sensitivity to 
unconjugated pregnanediol. Am. J. Obstet. Gynecol.. Z5, 
112-120 
HENNAM, J. F., COLLINS, W. P. & SOMMERVILLE, I. F. (1973) Radio- 
immunoassay of urinary testosterone glucuronosides. 
Steroids 21 285-306 
HERBERT, V., LAUt K. S. GOTTLIEB, C. W. & BLEICHER, S. J. (1965) 
Coated charcoal immunoassay of insulin. J. Clin. Endocrinol. 
Metab. 25,1375-1384 
HOLMSTROM, E. G. & SALHANIK9 H. A. (1956) Bioassay of follicle 
stimulating hormone by augmentation with human chorionic 
goandotrophin; summary of methods and results. I-lest. J. 
Surg. Obstet. Gynecol 64,, 270-279 
HOLZBAUERI M. (1976) Physiological aspects of steroids with 
anaesthetic properties. Red. Biol. 54,227-242 
HOLZBAUER, M. & YOUDIM, M. B. H. (1973) The oestrus cycle and 
monoamine oxidase activity. Br. J. Pharmacol. 48,6oo-608 
HOOKER, C. W. & FORBES, T. R. (1947) A bioassay for minute amounts 
of progesterone. Endocrinology 41,158-169 
HORROBIN, D. F. (1973) Prolactin; physiology and clinical significance. 
Chap. 18. M. T. P. Co. Ltd., Lancaster. 
HORROBIN, D. F. 9 MTABAJI, J. P., KARMALI, R. A. 9 MANKU, M. S. & NASSAR, 
B. A. (1976) Prolactin and mental illness. Postgrad. Mod. 
J. 52, (SuPP1 3) 79-85 
HURN, B. A. L. & LANDON, J. (1971) Antisera for radioimmunoassay. In 
Radioimmunoassay Methods(Kirkham, K. E. & Hunter, W. M., eds) 
pp 121-142 Churchill Livingstone, Edinburgh & London. 
ICHIKAWA, S., MURATA, K. & SH'IGIYAj R. (1974) Application of a 
marker dye on Sephadex. LH-20 column chromatography in 




ISRAELI. R., MISHELL, ý. R. j STONE, S., TIIORNEYCROFTI I. H. & 
MOYER, D. L. (1972) Single luteal phase serum progesterone 
assay as an indicator of ovulation. Am. J. Obstet. Gynecol. 
112, lo43-lo46 
ISRAEL, S. L. (1938) Premenstrual tension. J. Am. Med. Assocn. 
110,1721-1723 
ITO, T., WOO, J., HANING9 R. & HORTON, R. (1972) A radioimmunoansay 
for aldosterone in human peripheral plasmal including a 
comparison of alternate techniques. J. Clin. Endocrinol. 
Metab. 34,106-112 
ITTRICH, G. (1958) Eine neue methode zur chemischen bestimmung 
der ostrogenen hormone in harn. Hoppe-Seylers Z. Physiol- 
Chem. 2L2l. 1-14 
IVEY, M. E. & BARDWICK, J. M. (1968) Patterns of affective fluctuationL, 
in the menstrual cycle. Psychosom. Med. 20036-345 
JANOWSKY, D. S., GORNEY, R., CASTELNUOVC -TEDESCO I P. & STONE, 
C. B. 
(1969) Premenstrual-menstrual increases in psychiatric hospital 
admission rates. Am. J. Obstot. Gynecoli 103,189-191 
JANOWSKY, D. S., BERENS, S. C. & DAVIS, J. M. (1973) Correlations 
between mood, weight, and electrolytes during the menstruzLl 
cycle: a renin-angiotensin-aldosterone hypothesis of 
premenstrual tension. Psychosom. Res. 22,143-154 
JEIFTCOATE, S. L., FRASER, H. M., GUNN, A. & HOLLAND, D. T. (1973) Radio- 
immunoassay of luteinizing hormone releasing factor. J. 
Endocrinol. ý7,189-190 
JOHAINSSON, E. D. B. (1969) Pro&esterone levels in peripheral plasma 
the luteal phase of 
during/the normal human menstrual cycle measured by a rapid 
competitive protein binding technique. Acta Endocrinol. 
L1,592-6o6 
JOHANSSON, E. D. B. (1971) Depression of the progesterone levels in 
women treated with synthetic gestagens after ovulation. Acta 
Endocrinol. 68,779-792 
252 
JOHANSSON, E. D. B. & WIDE, L. (1969) Periovulatory levels of 
plasma progesterone and luteinizing hormone in women,. Acta. 
Endocrinol. 62,82-88 
JONES, K. M. 9 LLOYD-JONES9 R., RIONDEL, A., TAITj J. F., TAIT9 S. A. S., 
BULBROOK, R. D. & GREENWOOD, F. C. (1959) Aldosterone secretion 
and metabolism in normal men and women and in pregnancy. 
Acta Endocrinol. -30,321-342 
JORDHEIM, 0. (1972) The premenstrual syndrome - clinical trials 
of treatment with a progestogen combined with a diuretic 
compared with both a progestogen alone and with a placebo. 
Acta Obstet. Gynaecol. Scand. 51,77-80 
JOWETT, T. P., SLATER, J. D. H., PIYASENAI R. D. & EKINS, R. P. (1973) 
Radioimmunoassay of aldosterone in plasma and urine: validation 
of a novel separation technique and a rapid urine assay. Clin. 
Sci. Molec. Med. jtý, 607-623 
JOWETT, T. P., SMITH, E. & SLATER, J. D. H. (1975) Production and 
characteristics of highly specific antibodies to aldosteronee 
J. Steroid Biochem. 6,1415-1419 
JOYCE, B. G. 9 READ9 G. F. & FAHMY, D. R. (1977) A specific enzyme- 
immunoassay for progesterone in human plasma. Steroids 
ýL% 761-770 
JUDD9 H. L. & Yen, S. S. C. (1973) Serum androstenedione and testosterone 
levels during the menstrual cycle. J. Clin. Endocrinol. Metab. 
36,475-481 
JURJENS, H., PRATT, J. J. & WOLDRINUj M. G. (1975) Radioimmunoassay of 
plasma estradiol without extraction and chromatography. J,. 
Clin. Endocrinol. Metab. 40,19-25 
KARAVOLAS, H. J. & NUTI, K. M. (1976) Progesterono metabolism by 




Davies, J., eds) pp 305-326. 
(Naftoling F., Ryan, K. J. 9 
Elsevierg Amsterdam. 
KARIM, S. M. M. & HILLIER, K. (1975) Effect of prostaglandins on 
gonadotrophins. In Prostaglandins and Reproduction (Karim, 
S. M. M., ed) Chap. 2. M. T. P. Ltd. Lancaster. 
253 
KATZ, F. H. & ROMFHI P. (1972) Plasma aldosterone and renin activity 
during the menstrual cycle. J. Clin. Endocrinol Metab- 34, 
819-821 
KATZ, F. H., ROMFH, P. & SMITH, J. A. (1975) Diurnal variation of plasma 
aldosterone, cortisol and renin activity in supine man. J. 
Clin. Endocrinol- Metab. 4o, 125-134 
KAULHAUSEN, H. 9 MUHLBAUER, W. 9 BECKt K. J. & BREUER, H. 
(1974) 
The effect of 17cK-ethynyloestradiol-17Aon plasma renin activity 
in ovariectomised women. Acta Endocrinol. (Kbh) (Suppl) 184, 
54. 
KAULHAUSEN, H., LEYENDECKER, G., BENKER, G. & BREUER9 H. (1978) The 
relationship of the renin-angiotensin-aldosterone system to 
plasma gonadotrophin, prolactin and ovarian steroid patterns 
during the menstrual cycle. Arch. Gyn*ak. 22,9,179-200. '' 
KERR, G. D. (1977) The management of the premenstrual syndrome. Curr. 
Med. Res. Opin. 4, Suppi. 4,29-34 
KESSEL, N. & COPPEN. A. (1963) The prevalence of common premenstrual 
symptoms. Lancet ii 61-64 
KLAIBER, E. L. tKOBAYASHI, Y., BROVERMAN, D. M., & HALL9 F. (1971) 
Plasma monoamine oxidase activity in regularly menstruating women 
and in amenorrheic women receiving cyclic treatment with estrogens 
and a progestin. J. Clin. Endocrinol. Metab. 33,630-638 
KLAIBER, E. L., BROVERMAN, D. M., VOGEL, W. & KOBAYASHI, Y. (1974) 
Rhythms in plasma MAO activity, EEG and behaviour during the 
menstrual cycle. In Biorhythms and Human Reproduction (Ferin M. 
Halberg, F., Richart, R. H. & van de Wiele, R. L., eds) Chap. 22 
J. Wiley & Sons, New York. 
KLEINBERGI D. L., - NOEL, G. L. & FRANTZ, A. G. (1977) Galactorrhoa 
a study of 235-cases, including 48 with pituitary t=ours. New 
Engl. J. -Med. 296,589-6oo 
KLE-TZY, O. A., NAKAMURA, R. M., THORNEYCROFT', I. H. & MISHELL9. U. R. (1975) 
Log normal distribution of gonadotropins and ovarian steroid 




KLOPPER, A. I. (1957) The excretion of pregnanediol during the normal 
menstrual cycle. J. Obstet. Gynaecol. Br. Empire. 64,504-511 
KLOPPER, A. I., MICHIE, E. A. & BROWN, J. B. (1955) A method for the 
determination of urinary pregnanediol. J. Endocrinol. 12, 
209-219 
KLOPPER, A. & WILSON, G. R. (1962) A method for the assay of oestriol 
in pregnancy urine. J. Obstet. Gynaecol. Br. Commnwlth. ý9-9 
533-538 
KLYNE, W. (1965) The chemistry of the steroichpl45 Methuen. & Co, 
Ltd. London. 
KOBAYASHI9 T. t KOBAYASHI, T. 9 KATO, J. & MINAGUCHI, H. 
(1066) 
Cholinergic and adrenergic mechanisms in the female rat hypothalamus 
with special reference to feedback of ovarian hormones. In Steroid 
Dynamics. ( Pincus, G., Nakao, T., & Tait, J. F. Eds. ) P. 303. Academic 
Press, New York 
KOHEN, F., BAUMINGER, S. & LINDNER9 H. R. (1975) Preparation of antigenic 
steroid-protein conjugates. In Steroid Immunoassay (Camerong E. H. D, l 
Hillier, S. G. & Griffiths, K., eds) PP 11-32 Alpha Omega Publishing 
Ltd. Cardiff. 
KORENMAN9 S. G. . PERRIN, L. E. & McCALLUM, T. P. (1969) A radio-ligand 
binding assay system for estradiol measurement in human plasmas 
J. Clin. Endocrinol. Metab. 29,879-883 
KUMAR, D. (1962) In vitro inhibitory effect of progesterone on extra- 
uterine human smooth muscle. Am.. J. Obstet. Gynec. 84,1300-13o4 
KUSHINSKY, S. & ANDERSON, M. (1974) A non-chromatographic radio- 
immunoassay of estrone and estradiol-1713 in ser=. Steroids 
23,535-548 
KUTAS, M., CHUNGI. A. 9 BARTOS, D. & CASTRO, A. (1972) A aimple 
progesterone radioimmunoassay without column chromatography. 
Steroids 20,697-716 
KUTNER9 S. J. & BROWN, W. L. (1972) Types of oral contraceptivesq 
depression and premenstrual symptoms. J. Nerv. Ment. Dis. 
155,153-162 
LADISICH9 W. (1977) Influence of progesterone on serotonin metabolism: 




LAIDLAW, J. (1956) Catamenial epilepsy. Lancet. 2,1235-1237 
LAIDLAW9 J. C., RUSE, J. L. & GORNALLs A. G. (1962) The influence of 
estrogen and progesterone on aldosterone excretion. J. Clin. 
Endocrinol. Metab. 22,161-171 
, 
LANDAU, R. L. (1973) The metabolic influence of progesterone. In 
Handbook of Physiology. Section 7. Vol II. (Greep, R. O. ed. ) 
pp. 573-602. American Physiological Society, Washington. 
LANDAU, R. L., BERGENSTAL, D. M., LUGIBIHLv K., DIMICK, D. F. & RASHID9 R, 
(1957) The relationship of estrogen and of pituitary hormones to 
the metabolic effects of progesterone. J. Clin. Endocrinql. Metab. 
179 177-185. 
LANDAU, R. L., LUGIBIHL, K. & DIMICK9 D. F. 9 (1958) Metabolic effects 
in 
man of steroids with progestational activity. Ann. N. Y. Acad. 
Sci. 71,588-598 
LANDAU, R. L. & LUGIBIHL, K. (1961) The catabolic and natriuretic 
effects of progesterone in man. Recent. Progr. florm. Res. 
17,249-292 
LA TORRE, R. A. (1974) Estradiol inhibition of catecholaminergic eating 
in the castrated female rat. Biol. Psychiat. 8,337-341 
LEBLANC, H. 9 LACHELIN, G. C. L., ABU-FADIL, S. & YENt S-S-C- 
(1976) 
Effects of dopamine infusion on pituitary hormone secretion in 
humans. J. Clin. Endocrinol. Metab. 43,668-674 
LENTON, E. A., COOKE, I. D., SAMPSON, G. A. & SEXTONg L. (1978) 
Oestradiol secretion in men and pre-menopausal women. Clin. 
Endocrinol. 2,37-47 
LENTON, E. A. 9 SOBOWALE, O. S. & COOKE, I. D. (1977) Prolactin 
concentrations in ovulatory but infertile women: treatment 
with bromocryptine. Br. Med. J. 29 1179-1181 
LENT ON, E. A. 9 ADAMS9 M. & COOKE9 I. D. (1978) Plasma steroid and 
gonadotropin profiles in ovulatory but infertile women. Clin. 
Endocrinol. 8, -'241-255 
LEVINE, B. B., (1965) Immunochemical mechanisms involved in penicillin - 
hypersensitivity in experimental animals and in human beings. 
Fed. Proc. 24,45-50. 
256 
LITTLE, B. C. & ZAHN, T. P. (1974) Changes in mood and autonomic 
functioning during the menstrual cycle. Psychophysiology. 
11,579-590 
LLOYD, T. S., (1963) The mid-thirties syndrome. Virginia Med. 
Monthly 90,51-52 
LORAINE, J. A. & BELL, E. T. (1971) Hormone Assays and their Clinical 
Applications. p. 4o8. Third Edition. E. & S. Livingstone. 
Edinburgh & London. 
McARTHUR, J. W., WORCESTER, J. & INGERS011, F. M. (1958) The urinary 
excretion of interstitial-cell and follicle-stimulating hormone 
activity during the normal menstrual cycle. J. Clin, 
Endocrinol. Metab. 18,1186-1201 
McCANCE, R. A., LUFF, M. C. & WIDDOWSON, E. E. (1937) Physical and 
emotional periodicity in women. J. Hygiene 2Z, 571-611 
McCLINTOCK, M. K. (1971) Menstrual synchrony and suppression. 
Nature 229,244-245 
McGARRIGLE, H. H. G., SARRIS, S., LITTLE9 V., LAWRENCE, D., RADWANSKA, 
E. & SWYER, G. (1978) Induction of ovulati6n with clomiphene 
and human choi-ionic gonadotrophin in women with hyperprolactinaemic 
amenorrhoea. Br. J. Obstet. Gynaecol. 85,692-697 
McKENZIE, J. K. & CIR NTS, J. A. (1974) Simplified radio immunoassay for 
serum aldosterone utilizing, increased antibody specificity. 
J. Clin. Endocrinol. Metab. 38,622-627 
McKINLAY, S. M. & JEFFERYS, M. (1974) The menopausal syndrome. &r. J. 
Prev. Soc. - Med. 28, lo8_115 
McKINNON, P. C. B. & MacKINNON, I. L. (1956) Hazards of the menstrual 
cycle. Br. Med. J. 1,555 
McNATTY, K. P., SAVIERS, R. S. & McNEILLY, A. S. (1974) A possible role 
for prolactin in control of steroid production by the human 
Graafian follicle. Nature 250,653-655 
McNEILLY, A. S. (1975) Lactation and the physiology Of prolactin 
secretion. Postgrad. Med. J. 21,231-235 
McNEILLY9 A. S. & CHARD, T. (1974) Circulating levels of prolactin during 
the menstrual cycle. Clin. Endocrinol. 3,105-112 
257 
MALACARA, J. M., SEYLER, L. E. & REICHLIN, S. (1972) Luteinizing 
hormone releasing factor activity in peripheral blood from 
women during the mid-cycle luteinizing hormone ovulatory 
surge. J. Clin. Endocrinol. Metab. ý4,271-278 
MANDELL, A. &. MANDELL, M. (1967) Suicide and the menstrual cycleo 
J. Am. Med. Assocn. 200,792-795 
MARSHALL, J. (1963) Thermal changes in the normal menstrual cycle. 
Br. Med. J. 1 102-104 
MARTIN, B. T. & 14UGENTIC. A. (1973) A non-chromatographic radioimmunoassay 
for plasma aldosterone. Steroids 21,169-18o 
MATTSSON, B. & von SCHOULTZ, B. (1974). A comparison between lithium$ 
placebo and a diuretic in premenstrual tension. Acta Psychiatro 
Scand. Suppl 255,75-84 
MAYES, D. FURUYAMA, S., KEM, D. C. & NUGENT, C. A. (1970) A radioimmunoassay 
for plasma aldosterone. J. Clin. Endocrinol. Metab. 30,682-685 
MENAKER, W. & MENAKER, A. (1959) Lunear periodicity in human repro- 
duction: a likely unit of biological time. Am. J. Obsteto 
Gynecol. 77,905-914 
MERRYMAN, W. (1954) Progesteronelanaesthesial in human subjects* 
J. Clin. Endocrinol. Metab. 14,1567-1569 
MICHAEL, R. P. (1965) Oestrogens in the central nervous system. Bro Med. 
Bull. 21,87-90 
MICHELAKIS, A. M., STANT, E. G., & BRILL, A. B. (1971) Sodium space and 
electrolyte excretion during the menstrual cycle. An. J. Obstet. 
Gynecol. 109,150-154 
MICHELAKIS, A. M., YOSHIDAIH. &DORMOIS, J. C. (1975) Plasma renin'activity 
and-rlasma aldosterone during the normal menstrual cycle. Am., Je- 
Obstet. Gynecol. 123,724-726 
MIDGLEY, A. R. & JAFFE, R. B. (1968) Regulation of human gonadotrophins: 
IV. Correlations of serum concentrati-ions of follicle stimulating 
and luteinizing hormones during the menstrual cycle. J, Clin, 
Endocrinol. Metab. 28,1699-1703 
MIDGLEY, A. R., NISWENDER, G. D. & REBAR, R. W. (19ý69). Principles for the 
assessment of -the reliability of radio imrunoassay mAhods 
(precision, accuracy, sensitivity, specificity) Acta Endocrinol, 
(kbh) 63 Suppi 142,3.63-18o I 
, 258 
MIDGLEY, A. R. & FISWENDFR, G. D. (1970). Radioimmunoassay of steroids. 
Acta Endocrinol. (Kbh) 64 suppi 147,320-326 
MIGEON, C. J., KOWARSKI, A., BEITINSII. Z., & BAYARD, F. (1973) Radioimmuno- 
assay of plasma aidosterone. Irz Modern Methods of Steroid 
Analysis. (Heftmann, E., ed) Chap. 22 Academic Press, New York& 
London. 
MIKHAIL, G., WU, C. H., FERINIM. & vandeWTELE, R. L. (1970) Radioimmuno- 
assay of plasma estrone and estradiol. Steroids 1.5,333-352 
MILEWICH, L., GOMEZ-SANCHEZIC. 9 CROWLEY, G., PORTERIJ. C. 9 MADDENIJ. D. 
& MacDONALDI P-S. (1977) Progesterone and 50(-pregnane-3920- 
dione in peripheral blood of normal young women. Daily measurement6a 
throughout the cycle. J. Clin. Endocrinol. Metab. 45,617-622 
MILtIGAN, D., DRIFE, J. 0., & SHORT, R. V. (1975) Changes in breast volume 
during normal menstrual cycles and after oral contraceptives 
Br. Med. J. 41 494-496 
MISHELL, D. R., NAKAMURA, R. M., CROSIGNANIIP. G., STONEIS., KHARMAIK., 
NAGATA, Y. & THORNEYCROFTII. D. (19? 1) Serum gonadotropin and 
steroid patterns during the normal menstrual cycle. Am. Jo 
Obstet. Gynecol. 111,60-65 
van der MOLEN, H. J. & GROEN, D; (1965) Determination of progesterono in 
human peripheral blood using gas-liquid chromatography with 
electron-capture detection. J. Clin. Endocrinol. Metab.. gý 
1625-1639 
MOON, Y. S., TSANG, B. K., SIMPSON, C. & ARMSTRONG, D. T. (1978). 17/3- 
estradiol'biosynthesis in cultured granulosa and thecal cells 
of human ovarian follicles: stimulation by follicle-stimulating 
hormone. J. Clin. Endocrinol. Metab. 47,263-267 
MOOS, R. H. (1968) The development of a menstrual distress questionn- 
aire. Psychosom. Med. 30,853-867- 
MOOS, R. H. (1969) Typology of menstrual cycle symptoms. Am. J. Obstet. 
Gynecol. 103,390-402 
MOOS, R. H. (1977) Menstrual Distress Questionnaire Manual. Social 
Ecology Lab., Stanford University, California. 
MOOSIR. H., KOPELLIB. S., MELGES17. T., YALOM9I. D., LUNDE, D. T., CLAYTON, 
R. B., & HAMBURG, D. A. (1969) Fluctuations in symptoms and moods 




MORGAN, C. A. & COOIKE, I. D. (1972) A comparison of the competitive 
protein-binding assay and radjoimmunoassay for plasma 
-erone during the normal menstrual cycle. J. Endocrinol. progest 
445-456 
MORREI., L, F. (1959) The role of the oestrogens in catamenial exacerbation 
of epilepsy. Neitrology. 2,352-366 
MORRIS, D. J. & DAVIS9 R. P. (1974) Aldosterone: current conceptse 
Metabolism 239 473-494 
MORRISS, G. M. & KEVERNE, E. B. (1974) Premenstrual tension. Lancet ii, 
1317-1318 
MORTIMER, C. H., BESSER, G. M., McNEILLY, A. S., MARSHALL, J. C. l IIARSOULISIP-l 
TUNBRIDGEIW. M. G., GOIU; Z-PAN, A. I& HALL, R. 
(1973) Luteinising 
hormone and follicle stimulating hormone-releasing hormone tests 
in patients with hypothalamic-pituitary-gonadal dysfunctions 
Br. Med. is 4t 73-77 
MORTON, J. H. (1950) Premenstrual tension. Am. J. Obstet. Gynecol. 60, 
343-352 
MURPHY, B. E. P. (1967) Some 
, 
studies of the protein-binding of steroida 
and their application to the routine micro and ultramicro 
measurementýs of various steroids in body flui. ds by comPOtitivO 
protein-binding. radioassay. J. Clin. EndocAnql. Netab. 2z, 973§90 
MURPHY, B. E. P. (1970) Methodological problems in competitive protein- 
binding techniques; the use of Sephadex column chromatography to 
separate steroids. Acta Endocrinol. 64, Suppl 147,37-56 
iffiRPHY, B. E. P. (1971) 'SephadexI column chromatography as an adjunct to 
competitive protein binding assays of steroids. Nature-New Bibl 
232,21-24 
MURPffY-7B. E. P. & DIAUXIR. C. D. (1975) The use of Sephadex LH-20 column 
chromatography to separate unconjugated steroids. J. Steroid 
Biochem. 6,233-237 
NEILL, J. D., JOHANS80N, E. D. B., DATTAl J. K. & KNOBILlE. (1967) Relation- 
ship between the plasma leirels of luýeinizing hormone and progest- 
erone during the normal menstrual cycle. J. Clin. Endocrinole 
Metab. 27,1167-1173 
ITEILL, J. D. & REICHART, L. E. (1971) Development of a radioirmmunoassay 
for rat prolactin and evaluation of the NIAMD rat prolactin 
radioimmunoassay. Endocrinology L89 548-555 
260 
NIESCHLAG, E., KLEY, H. K. & USADEL, K. H. (1975) Production of steroid 
antisera in rabbits. in Steroid Immunoassay (Cameron, E. H. D., 
Hillier, S. C. & Griffiths, K. eds) pp87-96. Alpha Omega, Cardiff 
NILLT-US, S. J., FRIBERG, J. & WIDE, L. (1973) Midcyclic LH and FSH release 
after exogenous administration of the synthetic gonadotrophin- 
releasing decapeptide. Acta Endocrinol. (Kbh) SuPP1 177,349 
NILLIUS, S. J. & WIDE, L. (1976) Prodesterone-induced augmentation 
of pituitary gonadotrophin responses to luteinizing hormone- 
releasing hormone in oestrogen pre-treated amenorrheic women* 
Acta Endocrinol. 83,684-691 
NISWENDER, G. D. (1973) Influence of the site of conjugation on the 
specificity of antibodies to progesterone. Steroids 2-2.413-424 
NOEL, G. L., SUH, H. K.. & FRANTZ, A. G. (1971) Stimulation of prolactin 
release by stress in humans. "- Clin. Res. 19,718 I 
NOWACZYNSKIqW., KOIW, E. & GENEST, J. (1957) Chemical method for the 
determination of urinary aldosterýne. Can. J. Biochem. PhysiOlf 
35,425-443 
NOWACZYNSKI, W., SILAHIJ. & GENEST, J. (1967) Procedure for the determin- 
ation of'aldosterone in human peripheral plasma by double-isotope 
assay, and its application for measurement of secretory rates and 
urinary excretion. Can. J. Biochem. 4r- 5,1919-1936 
NOWACZYNSKII W., SASAKI, C., & GENEST, J(1974) Radioimmunoassay for 
aldosterone and normal values under various physiological conditions 
J. Steroid Biochem. ý, 123-134 
NOWACZYNSKI, W., MURAKAMIIT., RICHARDSON, K. & Genest, J. (1978) 
Increased plasma protein binding in women on combined oral 
contraceptives throughout the menstrual cycle. J. Clin. Endocrinol. 
Metab. 47,193-199 
O'BRIEN, P. M. S. & SYMOTIDS, E. M. (1977) A preliminary report of spiroft- 
olactone therapy in the premenstrual syndrome. 21 st British 
Congress of Obstetrics and Gynaecology Abstract no. 40 Sheffield.. 
ODELL, W. D., ROSS, G. T. & RAYFORD, P. L. (1967) Radioimmunoassay for 
luteinizing hormone in human plasma or serum: physiological 
studies. J. Clin. Invest. 46,248-255 
261 
OELKERS, W., MARSEN, B. ýj MOLZAHN, M. 9 LOHMANN, F. W. & HAMMERSTEIN, J 
(1973) Relationship between weight changes and renin, 
aldosterone, estrogens and progesterone in cyclical edema. 
Acta Endocrinol (Kbh) SUPP1 M 1159 
OELKERS, W., SHONESHOFER, M. & BLUMEL, A. (1974) Effecto of 
progesterone and four synthetic progestogens on sodium 
balance and the renin-aldosterone-system in man. J. Clin. 
Endocrinol. Metab. 22,882-8go 
OERTELI G. W., WEISS, S. P. & EIK-NESI K. B. (1959) Determination of 
progesterone in human blood plasma. J. Clin. Endocrinol.. 
Metab. 19,213-218 
OJEDA, S. R. & McCANN, S. M. (1974) Evidence for the participation of 
a catecholaminergic mechanism in tho post-castration rise in 
plasma gonadotrophins. Neuroendocrinology L2,295-315 
PAIGE, K. E. (1971) Effects of oral contraceptives on affective 
fluctuations associated with the menstrual cycle. Psychosom. 
Med. 33,515-537 
PALAIC, D& KHAIRALLAH, P. A. (1967) Effect of angiotensir, on uptake 
and release of norepinephrine by brain. ýiochem. Pharmacol. 
16,2291-2298 
PALLAS, K. G., HOLZWARTHI G. J., STERN, M-P- & LUCAS, C*P. (1977) 
The, effect of conjugated eatrogens on the renin-aneiotensin 
system. J. Clin. Endocrinol. Metab. 44, lo6l-lo67 
PARE, C. M. B. & SANDLER, M. J. (1959) A clinical and biochemical atudy 
of a trial of iproniazid in the treatment of depreasion. J. Neurol 
Neurosurg. Psychiat. 22,247-251 
PARLEE, M. *B. (1973) The premenstrual syndrome. Psychol. Bull. 809 
454-465 
PASTEEELS, J. L., DANGUYI A. FREROTTE, M. & ECTORSt F. (1971) 
Inhibition de la secreetion de prolactine par Vergocornine 
et la 2-Br- ergo-cryptine. Action directe nur 11hypophyse on 
culture. Ann. Endocrinol. (Paria) ý2,188--! 192 
PEARCE, 14.1 FAHIIY, C., MORGAN, C. EVANS, Cj'GROOM, G., BOYNS, A. R. 
& COOKE, I. D. (1971) Hormonal changes in patients with 
defective luteal phases. J. Endocrinol. 91, xxiv. 
262 
PENNINGTON, V. M. (1957Y Meprobromate (Miltown) in premenstrual 
tension. J. Am. Med. Assocn. 638-640 
IEPPERALLj R. J. 9 EVANS, J. H., BROWN, J. B. 9 SMITH, MA., HEALY, D, & 
BURGER, F. G. (1977) Serum prolactin levels and the valuo of 
bromocr-jptine in the treatment of anovulatory infertility. 
Br. J. Obstet. Gynaecol. 84,58-66 
PERRINI, M. & PILIEGO, N. (1959) L'aumento dell 'aldosterone nella 
sindrome premestruale. Minerva. Med. 50,2897-2899 
PERSSON, B. H. & McCORMICK, W. G. (1963) Patterns of urinary FSH 
excretion during ovulatory and anovulatory menstrual cycles* 
Acta Endocrinol. a, 573-578 
PETERSON, R. E. (1964) Determination of peripheral plasma oldonterono 
In Aldosterones(Baulieu E. E. & Robel, P. Eds) PP145-167 - 
. Blackwell, Oxford. % 
PIERSON9 W. R., & LOCKHART, A. (1963) Effect of menstruation on simple 
reaction time and movement time. Br. Mod. J. 1,796-797 
PILIEGO, N., ROSSINI, P., del ZOTTI, G. & SCARDAPANE, R. (1964) 
Gli effeti di un carico di follicolina sull laldooteronuria 0 
sulla catecholaminuria di donne normali a con aindrome 
premestruale. Folia Endocrinol. (Roma) jZ, 391-418 
PIZAPSO, M. A. & KOLANOWSKIq J. (1972) Problems arisin3 from blanka 
in protein-binding analysis. J. Steroid Biochem. 2,349-356 
POULSEN, K. SANCH09 J. & HABER, E. (1974) A Simplified radioimmunonscay 
for plasma aldosterone employing an antibody of uniquo spocificity. 
Clin. Immunol. Immunopath. 2,373-380 
POWELL, J. E. & STEVENS, V. C. (1973) Simple radioimmunoassay of five 
unconjugated ovarian steroids in a single sample of serum or 
plasma. Clin. Chem. 19,210-215 
del POZO, E., GOLDSTEINj M., FRIESEN, Hog BRUN dol RE, R. & MENBURGER, 
U- (1975) Lack of action of prolactin suppression on the 
regulation of the human menstrual cycle. Am; J. Obstet. Gynecol. 
123,719-723 
van PPAAG, H. M. (1978) Neuroendocrine disorders in depression and their 
significance for the monoamine hypothesis of depression. Acta 
Psychiat. Scand- 57,389-4o4. 
263 
PREECE9. P. E., RICHARDS, A. R., OWEN, G. M. & HUGHESs L. E. (1975) 
Mastalgia and total body water. Br. Med. J. -4,498-500 
PREECE, P. E. HUGHES, L. E., MANSEL9 R. E., BAUM, M., BOLT0149 P. M. & 
GRAVELLE, I. H. (1976) Clinical syndromes of mastalgia. Lancot -ii. 
67o-673 
PREEDY, J. R. K. & AITKEN, E. H. (1961) Column partitbn chromatography 
of estrone, estradiol- 17A and estriol in phenolic extracto of 
urine; fluorescence characteristic of interfering material. 
J. Biol. Chem. 236,1297-1299 
PRESSER, H. (1974) Temporal data relating to the menstrual cycle. 
In Biorhythms and Human Reproduction. (Ferin, M. 9 Halberg, F*j 
Richart, R. H., & van de Wiele R. L. Eds) Chap. 10. J. Wiloy & 
Sons, New York. 
PRILL, H. J. & KRUGER, E. (1963) Uber die ostrogenausacheidung bei 
Frauen mit premenstruallem syndrom. Endokrinologie, 44,34-38 
PULLAR, I. A. (1973) Amine metabolism in affective disordera. Biochem. 
Soc. Spec. Publ. 1,97-100 
REDGROVE, J. A. (1971) Menstrual cycles. In Biological Rhythms and 
Human Performance. (Colquhoun. W. , ed. 
)Chap. 6. Academic Press* 
London. 
REES, L. (1953) The premenstrual tension syndrome and its troatmonte 
Br. Med. J. i, 1014-1016 
REICH, M. (1962) The variations in urinary aldocterone lovola of 
normal females during their menstrual cycle. Austral. Anne Mod. 
ill 41-49 
RIBEIR09 A. L. (1962) Menstruation and crime. Br. Med. J. il 640 
RICE, B. F., HAMMERSTEINg J. & SAVARD, K. (1964) Steroid hormono 
formation in the human ovary: II action of gonadotrophins in 
vitro in the human corpus luteum. J. Clin. Endocrinol. Metab. 24,606-615 
RICE, B. F. & SAVARD, K. (1966) Steroid hormohe formation in the human 
ovary IV. J. Clin. Endocrinol. Metab. 26,593-609 
RICHARDSON, K. S. C., NOWACZYNSKI, -W. & GENEST, J. (1976) Aldostcroýe- 
binding proteins in human plasma. New. Engl. J. Med.? 22,114 
RIONDEL, A., TAIT, J. F. 9 TAIT, S*A. S. j GUT, M. & LITTLE, B. (1965) 35 Estimation of progesterone in human peripheral UDod using S-thio 
semi-carbazide. J. Clin. Endocrinol. Metab. 25,229-21+2 
264 
ROBINSON, D. S., LOVENBERG9 W., KEISER, H. & SJOERDSMAt A. (1968) 
Effects of drugs on human blood platelet and plasma amino 
oxidase activity in vitro and in vivo. Biochem. Pharmacol. 
17,109-119 
ROBINSON, J. E. & SHORT, R. V. (1977) Changes in breast sensitivity 
at puberty, during the menstrual cycle and at parturition. 
Br. Med. J. i, 1188-1191 
ROBINSON, R. G. & FANESTIL, D. D. (1970) Assay of aldosterono by 
competitive protein binding. Acta Endocrinol. (Kbh) 64, 
Suppl. 147,275-2M 
ROBYN, C., DELVOYE, P. t NOKIN, J., VEKEMANS9 M., BADAWI, M., PEREZ- 
LOPEZ, F. R. & LIHERMITE, N. (1973) Prolactin and human Reproduction*- 
In Human. Prolactin (Pasteels J. L. & Robyn, C. eds) p 98. Int. 
Congr. Ser. No. 308 Excerpta Medica. Amstordam. 
RODBARD, D., RUDER, H. J., VAITUKAITISI J. & JACOBS, H. S. (1971) 
Mathematical analysis of kinetics of radioligand assays: improvad 
sensitivity obtained by delayed addition of labelled ligand. 
J. Clin. Endocrinol. Metab. M, 343-355 
ROGERS, W. C. (1962) The role of endocrine allergy in the production 
of premenstrual tension. West. J. Surg. Obstet. Gynocol. 
70,100-102 
ROLLAND 9 R. 9 LEAVIN, R. M. q SCHELLEKENS , L. A. & do JONG 9 F. 11. 
(1975) 
The role of prolactin in the restoration of ovarian function 
during the early post-partum period in the human female. 
A study during physiological lactation. Clin. Endocrinol. 4,15-25 
ROSA, U. MALVAN09 R. & ROLLERIq E. (1974) Critical factors in the 
standardization of steroid radioimmunoassay. In Recent Progreas 
in Reproductive Endocrinology. (Crosignani P. G. & Jamea, V. H. T. 
Eds-) p27-39. Academic Press. London and New York. 
ROSE, D. P. (1969) Oral contraceptives and depression. Lancet 11 321 
ROSS, G. T., CARGILLEi C. M., LIPSETT9 M. B.,, RAYFORD, P. L., MARSIIALLj 
J. R., STROTT, C. A. & RODBARD, D. (1970) Pituitary and gonadal 
hormones in women during the spontaneous and induced ovulatory 
cycles. Recent. Progr. Horm. Res. 26,1-62 
ROSSEINSKYj D. R. & HALL, P. G. (1974) An evolutionary theory of 
premenstrual tension. Lancet 11,1024 
ROYAL COLLEGE GENERAL PRACTITIONERS (1974) 'Oral contraceptivos and 
Health' Pitman Medical, London. 
265 
RYAN, K. J. & SMITH, O. W. (1961) Biogenesis of estrogens by the human 
ovary. I. Conversion of acetate 1-C 
14 to estrone and estradiol. 
J. Biol. Chem. 236,705-709 
SACHkR, E. J., FRANTZ, E. G., ALTMAN, 14. & SkSSIN, J. (1973) Growth 
hormone and prolactin in unipolar and bipolar depressed patients: 
response to hypoglycaemia and L-Dopa. Am. J. Psychiatry. 1309 
1362-1366 
SACHAR, E. J., HELL14AN, L., ROFEVARG, H. P., HALPERN, F, S., FUKUSHIMAq 
D. K., GALLAGHER, T. F., & BRONX, N. Y. (1973) Disrupted 24 hour 
patterns of cortisol secretion in psychotic depression. Arch 
Gen. Psychiatry 28,19-29 
SANDBERG, A. A., ROSENTHALl H., SCHNEIDER, S. L. & SLAUNWHITE, W. R. 
. 
(1966) Protein-steroid interactions and their role in the 
transport and metabolism of steroids. In. Steroid Dynamics. 
(Pincus, G; j Nakao, T., & Tait, J. F., eds) pp 1-61. Academio 
Press New York & London. 
SASSARD, J., VINCENT9 M., ANNAT, G. & BIZOLLON, C. A. (1976) A kinotic 
study of plasma renin and aldosterone during changes of posture 
in man. J. Clin. Endocrinol. Metab. 42,20-27 
SAWYER, C. H. & KAWAKAMIj M. (1961) Interactions between the central 
nervous system and hormones influencing ovulation. In The 
control of Ovulation (Villee, C. A. ed) p 79. Pergamon Press. 
Oxford. 
SAXENA, B. N., DUSITSIN, N. & LAZARUS, L. (1974) Human Growth Hormone 
(HGH) Thyroid Stimulating Hormone (TSH) and cortisol levola in 
serum of menstruating Thai women. J. Obstet. Gynaccol. Br. 
Commnwlth 81,563-567 
SCARISBRICK, J. J. & CAMERON, E. H. D. (1975) Radioimmunoassay of 
progesterone: comparison of (1,2,6,7- 
3H 
4) -progesterono and 
progesterone-( 
125 I)-iodohistamine radioligands. J. Steroid 
Biochem. 6,51-56 
SCHALLY, A. V., ARIMURA, A., KASTIN, A. J., MATSU09 H., BABA, Y., REDDINGl 
T. W., NAIR, R. M. G., DEBELJUK, L. & WHITE9 W. F. (1971) 
. Gonadotropin-releasing horpone: one polypeptide regulates 
secretion of luteinizing and follicle-stimulating hormone. 
Science 173,1036-1038 % 
P-66 
SCHILDKRAUTI J. j (1965) The catecholamine hypothesis of affective 
disorders: a reiriew of supporting evidence. An.. J. Psychiatry. 
122, 
-509-522 
SCHURENKAMPER, P. & LISSE, K. (1978) In Vitro Studies on the effect 
of D-Norgestrel and norethisterone acetate on the formation 
of sex steroids in human ovary. Endokrinologio 71,25-34 
SCHWARTZ, U. D. & ABRAHAM, G. E. (1975) Corticosterone and aldostorono 
levels during the menstrual cycle. Obstet. Gynecol 45,339-342 
SEPiLAil M., HIRVONEN, E. & RANTA, T. (1976) Hyperprolactinaemia 
and luteal insufficiency. Lancet. i, 229-230 
SEPPALA, M., LEHTOVIRTA, P. & RANTA, T. (1977) Discordant patterns 
of hyperprolactinaemia and galactorrhoea in secondary amenorrhooa. 
Acta Endocrinol. 86,457-463 
I 
SHAW, D. M. t RILEY, G., TIDMARSH, S. & BLAZEK9 R. 
(1976) Unipolar 
affective illness. Lancet. i, 363-364 
SHAW, R. W., BUTT, W. R. & LONDON9 D. R. (1975) The effect of oostrogen 
pre-treatment on subsequent response to luteinizing hormone in 
normal women. Clin. Endocrinol. 4,297-30 
SHERMAN, B. M. & KORENMAN9 S. G. (1974) Measurement of plasma LH, FSHI 
estradiol and progester6ne in disordera of the human mon3trual 
cycle: the short luteal phase. J. Clin. Endocrinol. Motab. 
38,89-93 
SESHERMAN, B. M. & KORENMAN, S. G. (1975) Hormonal characteristics of the 
human menstrual cycle. throughout reproductive life. J. Clin. 
Invest. 55,699-7o6 
SHERMAN, B.. M., WEST, J. H. & KORENMANI S. G. (1976) The menopausal 
transition: analysis of LH, FSH, estradiol and progostorono 
concentrations during menstrual cycles of older womon. J& 
Clin. Endocrinol. Metab. 42,629-636 
SHORT, R. V. (1958) Progesterone in blood. l. 'The chemical determination 
of progesterone in peripheral blood. J. Endocrinol. 16,415-425 
SHORT, R. V. (1964) Ovarian steroid synthesis and secretion in vivoo 
Recent. Progr. Horm. Res. 20,303-340 
S 
267 
SHUTT, D. A. (1969) Measixement of estradiol-17ýin plasma by 
competitive protein-binding radioassay. Steroids.. 12,69-82 
SIMPSON, S. A. S. & TAIT, J. F. (1952) A quantitative method for 
the bioassay of the effect of adrenal cortical steroids on 
mineral metabolism. Endocrinology 50,150-161 
SITRUK-WARE, L. R., STERKERS9 N., MOWSZOWICZ, I. & MAUVAIS-JARVIS, Po 
(1977) Inadequate corpus luteal function in women with benign 
breast diseases. J. Clin. Endocrinol. Metab. 44,771-774 
SMITH, O. W. & RYAN, K. J. (1962) Estrogen in the human ovary. Am*J- 
Obstet. Gynecol. 84,141-153 
SMITH, S. L. (1975) Mood and the menstrual cycle. In Topics in 
Psychoendocrinology. ( Sachar, E. J. EdJ pp 19-58. Gruno & 
Stratton, New York & London. 
SMITH, S. L &SAUDER , C. (1969) Food cravings, depression and pro- 
menstrual problems. Psychosom. Med. 31,281-287 
SMYTHE, G. A. (1977) The role of serotonin and dopamine in hypothalamic 
pituitary function. Clin. Endocrinol.. Zi 325-341 
SNEDECOR, G. W. (1956) Cited by Johansson (1969) 
SOMMER, B. (1973) The effect of menstruation on cognitive and 
perceptual-motor behaviour: a review. Psychosom. Med,, Ul 515-534 
SOMMERVILLE, I. F., & DESHPANDE, G. N. (1958) The quantitative 
determination of progesterone and pregnanediol in human plasma. 
J. Clin. Endocrinol. Metab. 18,1223-1236 
SOUTHAM, A. L. & GONZAGA, F. P. (1965) Systemic changes during the 
menstrual cycle. Am. J. Obstet. Gynecol. 91,142-165 
SOUTHGATE9 J., GRANT9 E. C. G., POLLARD, W. 9 PRYSE-DAVIESj J, 
& SANDLER9 M. (1968) Cyclical variations in endometrial 
monoamine oxidase: correlation of histochemical and quantitativo 
biochemical assays. Biochem. Pharmacol. 17,, 721-726 
SPIELER, J. M., WEBB, R. L., SALDARINI, R. J. '& COPPOLA, J. A. (1972) 
A radioimmunoassay for progesterone. Steroids. 12,751-762 
van der STEEG, H. J. & COELINGH BENNINK, H. J. T. (1977) Bromocryptino 
for induction of ovulation in normoprolactinaemic post-pill 
anovulation. Lancet i, 502-504 
268 
STEVENS, V. C. (1969) Comparison of FSH and LH patterns in plasma, 
urine and urinary extracts during the menstrual cycle. J. Clin. 
Endocrinol. Metab.. ý2,904-910 
STIE)GLITZ, E. J. '& KIMBLE, S. T. (1949) Premenstrual intoxication. 
Am. i. Med. Sci. 218,616-623 
STOKES, J. & MENDELS, J. (1972) Pyridoxine and premenstrual tension. 
Lancet. i, 1177-1178 
STRIPP, B., TAYLOR9 A. A., BARTTER-1 F. C., GILLETTE, J. R., LORIAUX9 D. L. 
EASLEY, R. & MENARD9 R. H. (1975) Effect of spironolactone on sex 
hormones in man. J. Clin. Endocrinol. Metab. 41,777-781 
STROM, C. A. 9 YOSHIMI9 T. 9 ROSS, G. T. & LIPSLTTI M. B. (1969) Ovarian 
physiology: relationship between plasma LH and steroidogenesia by 
the follicle and corpus luteum: effect of HCG. J. Clin. Endocrinol. 
Metab. 29,1157-1167 
STROTT, C. A., CARGILLE, C. M., ROSS, G. T. & LIPSETT, M. B. (1970) 
The short luteal phase. J. Clin. Endocrinol. Metab. 30,246-251 
SUNDSFJORD, J. A. &'AAKVAAG, A. (1970) Plasma angiotensin II and 
aldosterone excretion durine the menstrual. cycle. Acta Endocrinol 
(Kbh) 64,452-458 
SUNDSFJORD9 J. A. & AAKVAAG, A. (1972) Plasma renin activity, plasma 
renin substrate and urinary aldosterone excretion in the menstrual 
cycle in relation to the concentration of progesterone and 
oestrogens in the plasma. Acta Endocrinol. 71,519-523 
SUNDSFJORD, J. A. & AAKVAAG, A. (1973) Variations in plasma aldostorone 
and plasma renin activity throughout the menstrual cycle, with 
special reference to the pre-ovulatory period. Acta Endocrinol. 
, 
Z3,499-508 
SUTHERLAND, H. & STEWART, 1 (1965) A critical analysis of the pro- 
menstrual syndrome. Lancet. i, 1180-1183 
TAYLOR, H. C. (1949) Vascular congestion and hyperemia. Their effect on 
structure and function in the female reproductive tract. Am. J. 
Obstet. Gynecol 57,211-230 
TAYLOR9 R. W. (1977a) The treatment of premenstrual tension with 
dydrogesterone ('Duphaston') Curr. Med. Res. Opin. 4 Suppi 4,35-40 
269 
TAYLOR, R. W. (1977b) In, troduction . Curr. Med. Res. Opin. 4, Suppl. 4, 
3-4 
THOMAS, W. A. (1933) Generalised edema occurring only at the menstrual 
period. J. Am. Med. Assocn. 101,. 1126-1127 
(1976) ' 
THOMSON, J, /Double blind study of the effect of oestrogen on sleeps 
anxiety and depression in perimenopausal women: preliminary 
result. Proc. Royal Soc. Med. 69,17-18 
THOMSON, J., MADDOCK9 J. 9 AYLWARD, M. & OSWALD, 1. (1977) Relationship 
between nocturnal plasma estrogen concentration and free plasma 
tryptophan in perimenopausal women. J. Endocrinol. 72t 395-396 
TRELOAR, A. E., BOYNTON, R. E., BEHN, B. G. & BROWN, B. W. (19b? ) Variation 
of the human menstrual cycle throughout reproductivo lifo. Int. 
J. Fertil. 129 77-125 
TURNER, J. C. (1971) Sample preparation for liquid scintillation 
counting. p. 18. The Radiochemical Centre, Amersham. 
VARSANO-AHARON, N. & ULICK, S. (1974) Further simplification in the 
immunoassay of plasma aldosterone. J. Clin. Endocrinol Motab. 
39,375-379 
VEKEMANS, M., DELVOYE, P., LIHERMITE, M. & ROBYN, C. (1977) Serum 
prolactin levels during the menstrual cycle. J. Clin. Endocrinol. 
Metab. 44,989-993 
VETTER, W., VETTER, H. & SIEGENTHALER9 W. (1973) Radioimmunoassay for 
aldosterone without chromatography. Acta Endocrinol. Z-4t 558-567 
VETTER, W., FREEDLENDER, E. & HABER, E. (1974) Specificity of anti- 
aldosterone antibodies in relation to the site of coupling. 
Clin. Immunol. Immunopathol. 2,361-372 
VYZANTIADES, A., EKINS, R. P. & SLATER9 J. D. H. (1970) Determination 
of aldosterone by saturation analysis using binding sites in 
mammalian and amphibian bladder., preliminary studies. In. In 
Vitro Procedures with Radioisotopes in Medicine. pp 427-451. 
International atomic Energy Agency, Vienna. 
00 WALDHAUSL, W., IIAYDL, H. & FRISCHAUF, H. (1972) Determination of 
aldosterone by Sephadex LH-20 chromatography and radioimmunoassay. 
Steroids 20,727-737 
270 
WEEKE, J. & HANSEN, A. P. (1975) Serum FSH and serum T3 levels during 
normal menstrual cycles and during cycles on oral contraceptives. 
Acta Endocrinol. 79,431-438 
van WEEMP11, B. K. & SCHUURS, A. H. W. M. (1971) Immunoassay using 
enzyme-hapten conjugates. FEBS Letters 24,77-81 
WEIR, J., BROWN, i. J., FRASER, R., LEVER, A. F., LOGAN, R. W., 
McILWAINE, G. M., MORTON, J. J., ROBERTSON, I. S. & TREE, M. 
(1975) Relationship between plasma renin, renin-substratel. 
angiotensin II, aldosterone and electrolytes in normal 
pregnancy. J. Clin. Endocrinol. Metab. 40,108-115 
WEISSMAN, M. M. & KLERMAN, G. D. (1977) Sex differences and the 
epidemiology of depression. Arch. Gen. Psychiatry. 34,98-111 
. WEST, C. D., MAHAJAN, D. K., CHAVRE, V. J., NABORS, C. J. & TYLER, F. H. (1973) 
Simultaneous measurement of multiple plasma steroids by 
radioimmunoassay demonstrating episodic secretion. J. Clin. 
Endocrinol. Metab. 36,1230-1236 
WESTPHAL, U. (19ý0) Preparation and characteristics of cortico- 
steroid7binding globulin (CBG, transcortiri). Acta Endocrinol. 
(Kbh) 64, (Suppl) 147,122-143 
WHITEHEAD, R. E. (1934) Women Pilots. J. Aviation Med. 2,47-49 
van de WIELE, R. L., BOGUMIL, J., DYRENFURTH, I., FERIN9 M-l JEWELEWICZ, 
R., WARREN, M., RIZKALLAHI T. & MIKHAIL, G. (1970) Mechanisms 
regulating the menstrual cycle in women. Recent Progr. lbrmone 
Res. 26,63-103 
WIRZ-JUSTICE, A. 9 HACKMANN 
'9E. 
& LICHTSTIER, M. (1974) The effect of 
oestradiol diproprionate and progesterone on monamine uptake 
in rat brain. J. Neurochem. 22,, 187-189 
WOOLLEY, D. E. & TIMIRAS, P. S. (1962) The gonad-brain relationship. 
Effects of female sex hormones on electr6shock convulsions in 
the rat. Endocrinology 70,196-209 
WOTIZ, H. CHARRANSOL, G. & SMITH, I. N. (1967) Gas chromatographic 
measurement of plasma estrogens using an electron capture 
detector. Steroids. 10,127-154 
271 
lu'UT-TKE, W., ARNOLD, P., BECKER, D., CRVJTZFELDT, 01 LANGENSTEIN, S. 
& TIRSCH, W. (1975) Circulating hormones, EEG and performanco in 
psychological testp in women with and without oral contraceptives. 
Psychoneuroendocrinology 11 1-12 
YANNONE, M. E., McCOMAS, D. B. & GOLDFIEN, A. (1964) The assay of plasma 
progesterone. J. Gas Chromatography.. L, 30-33 
YEN, S. S. C., VANDENBERG, G., TSAI, C. C. & PARKER, D. C. (1974) Ultra- 
radian fluctuations of gonadotropins. In. Biorhythms and Human 
Reproduction. (Ferin, M., Halberg, F., Richart, R. M. and vanden- 
Wiele, R. L. eds) Chap. 13. J. Wiley & Sons New York. 
YOSHIMI, T. & LIPS M, M. B. (1968) The measurement of plasma progootorono 
Steroids. 11,527-544 
YOUSSEFNAJADIAN, E. $ FLORENSA, E., COLLINS, W. P. & SOMMERVILLE, I. F. 
(1972) Radioimmunoassay of plasma progesterone. J. Steroid 
Biochem. 3,893-901 
YUSSMAN, M. A. & TAYMOR, M. L. (1970) Serum levels of follicle stimulating 
hormone and luteinizing hormone and of plasma progesteroylo rolated 
to ovulation by corpus luteum biopsy. J. Cliii. Endocrinol. Metab. 
30,396-399 
ZANDER,. J. & SIMMER, H. (1954) Die chemische. Bestimmung von progesteron 
in organischen substraten. Klin. Wschr. ýI, 529-540 
ZARATE, A., JACOBS, L. S., CANALES,. E. S. 9 SCHALLY, A. V., de !a CRUZ9 A., 
SORIA, J. & DAUGHADAY, W. H. (1973) Functional evaluation of 
pituitary reserve in patients with the amenorrhoea-galactorrhoca 
syndrome utilizing luteinising-hormone-releasing-hcrmone (M-RH), 
1-Dopa and chlorpromazine. J. Clin. Endocrinol. Metab. 
855-859 
ZUV-PE, D. & MICHAEL, R. P. (1970) Redirected aggression and gonadal 
hormones in captive rhesus monkeys (Macaca Mulatta) Anim. Behav. 
18', 11-19, 
**YEN, S. S. C., VANDENBERGIG., TSAI, C. C. & SILER, T. (1974) Causal 
tionships between hormonal variables in the menstrual cycle. relat 
In. Biorhythms and Ifuman Reproduction. (Ferin, M., Halberg, F. " 
Richart, R. M. & vande Wiele, R. L. eds) Chap. 14 J. Wiley & Sons. N. Y. 
[REPRINTED FROM THE PROCEEDINGS OF THE SOCIETY FOR ENDOCRINOLOGY, 25 -26 NowmBER 1976.1 
JOURNAL OF ENDOCRINOLOGY, [1977], 73,21P 
[All rights reserved] PRINTED IN GREAT BRITAIN 
Progesterone and aldosterone levels in the premenstrual tension syndrome. By Madeleine 
Munday, M. G. Brush and R. W. Taylor. Department of' qvnaecology, St Thomass 
Hospital Medical School, London, SE] 7EH 
The premenstrual tensioO syndrome (PMT) is characterized by depression, irritability, person- 
ality change and swelling of abdomen and breasts during the 7-14 days before the onset of' 
menstruation. Not all symptoms are present in all patients and some may appear later than 
others in the premenstrual phase. Little evidence is so far available on the endocrine status of' 
these patients and, therefore, we have measured plasma progesterone and aldosterone levels ill 
eight PMT patients aged 22-49 years (mean 35 ± 10) and in eight control patients aged 22-32 
years (mean 27±3). 
Atleast six blood samples were taken from each subject throughout each menstrual cycle and 
progesterone and aldosterone levels were measured in plasma using a radioilillnulioas%ay. 'File 
approximate time of ovulation was determined by basal body temperature measurements. 
Posture was standardized by 30 min recumbency but diet and time of day of' blood sampling 
were not controlled. 
The menstrual cycles of the PMT patients were shorter than those of the controls (26-3 ýI-I 
days compared with 29.6 ± 1-6 days). 
Progesterone values for the PMT patients for each day of the cycle (dated from the next 
menstrual period) did not differ significantly from those of controls except during (lie Illid- 
luteal phase. At this time (5-8 days before menstruation) the mean plasma progesterone value 
was 31 ± 10 (S. E. M. ) nmol/I for PMT patients and 45 ± 14 nmol/I for cont rols (P = 0-02, using 
Student's t-test). 
Plasma aldosterone values in the control group showed an increase ill the preovulatory and 
early luteal phases, in agreement with the results of Frolich, Brand & van I fall ( 1976). 
In PMT patients, the plasma aldosterone values were not consistently different from those of' 
controls. There was a small surge in the late luteal phase of the PMT group but this was not 
statistically significant. 
When the ratio of progesterone to aldosterone was estimated, it was found that this ratio was 
markedly lower in the PMT group in the mid-luteal phase only (P = 0-05). This difference was 
probably due to the influence of progesterone values alone. 
A large group (105) of PMT patients is now being studied to elucidate the steroid and 
prolactin profile in detail, with initial results giving further evidence for impaired proge-Acione levels in the luteal phase in some patients. 
These findings can be compared with those of Backstrom & Carstensen ( 1974) who found .1 depression of plasma progesterone in ten PMT patients with marked anxiety at 4-6 days before 
menstruation. They also found higher plasma oestradiol levels at 2-5 days before menstruation. The role of aldosterone in this condition is incompletely understood but clearly any excess 
a1dosterone secretion would tend to promote the fluid retention often seen ill I)MT. Equally, it is known that progesterone tends to oppose aldosterone action and promote sodium 'loss (Landau & Lugibihl, 1961; Oelkers, Schoneshofer & Bluniel, 1974). Prolactin may also be implicated (Halbreich, Assael, Ben-David & Bornstein, 1976) with higher serum levels being seen 
in some PMT patients. Studies are in progress to assess the fluctuation of' prolactin and 
oestradiol in this syndrome. 
We are indebted to the Endowment Fund ot'St Thomas's Hospital for a rescarcil glaill. 
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Plasma levels ofprogesterone and a1dosterone dur. *ng the menstrual cycle were studied 
ha 8pa. "ients ivith premenstrual tension and in 8 controls. 77te results showed a dericit 
in progeverore 8 days premerstrually ts the wornen with severe Symptoms. In 6 of the 
8padents In this first study, symptoms started before this, suggestirg the Involvement 
of some otherfactor earlier in the cycle. Aldosterone levels, however, showed no con. 
sistent change even in women with low progesterone levels, andthere was no difference 
between patients who gained weight cyclically and those who did not. [if a second on- 
going study the levels of these hormones and of prolacii" were followed in a lqýlzer 
group of 58 women with severe premenstrual symptoTs. Ralsed prolactin and hm, 
progesterone levels were found in approximately 30 % of the 58 patients during the 
second half of the cycle suggesting that prolactin reduces progesterone production 
In corpus luteum cells, and this slight deficiency was reflecled in somewhat shorter 
length menstrual cycles. Further studies are being carried out to clarify the roles of 
prolactin and oestradfol in this syndrome. 
Key words: Prcmenstrual tension - progesterone - aldosterone - prolactin 
Introduction 
Until recently, little work has been carried out to investigate the hormonal basis of 
the premenstrual tension syndrome. This was due, in partý to the lack of adequate 
laboratory methods to measure hormone blood levels. In the last few years. how- 
cycr, the technique of radioimmunoassay has made possible the study of very slight 
changes in the hormonal pattern. 
Many theories have been put forward to account for premenstrual tension. III 
particular there has been a long standing belief, first suggt-sted by Frank, 3 that an 
imbalance exists between the ovarian stcroids, oestradiol -and progestcrone. This 
idea was supported by several authors such as IsracP wrio thought that the ratio of 
ocstradiol to progestercrie was excessive. A second idva fOr the actiology of pre- 
menstrual tension was prompted by the finding6 that a1dosterone sccrction -wes 
were raised in the second half of the normal cycle. Several %orkers' 0 hnvc suggcsted 
that increased activity of tne ien; il-angiotensin-aidost:., rk)rc systcm might be in- 
volvcd, and this might account for the symptonis of ýtcr retention seen in *, his 
condition. Recently, a th: W1 idea was put forward by I L: : rooin. 13 tic suggested that 
16 
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prolactin might -play a crucial role in this syndrome. Ile also pointed out that 
prolactin retains sodium, water and potassium and he reported that this also 
occurred in premenstrual tension. Prolactin, however, does not have a consistent 
cyclical pattern. 13 
There has been some evidence so far for all of these hypotheses, although some 
of the evidence is conflicting. It was decided, therefore, to study three steroids - 
progestcrone, aldosterone, and oestradiol - in a small group of patients and later to 
study these hormones and prolactin in a larger number of women to see what varia- 
tions there were in levels during the menstrual cycle and if there were any corrcla- 
tions with premenstrual symptoms. The study is still in progress and this paper is 
an interim report of the findings. 
Methods and patients 
The first group of women consisted of 8 with premenstrual tension who had been 
referred to the gynaecological clinic, and 8 controls from the hospital staff. During 
one cycle cach patient and control completed a daily record of symptoms and 
attended for at least 6 blood samples. Diet and time of day were not controlled, 
although the patients remained recumbent for 30 minutes before blood sampling. 
The second group of 58 women complained of severe premenstrual tcnsion and 
were obtained via an appeal in the press. Their symptoms were much more variable 
than those of the first group. The patients also completed a daily record of symp- 
toms, but on average only I blood sample was taken in the follicular phase and 3 
samples in the lutcal phase. Since it has been found recently that 30 minutes re- 
cumbency does not reduce aldosterone to basal levels, 15 patients in the second group 
were not recumbent during blood sampling. Progesterone was measured by radio- 
immunoassay using an antiserum to pro-esterone-lla-hcmisuccinatc-BSA. and 
conditions modified from those of Furr. 5 Aldostcrone was measured by radio- 
immunoassay using an antiserum to aldostcrone- 18,2 1 -dihemisuccinatc- BSA, 
kindly supplied by the National Institutes of Health, U. S. A. Aldost-. rone was 
extracted with dichloromethane and purified by column chromatography on 
Sephadex LF120 (Phannacia) before assay. The prolactin assays were carried out in 
the Chemical Pathology Department. 
Results 
Group I 
The pattern of cyclical symptoms experienced by the patients and controls is Shown 
in Table 1. The average duration of symptoms was 10 days. Out of the 6 patients 
who kept regular weight records, only 3 experienced weight glin of more than 2 
pounds. It Is also interesting that the symptom of breast tcndccness was recorded 
by half the controls. 
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Table 1. Pattern of cyclical symptoms experienced premcnstrually by 8 women with sevcre pre- 
menstrual tension syndrome and by 8 controls 





Breast tendctness 5 
Abdomirplocdema 7 
Headache 2 
Weight gain over 2 lbs 3 
The agcý; and menstrual cycle lengths of the 16 women studied are given in Table 
H. Unfortunately, we could find only rather young control volunteers. Differences 
in mean menstrual cycle length and luteal phase length (judged by body basal 
temperature) were evident. 
Table 11. Age, length of cycle, and length of luteal phase In 8 vromen with severo premenstrual 
tension and in 8 controls: mean values (-+S. D. ) 
Data Premnstrual tension Control group 
patients 
As (years) 35.0 2). 1 
±10.0 2.9 
Length of menstrual cycle (days) 26.3 29.6 
d: 1.1 ± 1.6 
Lomgth of lutcal phase (days) 13.1 14.5 
± 1.7 0.5 
Shorter luteal phases have been shown to be unrelated to age. 16 It seems, there- 
fore, that the premenstrual tension patients had shorter cycles and shorter luteal 
phases than the controls. 
Plasma progcstcrone values for the patients and controls are given in Figure 1. All 
cycles in both groups showed a progesterone peak, indicating ovulation, but there 
were lower values for the premenstrual tension patients for the Days minus 8 to 
Days minus 5 period before menstruation. 
These results are in agreement with those reported by Backstrorn and Carsten- 
sen. ' They studied the last 6 days of the cycle and found lower progesterone levels 
on Days mirtus; 6 to Days minus 4 before menstruation in their 10 patients ard 
controls. These results suggest that the ratio of progcsterone to oestradiol is reduced 
at least in the last week of the cycle. 
Aldosterone levels were also measured in 6e 8 premenstrual tension patients. 
The results are shown in Figure 2. As will be seen, thcre was a small pcak in the 
controls just prior to ovulation, but the second rise afterovulation was not niain- 
tained after the third week of the cycle. This general pattern is in agreement with the 
results of Frolich C1 al. 4 In the premenstrual tension grot., p there was no consistent 
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Figurel. Meatt (: t--S. F-NL) plasms progesterone values In 8 controls and In 8 premenstrual tension 
patients 
70 -1 - Controls 
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change in aldosterone although there was a small peak in the last 2 days pre- 
menstrually. In fact, there was very high variability between individuals and from 
day to day. There was no difference in aldosterone levels between those who gained 
weight cyclically and those who did not, but the numbers were very small. 
Group 2 
A much wider variability of progesterone levels was found in this group of 58 
patients than in the smaller first group of patients studied. Patients were sub-divided 
into those with normal progesterone values and those with values below the 90% 
confidence limits of the controls (Table III). There was no age difference between 
the sub-groups but those with low prOgesterone levels had shorter cycles. Also, the 
low progesterone levcl sub-group was larger than one would have expected on 
statistical grounds from. the gcneral population. 
Table III. Progesterone values, age, and length of menstrual cycle in 58 patients with Selere 
premenstrual s3imptoms: mean values (±S. D. ) 
Progesterone No. patients Age (yrs) Len2th of menstrual 
values cycle (days) 
Within normal 41 (71 36 ±5 29 ±2 
range 
Below normal 17 (29 34 +6* 27 ±200 
range 
*not significant **p<0.02 
Figure 3 gives the prolactin levels of the luteal phase in relation to the pro- 
gesterone values at the same time in the two sub-groups. 
Figure 3. Prolactin levels In sub-groups of premenstrual tension patients with normal procesteronu 
























It appears that the low progesterone sub-group tended to have rather raised and 
variable prolactin results, although only 2 patients had prolactin levels above the 
normal limits. These results compare with those of Halbreich et aL7 who found 
raised prolactin levels in premenstrual tension patients compared to controls in the 
last 3 weeks of the cycle. These investigators, however, gave no reference to 
normal values. 
Discussion 
These results show a deficit of progesterone 8 days premenstrually in women with 
severe premenstrual tension; yet in 6 of the 8 patients studied, symptoms started 
more than 8 days premenstrually. This suggests some other factor is acting earlier 
in the cycle, with secondary effects on the corpus luteuni. Possible candidatcs for 
this factor include prolactin, a1dostcrone and oestradiol. 
It has been shownl 7 that the rise in aldosterone excretion in the second half of Lhe 
cycle only occurs when a corpus luteum is formed. Thus, the natriuresis and diuresis 
brought about by the anti-aldosterone effect of progesteronel 1 is compensated by 
increased aldosterone secretion. No disturbance in a1dosterone plasma levels, how- 
ever, was found in premenstrual tension patients even when the progesterone levels 
were low. It seems likely, therefore, that soine other faýtor, cither in the renin- 
angiotensin system or elsewhere, must be responsible for the ocdcma seen in pre- 
menstrual tension. Other workers have found that aldostero=, excretion is indeed 
low in women with cyclical oedema. 14 
The work of Backstrorn and Carstensen' on a small group of patients suggests 
that plasma o6stradiol is raised in the last 6 days of the c)-cle. Backstrom ard 
Mattsson2 have found that oestradiol is raised 3 days premenstrually in patients 
with psychological symptoms, but not in those who complained of feelings of swell- 
ing. It would be interesting to study the levels of oestradiol earlier in the cycle and 
it is hoped to investigate this in our present patients. Prolactin may also have a role 
to play in this syndrome. The raised values found in some of our patients, especially 
those with low progesterone, would seem to agree with some recent evidence that 
prolactin reduces progesterone production by corpus luteurn CC11S. 12 
It appears that there may be several sub-groups within the large proportion of 
women who complain of premenstrual tension. In about 30% of the 53 women 
studied, we found lower progesterone and raised prolactin in the second half of the 
cycle. We also found that in these women, the slight deficiency orthe corpus luteum 
was reflected in slightly shorter cycles. These preliminary audies suggest that 
a1dosterone has no striking role to play. Further studies are =ded to clariýv the 
detailed roles of prolactin and oestradiol in this syndrome. 
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